<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>1500</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="1500"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=1500&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=1400&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=1600&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929323554"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929323554?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929323554&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929323554&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929323554</prism:url><dc:identifier>SCOPUS_ID:84929323554</dc:identifier><eid>2-s2.0-84929323554</eid><dc:title>Performance Evaluation of Heartbeat Classification Methods Based on Morphological Descriptors</dc:title><dc:creator>Haider A.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>1-2</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030120</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026161</affiliation-url><afid>60026161</afid><affilname>University of North Dakota</affilname><name-variant>University of North Dakota</name-variant><affiliation-city>Grand Forks</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644203400</author-url><authid>56644203400</authid><authname>Haider A.</authname><surname>Haider</surname><given-name>Ali</given-name><initials>A.</initials><afid>60026161</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6505837295</author-url><authid>6505837295</authid><authname>Tavakolian K.</authname><surname>Tavakolian</surname><given-name>Kouhyar</given-name><initials>K.</initials><afid>60026161</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23388874700</author-url><authid>23388874700</authid><authname>Fazel-Rezai R.</authname><surname>Fazel-Rezai</surname><given-name>Reza</given-name><initials>R.</initials><afid>60026161</afid></author><intid>35945996</intid><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928885895"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928885895?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928885895&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928885895&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928885895</prism:url><dc:identifier>SCOPUS_ID:84928885895</dc:identifier><eid>2-s2.0-84928885895</eid><dc:title>Single-port laparoscopic colorectal surgery shows equivalent or better outcomes to standard laparoscopic surgery: results of a 190-patient, 7-criterion case-match study</dc:title><dc:creator>Marks J.</dc:creator><prism:publicationName>Surgical Endoscopy and Other Interventional Techniques</prism:publicationName><prism:issn>09302794</prism:issn><prism:eIssn>14322218</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1492-1499</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00464-014-3830-1</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Introduction: Single-port (SP) surgery has been characterized as having limited applicability regarding procedure, disease, and patient characteristics. There is a question if SP procedures offer disadvantages or advantages to multiport (MP) colorectal surgery. We hypothesize that SP is equivalent to MP and is a safe alternative in the full spectrum of colorectal disease and procedures. Methods: A case-matched analysis of a prospectively maintained database to compare perioperative outcomes in SP versus MP was performed. Criteria included age, gender, BMI, previous abdominal surgery, previous XRT, disease process, and procedure. 95 exact matches for all 7 criteria were found between 159 SP and 1,617 MP cases. Perioperative outcomes, surgical technique, morbidity, mortality, local recurrence, and 5-year survival were analyzed. Results: There was lower mean EBL in SP but no difference in transfusion requirement. OR time for SP left colectomy was shorter, with a trend to shorter OR times found in all procedures. 99 % SP and 98 % MP had no intra-operative complications. Conversion to open was equivalent (0/1). Mean largest incision was smaller for SP. There were no differences in return of bowel function or length of hospital stay. There were no mortalities. There were no differences in perioperative morbidity, local recurrence, distant metastasis, or overall 5-year survival. Conclusions: SP is a safe alternative to MP colorectal surgery across the full array of procedures in equivalent patients. This study demonstrates SP has less blood loss, smaller incisions, is quicker in left colectomy, and tends to be quicker across all procedures. Conversion and morbidity rates are equivalent to MP, without compromise in quality of surgical technique. While proper training is essential, concerns regarding the inability to use SP laparoscopic colorectal surgery safely are unfounded in nearly exactly matched patients. These issues will require further study as SP laparoscopic colorectal surgery is practiced more widely.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006187</affiliation-url><afid>60006187</afid><affilname>Lankenau Institute for Medical Research</affilname><name-variant>Lankenau Medical Research Center</name-variant><affiliation-city>Wynnewood</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109487871</affiliation-url><afid>109487871</afid><affilname>Lankenau Medical Center</affilname><name-variant>Lankenau Medical Centre</name-variant><affiliation-city>Wynnewood</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:19636045000</author-url><authid>19636045000</authid><authname>Marks J.</authname><surname>Marks</surname><given-name>John H.</given-name><initials>J.H.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:19636045000</author-url><authid>19636045000</authid><authname>Marks J.</authname><surname>Marks</surname><given-name>John H.</given-name><initials>J.H.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56622620100</author-url><authid>56622620100</authid><authname>Montenegro G.</authname><surname>Montenegro</surname><given-name>Grace A.</given-name><initials>G.A.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56622620100</author-url><authid>56622620100</authid><authname>Montenegro G.</authname><surname>Montenegro</surname><given-name>Grace A.</given-name><initials>G.A.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56622330500</author-url><authid>56622330500</authid><authname>Shields M.</authname><surname>Shields</surname><given-name>Margaret V.</given-name><initials>M.V.</initials><afid>60006187</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:53263615000</author-url><authid>53263615000</authid><authname>Frenkel J.</authname><surname>Frenkel</surname><given-name>Joseph L.</given-name><initials>J.L.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:53263615000</author-url><authid>53263615000</authid><authname>Frenkel J.</authname><surname>Frenkel</surname><given-name>Joseph L.</given-name><initials>J.L.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56622289600</author-url><authid>56622289600</authid><authname>Marks G.</authname><surname>Marks</surname><given-name>Gerald J.</given-name><initials>G.J.</initials><afid>60006187</afid><afid>109487871</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56622289600</author-url><authid>56622289600</authid><authname>Marks G.</authname><surname>Marks</surname><given-name>Gerald J.</given-name><initials>G.J.</initials><afid>60006187</afid><afid>109487871</afid></author><authkeywords>Colorectal surgery | Laparoscopy | Minimally invasive surgery | Single-port surgery</authkeywords><intid>1035858624</intid><source-id>19196</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923379425"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923379425?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923379425&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923379425&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2214180415000033"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923379425</prism:url><dc:identifier>SCOPUS_ID:84923379425</dc:identifier><eid>2-s2.0-84923379425</eid><dc:title>Design and implementation of a simple portable biomedical electronic device to diagnose cardiac arrhythmias</dc:title><dc:creator>Azucena H.</dc:creator><prism:publicationName>Sensing and Bio-Sensing Research</prism:publicationName><prism:eIssn>22141804</prism:eIssn><prism:volume>4</prism:volume><prism:pageRange>1-10</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.sbsr.2015.01.001</prism:doi><pii>S2214180415000033</pii><dc:description>© 2015 The Authors. This paper presents the development of a simple portable biomedical electronic device to detect cardiac arrhythmias in humans. It identifies three main parts: an electrocardiograph, a device for data communication and a personal computer with software for diagnosis. The system performs automatic diagnosis of cardiac arrhythmias by comparing the patient's electrocardiogram with those contained in a database stored in a personal computer. The biomedical device performance is satisfactory and it demonstrated its usefulness even in the absence of medical specialist in cardiology.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024830</affiliation-url><afid>60024830</afid><affilname>Benemerita Universidad Autonoma de Puebla</affilname><name-variant>Benemérita Universidad Autónoma de Puebla</name-variant><affiliation-city>Puebla</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024830</affiliation-url><afid>60024830</afid><affilname>Benemerita Universidad Autonoma de Puebla</affilname><name-variant>Benemérita Universidad Autónoma de Puebla</name-variant><affiliation-city>Puebla</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56527426600</author-url><authid>56527426600</authid><authname>Azucena H.</authname><surname>Azucena</surname><given-name>H.</given-name><initials>H.</initials><afid>60024830</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8697146500</author-url><authid>8697146500</authid><authname>Ríos E.</authname><surname>Ríos</surname><given-name>E.</given-name><initials>E.</initials><afid>60024830</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56526355000</author-url><authid>56526355000</authid><authname>Peña R.</authname><surname>Peña</surname><given-name>R. D.</given-name><initials>R.D.</initials><afid>60024830</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56525983100</author-url><authid>56525983100</authid><authname>Díaz J.</authname><surname>Díaz</surname><given-name>J.</given-name><initials>J.</initials><afid>60024830</afid></author><authkeywords>Bioelectric signals | Cardiac arrhythmias | Cardiology software | Electrocardiograph | Heart diseases automatic diagnosis | USB</authkeywords><intid>34960089</intid><source-id>21100356802</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929070536"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929070536?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929070536&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929070536&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929070536</prism:url><dc:identifier>SCOPUS_ID:84929070536</dc:identifier><eid>2-s2.0-84929070536</eid><dc:title>Nopaine no gain: Recreational ethylphenidate toxicity</dc:title><dc:creator>Bailey G.</dc:creator><prism:publicationName>Clinical Toxicology</prism:publicationName><prism:issn>15563650</prism:issn><prism:eIssn>15569519</prism:eIssn><prism:volume>53</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>498-499</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.3109/15563650.2015.1033062</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005518</affiliation-url><afid>60005518</afid><affilname>Guy's and St Thomas' NHS Foundation Trust</affilname><name-variant>Guy's and St. Thomas' NHS Foundation Trust</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005518</affiliation-url><afid>60005518</afid><affilname>Guy's and St Thomas' NHS Foundation Trust</affilname><name-variant>Guy's and St. Thomas' NHS Foundation Trust</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005889</affiliation-url><afid>60005889</afid><affilname>LGC Ltd.</affilname><name-variant>Laboratory of the Government Chemist</name-variant><affiliation-city>Teddington</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011520</affiliation-url><afid>60011520</afid><affilname>King's College London</affilname><name-variant>King's College London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637774300</author-url><authid>56637774300</authid><authname>Bailey G.</authname><surname>Bailey</surname><given-name>George P.</given-name><initials>G.P.</initials><afid>60005518</afid><afid>60005518</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637774300</author-url><authid>56637774300</authid><authname>Bailey G.</authname><surname>Bailey</surname><given-name>George P.</given-name><initials>G.P.</initials><afid>60005518</afid><afid>60005518</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637576000</author-url><authid>56637576000</authid><authname>Ho J.</authname><surname>Ho</surname><given-name>James H.</given-name><initials>J.H.</initials><afid>60005518</afid><afid>60005518</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637576000</author-url><authid>56637576000</authid><authname>Ho J.</authname><surname>Ho</surname><given-name>James H.</given-name><initials>J.H.</initials><afid>60005518</afid><afid>60005518</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36087429200</author-url><authid>36087429200</authid><authname>Hudson S.</authname><surname>Hudson</surname><given-name>Simon</given-name><initials>S.</initials><afid>60005889</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603353143</author-url><authid>6603353143</authid><authname>Dines A.</authname><surname>Dines</surname><given-name>Alison</given-name><initials>A.</initials><afid>60011520</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56233324600</author-url><authid>56233324600</authid><authname>Archer J.</authname><surname>Archer</surname><given-name>John R H</given-name><initials>J.R.H.</initials><afid>60005518</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004249431</author-url><authid>7004249431</authid><authname>Dargan P.</authname><surname>Dargan</surname><given-name>Paul I.</given-name><initials>P.I.</initials><afid>60005518</afid><afid>60011520</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004249431</author-url><authid>7004249431</authid><authname>Dargan P.</authname><surname>Dargan</surname><given-name>Paul I.</given-name><initials>P.I.</initials><afid>60005518</afid><afid>60011520</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55322365400</author-url><authid>55322365400</authid><authname>Wood D.</authname><surname>Wood</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60005518</afid><afid>60011520</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55322365400</author-url><authid>55322365400</authid><authname>Wood D.</authname><surname>Wood</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60005518</afid><afid>60011520</afid></author><intid>1035896760</intid><source-id>4000148406</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925620068"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925620068?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925620068&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925620068&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493115001940"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925620068</prism:url><dc:identifier>SCOPUS_ID:84925620068</dc:identifier><eid>2-s2.0-84925620068</eid><dc:title>Anti-biofilm formation of a novel stainless steel against Staphylococcus aureus</dc:title><dc:creator>Nan L.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>51</prism:volume><prism:pageRange>356-361</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2015.03.012</prism:doi><pii>S0928493115001940</pii><dc:description>© 2015 The Authors. Abstract Staphylococcus aureus (S. aureus) is a bacterium frequently found proliferating on metal surfaces such as stainless steels used in healthcare and food processing facilities. Past research has shown that a novel Cu-bearing 304 type stainless steel (304CuSS) exhibits excellent antibacterial ability (i.e. against S. aureus) in a short time period (24 h.). This work was dedicated to investigate the 304CuSS's inhibition ability towards the S. aureus biofilm formation for an extended period of 7 days after incubation. It was found that the antibacterial rate of the 304CuSS against sessile bacterial cells reached over 99.9% in comparison with the 304SS. The thickness and sizes of the biofilms on the 304SS surfaces increased markedly with period of contact, and thus expected higher risk of bio-contamination, indicated by the changes of surface free energy between biofilm and the steel surfaces. The results demonstrated that the 304CuSS exhibited strong inhibition on the growth and adherence of the biofilms. The surface free energy of the 304CuSS after contact with sessile bacterial cells was much lower than that of the 304SS towards the same culture times. The continuously dissolved Cu2+ ions well demonstrated the dissolution ability of Cu-rich precipitates after exposure to S. aureus solution, from 3.1 ppm (2 days) to 4.5 ppm (7 days). For this to occur, a hypothesis mechanism might be established for 304CuSS in which the Cu2+ ions were released from Cu-rich phases that bond with extracellular polymeric substances (EPS) of the microorganisms. And these inhibited the activities of cell protein/enzymes and effectively prevented planktonic bacterial cells attaching to the 304CuSS metal surface.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020745</affiliation-url><afid>60020745</afid><affilname>Institute of Metal Research Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032760</affiliation-url><afid>60032760</afid><affilname>University of Hertfordshire</affilname><name-variant>University of Hertfordshire</name-variant><affiliation-city>Hatfield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36865693400</author-url><authid>36865693400</authid><authname>Nan L.</authname><surname>Nan</surname><given-name>Li</given-name><initials>L.</initials><afid>60020745</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7404291962</author-url><authid>7404291962</authid><authname>Yang K.</authname><surname>Yang</surname><given-name>Ke</given-name><initials>K.</initials><afid>60020745</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23020031700</author-url><authid>23020031700</authid><authname>Ren G.</authname><surname>Ren</surname><given-name>Guogang</given-name><initials>G.</initials><afid>60032760</afid></author><authkeywords>Antibacterial | Biofilm | Cu-bearing stainless steel | S. aureus</authkeywords><intid>535330556</intid><article-number>5335</article-number><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926443368"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926443368?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926443368&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926443368&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002014"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926443368</prism:url><dc:identifier>SCOPUS_ID:84926443368</dc:identifier><eid>2-s2.0-84926443368</eid><dc:title>Effect of smoking on endothelium-independent vasodilatation</dc:title><dc:creator>Lanza G.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>330-332</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.041</prism:doi><pii>S0021915015002014</pii><dc:description>© 2015 Elsevier Ireland Ltd. Background: Smoking induces an impairment of endothelium-dependent vasodilatation. In this study we assessed whether smoking also causes an impairment of endothelium-independent vasodilatation. Methods: We studied 2 groups of young healthy subjects: 1) 12 medical students (24.5±0.9 years; 6 male) without cardiovascular risk factors (CVRFs), except smoking (≥10 cigarettes/day); 2) 12 matched controls (24.5±1.1 years; 6 male) without any CVRF. Nitrate-mediated dilatation (NMD) of the brachial artery was assessed in response to the random administration of 4 different doses (10, 20, 30 and 40μg) of sublingual nitroglycerin (NTG). Flow-mediated dilatation (FMD) was also assessed. Results: The increasing doses of NTG determined a progressive increase of NMD in both groups, but the dose-response curve was significantly lower in smokers compared to controls (p&lt;0.001). FMD was also lower in smokers, compared to controls (6.12+0.6 vs. 8.06+0.9%, p&lt;0.001). Conclusions: Our data show that smoking induces an early impairment of endothelium-independent arterial dilatation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031984</affiliation-url><afid>60031984</afid><affilname>Universita Cattolica del Sacro Cuore, Rome</affilname><name-variant>Catholic University</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35428525600</author-url><authid>35428525600</authid><authname>Lanza G.</authname><surname>Lanza</surname><given-name>Gaetano A.</given-name><initials>G.A.</initials><afid>60031984</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56583947800</author-url><authid>56583947800</authid><authname>Spera F.</authname><surname>Spera</surname><given-name>Francesco R.</given-name><initials>F.R.</initials><afid>60031984</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55375495100</author-url><authid>55375495100</authid><authname>Villano A.</authname><surname>Villano</surname><given-name>Angelo</given-name><initials>A.</initials><afid>60031984</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55375529600</author-url><authid>55375529600</authid><authname>Russo G.</authname><surname>Russo</surname><given-name>Giulio</given-name><initials>G.</initials><afid>60031984</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37025809400</author-url><authid>37025809400</authid><authname>Di Franco A.</authname><surname>Di Franco</surname><given-name>Antonino</given-name><initials>A.</initials><afid>60031984</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22941669100</author-url><authid>22941669100</authid><authname>Lamendola P.</authname><surname>Lamendola</surname><given-name>Priscilla</given-name><initials>P.</initials><afid>60031984</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35371766500</author-url><authid>35371766500</authid><authname>Crea F.</authname><surname>Crea</surname><given-name>Filippo</given-name><initials>F.</initials><afid>60031984</afid></author><authkeywords>Endothelial function | Nitrate-mediated dilatation | Smoking</authkeywords><intid>1535454576</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928943560"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928943560?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928943560&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928943560&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928943560</prism:url><dc:identifier>SCOPUS_ID:84928943560</dc:identifier><eid>2-s2.0-84928943560</eid><dc:title>Feasibility of common carotid artery point of care ultrasound in cardiac output measurements compared to invasive methods</dc:title><dc:creator>Gassner M.</dc:creator><prism:publicationName>Journal of Ultrasound</prism:publicationName><prism:issn>19713495</prism:issn><prism:eIssn>18767931</prism:eIssn><prism:volume>18</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>127-133</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40477-014-0139-9</prism:doi><dc:description>© 2014, Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB). Background: Cardiac output (CO) measurement in the intensive care unit (ICU) requires invasive devices such as the pulmonary artery (PA) catheter or arterial waveform pulse contour analysis (PCA). This study tests the accuracy and feasibility of point of care ultrasound (POCUS) of the common carotid artery to estimate the CO non-invasively and compare it to existing invasive CO measurement modalities.Methods: Patients admitted to the surgical and cardiothoracic ICU in a tertiary university-affiliated academic center during a 4-month period, with invasive hemodynamic monitoring devices for management, were included in this cohort study. Common carotid artery POCUS was performed to measure the CO and the results were compared to an invasive device.Results: Intensivists and ICU fellows, using ultrasound of the common carotid artery, obtained the CO measurements. Images of the Doppler flow and volume were obtained at the level of the thyroid gland. Concurrent CO measured via invasive devices was recorded. The patient cohort comprised 36 patients; 52 % were females. The average age was 59 ± 13 years, and 66 % were monitored via PCA device and 33 % via PA catheter. Intraclass correlation coefficient (ICC) analysis demonstrated almost perfect correlation (0.8152) between measurements of CO via ultrasound vs. invasive modalities. The ICC between POCUS and the invasive measurement via PCA was 0.84 and via PA catheter 0.74, showing substantial agreement between the ultrasound and both invasive modalities.Conclusions: Common carotid artery POCUS offers a non-invasive method of measuring the CO in the critically ill population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008578</affiliation-url><afid>60008578</afid><affilname>Henry Ford Hospital</affilname><name-variant>Henry Ford Hospital</name-variant><affiliation-city>Detroit</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55972458100</author-url><authid>55972458100</authid><authname>Gassner M.</authname><surname>Gassner</surname><given-name>Marika</given-name><initials>M.</initials><afid>60008578</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35620619800</author-url><authid>35620619800</authid><authname>Killu K.</authname><surname>Killu</surname><given-name>Keith</given-name><initials>K.</initials><afid>60008578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55972320200</author-url><authid>55972320200</authid><authname>Bauman Z.</authname><surname>Bauman</surname><given-name>Zachary</given-name><initials>Z.</initials><afid>60008578</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:11739055300</author-url><authid>11739055300</authid><authname>Coba V.</authname><surname>Coba</surname><given-name>Victor</given-name><initials>V.</initials><afid>60008578</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56624182600</author-url><authid>56624182600</authid><authname>Rosso K.</authname><surname>Rosso</surname><given-name>Kelly</given-name><initials>K.</initials><afid>60008578</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16506399500</author-url><authid>16506399500</authid><authname>Blyden D.</authname><surname>Blyden</surname><given-name>Dionne</given-name><initials>D.</initials><afid>60008578</afid></author><authkeywords>Cardiac output | Carotid doppler | Point of care ultrasound | Pulmonary artery catheter | Pulse contour analysis | Ultrasound</authkeywords><intid>1785877243</intid><source-id>6400153118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929077114"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929077114?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929077114&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929077114&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929077114</prism:url><dc:identifier>SCOPUS_ID:84929077114</dc:identifier><eid>2-s2.0-84929077114</eid><dc:title>2-Methyl-4-chlorophenoxyacetic acid and bromoxynil herbicide death</dc:title><dc:creator>Berling I.</dc:creator><prism:publicationName>Clinical Toxicology</prism:publicationName><prism:issn>15563650</prism:issn><prism:eIssn>15569519</prism:eIssn><prism:volume>53</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>486-488</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.3109/15563650.2015.1030025</prism:doi><dc:description>Copyright © 2015 Informa Healthcare USA, Inc. Case report. We report a fatal case of a 37 year old gentleman who ingested a MCPA/bromoxynil co-formulation herbicide. Although clinically well on initial examination, our patient declined dramatically over his 18 h admission with increasing CO2 production, hyperthermia and metabolic derangement to eventually die from cardiac asystole 20 h post ingestion. Two hours after ingestion the MCPA concentration was 83.9 μg/mL and bromoxynil concentration was 137 μg/mL. Discussion. The patients' mechanism of death appeared to be uncoupling of oxidative phosphorylation, excess CO2 production and hyperthermia. There is limited knowledge on the acute toxicity of these herbicides, in particular bromoxynil, and this case highlights the relentless progression of severe toxicity in humans.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010571</affiliation-url><afid>60010571</afid><affilname>University of Newcastle, Australia</affilname><name-variant>University of Newcastle</name-variant><affiliation-city>Callaghan</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Calvary Mater Newcastle</affilname><name-variant>Department of Clinical Toxicology and Pharmacology</name-variant><affiliation-city>Edith St. Waratah, Newcastle</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029258</affiliation-url><afid>60029258</afid><affilname>Helwan University</affilname><name-variant>Helwan University</name-variant><affiliation-city>Cairo</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031846</affiliation-url><afid>60031846</afid><affilname>University of South Australia</affilname><name-variant>University of South Australia</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:47762136300</author-url><authid>47762136300</authid><authname>Berling I.</authname><surname>Berling</surname><given-name>Ingrid</given-name><initials>I.</initials><afid>60010571</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:47762136300</author-url><authid>47762136300</authid><authname>Berling I.</authname><surname>Berling</surname><given-name>Ingrid</given-name><initials>I.</initials><afid>60010571</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102676778</author-url><authid>7102676778</authid><authname>Buckley N.</authname><surname>Buckley</surname><given-name>Nicholas A.</given-name><initials>N.A.</initials><afid>60025709</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006119393</author-url><authid>7006119393</authid><authname>Mostafa A.</authname><surname>Mostafa</surname><given-name>Ahmed</given-name><initials>A.</initials><afid>60031004</afid><afid>60029258</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006119393</author-url><authid>7006119393</authid><authname>Mostafa A.</authname><surname>Mostafa</surname><given-name>Ahmed</given-name><initials>A.</initials><afid>60031004</afid><afid>60029258</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8599138300</author-url><authid>8599138300</authid><authname>Downes M.</authname><surname>Downes</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>60010571</afid><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8599138300</author-url><authid>8599138300</authid><authname>Downes M.</authname><surname>Downes</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>60010571</afid><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7103269259</author-url><authid>7103269259</authid><authname>Grice J.</authname><surname>Grice</surname><given-name>Jeffrey</given-name><initials>J.</initials><afid>60031004</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36797040500</author-url><authid>36797040500</authid><authname>Medley G.</authname><surname>Medley</surname><given-name>Gregory</given-name><initials>G.</initials><afid>60031004</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404029879</author-url><authid>7404029879</authid><authname>Roberts M.</authname><surname>Roberts</surname><given-name>Michael S.</given-name><initials>M.S.</initials><afid>60031004</afid><afid>60031846</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404029879</author-url><authid>7404029879</authid><authname>Roberts M.</authname><surname>Roberts</surname><given-name>Michael S.</given-name><initials>M.S.</initials><afid>60031004</afid><afid>60031846</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:34975054300</author-url><authid>34975054300</authid><authname>Isbister G.</authname><surname>Isbister</surname><given-name>Geoffrey K.</given-name><initials>G.K.</initials><afid>60010571</afid><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:34975054300</author-url><authid>34975054300</authid><authname>Isbister G.</authname><surname>Isbister</surname><given-name>Geoffrey K.</given-name><initials>G.K.</initials><afid>60010571</afid><afid/></author><authkeywords>2-Methyl-4-chlorophenoxyacetic Acid | Herbicides | Overdose, Poisoning, Uncoupling agents, Analysis, Bromoxynil, Death</authkeywords><intid>2035895268</intid><source-id>4000148406</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923075961"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923075961?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923075961&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923075961&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0272494415000183"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923075961</prism:url><dc:identifier>SCOPUS_ID:84923075961</dc:identifier><eid>2-s2.0-84923075961</eid><dc:title>"Now we understand what community really means": Reconceptualizing the role of sense of place in the disaster recovery process</dc:title><dc:creator>Silver A.</dc:creator><prism:publicationName>Journal of Environmental Psychology</prism:publicationName><prism:issn>02724944</prism:issn><prism:eIssn>15229610</prism:eIssn><prism:volume>42</prism:volume><prism:pageRange>32-41</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jenvp.2015.01.004</prism:doi><pii>S0272494415000183</pii><dc:description>© 2015 Elsevier Ltd. This study examines the impacts of the F3 tornado that struck the commercial and civic heart of the community of Goderich, Ontario, Canada on 21 August 2011. Using semi-structured interviews (n=35) and close-ended questionnaires (n=268), issues relating to sense of place and long-term recovery were explored. Many residents-not merely those directly impacted by the tornado-expressed feelings of loss, worry, and grief as a result of the changes to their familiar landscapes. However, participants also relayed positive outcomes stemming from their shared experiences during and after the disaster, including strong feelings of social cohesion and optimism that persisted well beyond the short-term "honeymoon phase" predicted by the literature. Drawing on and extending recent discussion of "disorientation" and "reorientation" in relation to the disaster-response-recovery experience, this paper contributes to the literature on natural disasters and sense of place.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014171</affiliation-url><afid>60014171</afid><affilname>University of Waterloo</affilname><name-variant>Univ of Waterloo</name-variant><affiliation-city>Waterloo</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016297</affiliation-url><afid>60016297</afid><affilname>Saint Mary's University</affilname><name-variant>Saint Mary's University</name-variant><affiliation-city>Halifax</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55643102600</author-url><authid>55643102600</authid><authname>Silver A.</authname><surname>Silver</surname><given-name>Amber</given-name><initials>A.</initials><afid>60014171</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:21734384000</author-url><authid>21734384000</authid><authname>Grek-Martin J.</authname><surname>Grek-Martin</surname><given-name>Jason</given-name><initials>J.</initials><afid>60016297</afid></author><authkeywords>Disaster recovery | Disorientation/reorientation | Environmental aesthetics | Place attachment | Sense of place</authkeywords><intid>1784918850</intid><source-id>15470</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929091280"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929091280?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929091280&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929091280&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929091280</prism:url><dc:identifier>SCOPUS_ID:84929091280</dc:identifier><eid>2-s2.0-84929091280</eid><dc:title>Acute toxicity profile of tolperisone in overdose: Observational poison centre-based study</dc:title><dc:creator>Martos V.</dc:creator><prism:publicationName>Clinical Toxicology</prism:publicationName><prism:issn>15563650</prism:issn><prism:eIssn>15569519</prism:eIssn><prism:volume>53</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>470-476</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.3109/15563650.2015.1022896</prism:doi><dc:description>© 2015 Informa Healthcare USA, Inc. Introduction. Tolperisone is a centrally acting muscle relaxant that acts by blocking voltage-gated sodium and calcium channels. There is a lack of information on the clinical features of tolperisone poisoning in the literature. The aim of this study was to investigate the demographics, circumstances and clinical features of acute overdoses with tolperisone. Methods. An observational study of acute overdoses of tolperisone, either alone or in combination with one non-steroidal anti-inflammatory drug in a dose range not expected to cause central nervous system effects, in adults and children (&lt; 16 years), reported to our poison centre between 1995 and 2013. Results. 75 cases were included: 51 females (68%) and 24 males (32%); 45 adults (60%) and 30 children (40%). Six adults (13%) and 17 children (57%) remained asymptomatic, and mild symptoms were seen in 25 adults (56%) and 10 children (33%). There were nine adults (20%) with moderate symptoms, and five adults (11%) and three children (10%) with severe symptoms. Signs and symptoms predominantly involved the central nervous system: somnolence, coma, seizures and agitation. Furthermore, some severe cardiovascular and respiratory signs and symptoms were reported. The minimal dose for seizures and severe symptoms in adults was 1500 mg. In 11 cases the latency between the ingestion and the onset of symptoms was known and was reported to be 0.5-1.5 h. Conclusions. The acute overdose of tolperisone may be life-threatening, with a rapid onset of severe neurological, respiratory and cardiovascular symptoms. With alternative muscle relaxants available, indications for tolperisone should be rigorously evaluated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012614</affiliation-url><afid>60012614</afid><affilname>Universitat Zurich</affilname><name-variant>University of Zurich</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019619</affiliation-url><afid>60019619</afid><affilname>UniversitatsSpital Zurich</affilname><name-variant>University Hospital Zurich</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:43761304000</author-url><authid>43761304000</authid><authname>Martos V.</authname><surname>Martos</surname><given-name>Viktor</given-name><initials>V.</initials><afid>60012614</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36970487100</author-url><authid>36970487100</authid><authname>Hofer K.</authname><surname>Hofer</surname><given-name>Katharina E.</given-name><initials>K.E.</initials><afid>60012614</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26538808800</author-url><authid>26538808800</authid><authname>Rauber-Lüthy C.</authname><surname>Rauber-Lüthy</surname><given-name>Christine</given-name><initials>C.</initials><afid>60012614</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55183881000</author-url><authid>55183881000</authid><authname>Schenk-Jaeger K.</authname><surname>Schenk-Jaeger</surname><given-name>Katharina M.</given-name><initials>K.M.</initials><afid>60012614</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005181519</author-url><authid>7005181519</authid><authname>Kupferschmidt H.</authname><surname>Kupferschmidt</surname><given-name>Hugo</given-name><initials>H.</initials><afid>60012614</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35867812100</author-url><authid>35867812100</authid><authname>Ceschi A.</authname><surname>Ceschi</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60012614</afid><afid>60019619</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35867812100</author-url><authid>35867812100</authid><authname>Ceschi A.</authname><surname>Ceschi</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60012614</afid><afid>60019619</afid></author><authkeywords>Centrally acting muscle relaxant | Poisoning | Seizures | Sodium channel blocker | Toxicity</authkeywords><intid>535902492</intid><source-id>4000148406</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928893080"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928893080?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928893080&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928893080&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928893080</prism:url><dc:identifier>SCOPUS_ID:84928893080</dc:identifier><eid>2-s2.0-84928893080</eid><dc:title>Routine use of fluorescent incisionless cholangiography as a new imaging modality during laparoscopic cholecystectomy</dc:title><dc:creator>Dip F.</dc:creator><prism:publicationName>Surgical Endoscopy and Other Interventional Techniques</prism:publicationName><prism:issn>09302794</prism:issn><prism:eIssn>14322218</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1621-1626</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00464-014-3853-7</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Background: Intraoperative incisionless fluorescent cholangiography (IOIFC) has been described to identify extrahepatic biliary anatomy. Potential advantages of the routine use of intraoperative incisionless fluorescent cholangiography were evaluated in a consecutive series of cases. Methods: A total of 45 patients undergoing laparoscopic cholecystectomy between January and July 2013 were consented and included in this study. We analyzed a prospectively collected database for feasibility, cost, time, usefulness, teaching tool, safety, learning curve, X-ray exposure, complexity, and real-time surgery of IOIFC. A single dose of 0.05 mg/kg of Indocyanine green was administered prior to surgery. During the procedure, a laparoscopic fluorescence system was used. Results: IOIFC could be performed in all 45 patients, whereas intraoperative cholangiography could be performed in 42 (93 %). Individual median cost of performing IOFC was cheaper than IOC (13.97 ± 4.3 vs 778.43 ± 0.4 USD) per patient, p = 0.0001). IOFC was faster than IOC (0.71 ± 0.26 vs 7.15 ± 3.76 minutes, p &lt; 0.0001). The cystic duct was identified by IOFC in 44 out of 45 patients (97.77 %). Conclusion: IOIFC appears to be a feasible, low-cost, expeditious, useful, and effective imaging modality when performing LC. It is safe, easy to perform and interpret, and does not require a learning curve or X-ray. It can be used for real time surgery to delineate the extrahepatic biliary structures</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029770</affiliation-url><afid>60029770</afid><affilname>Cleveland Clinic Florida</affilname><name-variant>Cleveland Clinic Florida</name-variant><affiliation-city>Fort Lauderdale</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55946496900</author-url><authid>55946496900</authid><authname>Dip F.</authname><surname>Dip</surname><given-name>Fernando</given-name><initials>F.</initials><afid>60029770</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:52564354400</author-url><authid>52564354400</authid><authname>Roy M.</authname><surname>Roy</surname><given-name>Mayank</given-name><initials>M.</initials><afid>60029770</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6504275616</author-url><authid>6504275616</authid><authname>Menzo E.</authname><surname>Menzo</surname><given-name>Emanuele Lo</given-name><initials>E.L.</initials><afid>60029770</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8233694500</author-url><authid>8233694500</authid><authname>Simpfendorfer C.</authname><surname>Simpfendorfer</surname><given-name>Conrad</given-name><initials>C.</initials><afid>60029770</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603435372</author-url><authid>6603435372</authid><authname>Szomstein S.</authname><surname>Szomstein</surname><given-name>Samuel</given-name><initials>S.</initials><afid>60029770</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35592115900</author-url><authid>35592115900</authid><authname>Rosenthal R.</authname><surname>Rosenthal</surname><given-name>Raul J.</given-name><initials>R.J.</initials><afid>60029770</afid></author><authkeywords>CBD (Common Bile Duct) | Cholecystectomy | Gut | Imaging &amp; VR</authkeywords><intid>1785862765</intid><source-id>19196</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926285281"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926285281?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926285281&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926285281&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926285281</prism:url><dc:identifier>SCOPUS_ID:84926285281</dc:identifier><eid>2-s2.0-84926285281</eid><dc:title>Angiostrongylus vasorum infection in red foxes (Vulpes vulpes) in southern Italy</dc:title><dc:creator>Santoro M.</dc:creator><prism:publicationName>Acta Parasitologica</prism:publicationName><prism:issn>12302821</prism:issn><prism:volume>60</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>356-359</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1515/ap-2015-0050</prism:doi><dc:description>© 2015 W. Stefański Institute of Parasitology, PAS. Angiostrongylus vasorum (Nematoda: Angiostrongylidae) infection was detected at post-mortem examination in the pulmonary arteries and hearts of 34/102 (33,3%) of red foxes (Vulpes vulpes) from the Campania Region in southern Italy. Pathological changes consisted of granulomatous interstitial pneumonia caused by larvae and intravascular pulmonary adult nematodes. These changes confirm that angiostrongylosis infection in red foxes has a mainly chronic course, in which the infected host may disperse parasite larvae in the environment over its lifetime. Results suggest that the life cycle of A. vasorum is well established in the red fox in the Campania Region representing a potential infection risk for dogs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60083734</affiliation-url><afid>60083734</afid><affilname>Istituto Zooprofilattico Sperimentale del Mezzogiorno</affilname><name-variant>Istituto Zooprofilattico Sperimentale del Mezzogiorno</name-variant><affiliation-city>Portici</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56450180100</author-url><authid>56450180100</authid><authname>Santoro M.</authname><surname>Santoro</surname><given-name>Mario</given-name><initials>M.</initials><afid>60032350</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55541470500</author-url><authid>55541470500</authid><authname>D'Alessio N.</authname><surname>D'Alessio</surname><given-name>Nicola</given-name><initials>N.</initials><afid>60083734</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55541859600</author-url><authid>55541859600</authid><authname>Di Prisco F.</authname><surname>Di Prisco</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60083734</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56109608300</author-url><authid>56109608300</authid><authname>Neola B.</authname><surname>Neola</surname><given-name>Benedetto</given-name><initials>B.</initials><afid>60017293</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701792412</author-url><authid>6701792412</authid><authname>Restucci B.</authname><surname>Restucci</surname><given-name>Brunella</given-name><initials>B.</initials><afid>60017293</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55771124100</author-url><authid>55771124100</authid><authname>Pagano T.</authname><surname>Pagano</surname><given-name>Teresa B.</given-name><initials>T.B.</initials><afid>60017293</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603150762</author-url><authid>6603150762</authid><authname>Veneziano V.</authname><surname>Veneziano</surname><given-name>Vincenzo</given-name><initials>V.</initials><afid>60017293</afid></author><authkeywords>Angiostrongylus vasorum | cardiopulmonary infection | red fox | Vulpes vulpes</authkeywords><intid>1035426079</intid><source-id>19092</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928981481"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928981481?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928981481&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928981481&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928981481</prism:url><dc:identifier>SCOPUS_ID:84928981481</dc:identifier><eid>2-s2.0-84928981481</eid><dc:title>Increasing signal processing sophistication in the calculation of the respiratory modulation of the photoplethysmogram (DPOP)</dc:title><dc:creator>Addison P.</dc:creator><prism:publicationName>Journal of Clinical Monitoring and Computing</prism:publicationName><prism:issn>13871307</prism:issn><prism:eIssn>15732614</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>363-372</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10877-014-9613-3</prism:doi><dc:description>© 2014, The Author(s). DPOP (∆POP or Delta-POP) is a non-invasive parameter which measures the strength of respiratory modulations present in the pulse oximetry photoplethysmogram (pleth) waveform. It has been proposed as a non-invasive surrogate parameter for pulse pressure variation (PPV) used in the prediction of the response to volume expansion in hypovolemic patients. Many groups have reported on the DPOP parameter and its correlation with PPV using various semi-automated algorithmic implementations. The study reported here demonstrates the performance gains made by adding increasingly sophisticated signal processing components to a fully automated DPOP algorithm. A DPOP algorithm was coded and its performance systematically enhanced through a series of code module alterations and additions. Each algorithm iteration was tested on data from 20 mechanically ventilated OR patients. Correlation coefficients and ROC curve statistics were computed at each stage. For the purposes of the analysis we split the data into a manually selected ‘stable’ region subset of the data containing relatively noise free segments and a ‘global’ set incorporating the whole data record. Performance gains were measured in terms of correlation against PPV measurements in OR patients undergoing controlled mechanical ventilation. Through increasingly advanced pre-processing and post-processing enhancements to the algorithm, the correlation coefficient between DPOP and PPV improved from a baseline value of R = 0.347 to R = 0.852 for the stable data set, and, correspondingly, R = 0.225 to R = 0.728 for the more challenging global data set. Marked gains in algorithm performance are achievable for manually selected stable regions of the signals using relatively simple algorithm enhancements. Significant additional algorithm enhancements, including a correction for low perfusion values, were required before similar gains were realised for the more challenging global data set.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60093273</affiliation-url><afid>60093273</afid><affilname>Covidien</affilname><name-variant>Covidien Inc.</name-variant><affiliation-city>Mansfield</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006372605</author-url><authid>7006372605</authid><authname>Addison P.</authname><surname>Addison</surname><given-name>Paul S.</given-name><initials>P.S.</initials><afid>60093273</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56625358500</author-url><authid>56625358500</authid><authname>Wang R.</authname><surname>Wang</surname><given-name>Rui</given-name><initials>R.</initials><afid>60093273</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55385549800</author-url><authid>55385549800</authid><authname>Uribe A.</authname><surname>Uribe</surname><given-name>Alberto A.</given-name><initials>A.A.</initials><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56530467700</author-url><authid>56530467700</authid><authname>Bergese S.</authname><surname>Bergese</surname><given-name>Sergio D.</given-name><initials>S.D.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56530467700</author-url><authid>56530467700</authid><authname>Bergese S.</authname><surname>Bergese</surname><given-name>Sergio D.</given-name><initials>S.D.</initials><afid>60003500</afid><afid>60003500</afid></author><authkeywords>DPOP | Fluid responsiveness | Hemodynamic monitoring | PPV | Pulse oximetry</authkeywords><intid>1535884466</intid><source-id>15872</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923867447"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923867447?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923867447&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923867447&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0195666315000562"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923867447</prism:url><dc:identifier>SCOPUS_ID:84923867447</dc:identifier><eid>2-s2.0-84923867447</eid><dc:title>Consumption of a high-fat soup preload leads to differences in short-term energy and fat intake between PROP non-taster and super-taster women</dc:title><dc:creator>Shafaie Y.</dc:creator><prism:publicationName>Appetite</prism:publicationName><prism:issn>01956663</prism:issn><prism:eIssn>10958304</prism:eIssn><prism:volume>89</prism:volume><prism:pageRange>196-202</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.appet.2015.02.009</prism:doi><pii>S0195666315000562</pii><dc:description>© 2015 Elsevier Ltd. Taste blindness to the bitterness of PROP (6-n-propylthiouracil) has been used as a genetic marker for food selection and adiposity. We have shown that PROP non-taster (NT) women have higher BMIs and habitually consume more fat and energy than either medium-taster (MT) or super-taster (ST) women. These data imply that differences in dietary selection underlie the body weight differences among PROP taster groups. However, no studies investigated energy compensation in women classified by PROP status. We investigated if NTs would compensate less accurately for the calories and fat in a high-fat soup preload in a subsequent test meal compared to MTs and STs. Energy intake from a buffet meal was measured in 75 healthy non-diet-restrained, lean women 30 min after the ingestion of a high-fat soup preload (0.8 kcal/g; 55% calories from fat), calculated to represent 10% of resting energy expenditure for each subject, or the same volume of water. Subjects (n = 20-28/taster group) ate a standard breakfast followed 3 hr later by an ad-libitum buffet lunch, on two occasions. There were no differences in energy intake or macronutrient selection across taster groups after water. After soup, NTs consumed more energy than STs. Fat intake (as %-energy) was higher in NTs (46.4% ± 2.4) compared to either MTs (36.1 ± 1.9%) or STs (38.1% ± 2.3; p &lt; 0.05). NTs overate by 11% ± 5 after the soup compared to MTs and STs who underrate by 16% ± 6 and 26% ± 10, respectively (p &lt; 0.01). These data suggest that small discrepancies in short-term energy compensation and selection of fat after a mixed-nutrient, high-fat preload may play a role in positive energy balance and increased adiposity in women with the PROP non-taster phenotype.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030623</affiliation-url><afid>60030623</afid><affilname>Rutgers, The State University of New Jersey</affilname><name-variant>Rutgers University</name-variant><affiliation-city>New Brunswick</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030623</affiliation-url><afid>60030623</afid><affilname>Rutgers, The State University of New Jersey</affilname><name-variant>Rutgers University</name-variant><affiliation-city>New Brunswick</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55938342100</author-url><authid>55938342100</authid><authname>Shafaie Y.</authname><surname>Shafaie</surname><given-name>Yasmine</given-name><initials>Y.</initials><afid>60030623</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24074412400</author-url><authid>24074412400</authid><authname>Hoffman D.</authname><surname>Hoffman</surname><given-name>Daniel J.</given-name><initials>D.J.</initials><afid>60030623</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005360540</author-url><authid>7005360540</authid><authname>Tepper B.</authname><surname>Tepper</surname><given-name>Beverly J.</given-name><initials>B.J.</initials><afid>60030623</afid></author><authkeywords>Energy compensation | Fat intake | Preload | PROP status</authkeywords><intid>35078822</intid><source-id>29994</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928545405"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928545405?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928545405&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928545405&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1201971215000892"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928545405</prism:url><dc:identifier>SCOPUS_ID:84928545405</dc:identifier><eid>2-s2.0-84928545405</eid><dc:title>A case of infectious endocarditis due to BCG</dc:title><dc:creator>Fournier A.</dc:creator><prism:publicationName>International Journal of Infectious Diseases</prism:publicationName><prism:issn>12019712</prism:issn><prism:eIssn>18783511</prism:eIssn><prism:volume>35</prism:volume><prism:pageRange>e27-e28</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijid.2015.04.003</prism:doi><pii>S1201971215000892</pii><dc:description>© 2015 The Authors. The occurrence of bacillus Calmette-Guérin (BCG) disease following instillation for bladder cancer is commonly documented. The intravesical administration of BCG is generally safe, but may present severe complications. A fatal case of native aortic valve infectious endocarditis with septicemia due to BCG in a patient treated with intravesical instillation is reported herein.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024144</affiliation-url><afid>60024144</afid><affilname>Hopital La Timone</affilname><name-variant>CHU Timone</name-variant><affiliation-city>Marseille</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102127</affiliation-url><afid>60102127</afid><affilname>Aix Marseille Universite</affilname><name-variant>Aix-Marseille University</name-variant><affiliation-city>Marseille</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024144</affiliation-url><afid>60024144</afid><affilname>Hopital La Timone</affilname><name-variant>CHU Timone</name-variant><affiliation-city>Marseille</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56606703700</author-url><authid>56606703700</authid><authname>Fournier A.</authname><surname>Fournier</surname><given-name>Alice</given-name><initials>A.</initials><afid>60024144</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506398797</author-url><authid>6506398797</authid><authname>Gouriet F.</authname><surname>Gouriet</surname><given-name>Frédérique</given-name><initials>F.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506398797</author-url><authid>6506398797</authid><authname>Gouriet F.</authname><surname>Gouriet</surname><given-name>Frédérique</given-name><initials>F.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202879683</author-url><authid>7202879683</authid><authname>Fournier P.</authname><surname>Fournier</surname><given-name>Pierre Edouard</given-name><initials>P.E.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202879683</author-url><authid>7202879683</authid><authname>Fournier P.</authname><surname>Fournier</surname><given-name>Pierre Edouard</given-name><initials>P.E.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603846304</author-url><authid>6603846304</authid><authname>Casalta J.</authname><surname>Casalta</surname><given-name>Jean Paul</given-name><initials>J.P.</initials><afid>60024144</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55371987500</author-url><authid>55371987500</authid><authname>Saby L.</authname><surname>Saby</surname><given-name>Ludivine</given-name><initials>L.</initials><afid>60024144</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56496467200</author-url><authid>56496467200</authid><authname>Habib G.</authname><surname>Habib</surname><given-name>Gilbert</given-name><initials>G.</initials><afid>60024144</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35232870100</author-url><authid>35232870100</authid><authname>Drancourt M.</authname><surname>Drancourt</surname><given-name>Michel</given-name><initials>M.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35232870100</author-url><authid>35232870100</authid><authname>Drancourt M.</authname><surname>Drancourt</surname><given-name>Michel</given-name><initials>M.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36040059800</author-url><authid>36040059800</authid><authname>Raoult D.</authname><surname>Raoult</surname><given-name>Didier</given-name><initials>D.</initials><afid>60024144</afid><afid>60102127</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36040059800</author-url><authid>36040059800</authid><authname>Raoult D.</authname><surname>Raoult</surname><given-name>Didier</given-name><initials>D.</initials><afid>60024144</afid><afid>60102127</afid></author><authkeywords>BCG | Endocarditis | Mycobacterium bovis</authkeywords><intid>1535801046</intid><source-id>22380</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923134020"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923134020?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923134020&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923134020&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S8756328215000411"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923134020</prism:url><dc:identifier>SCOPUS_ID:84923134020</dc:identifier><eid>2-s2.0-84923134020</eid><dc:title>The decrease in silicon concentration of the connective tissues with age in rats is a marker of connective tissue turnover</dc:title><dc:creator>Jugdaohsingh R.</dc:creator><prism:publicationName>Bone</prism:publicationName><prism:issn>87563282</prism:issn><prism:volume>75</prism:volume><prism:pageRange>40-48</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bone.2015.02.004</prism:doi><pii>S8756328215000411</pii><dc:description>© 2015. Silicon may be important for bone and connective tissue health. Higher concentrations of silicon are suggested to be associated with bone and the connective tissues, compared with the non-connective soft tissues. Moreover, in connective tissues it has been suggested that silicon levels may decrease with age based upon analyses of human aorta. These claims, however, have not been tested under controlled conditions. Here connective and non-connective tissues were collected and analysed for silicon levels from female Sprague-Dawley rats of different ages (namely, 3, 5, 8, 12, 26 and 43. weeks; n = 8-10 per age group), all maintained on the same feed source and drinking water, and kept in the same environment from weaning to adulthood. Tissues (696 samples) were digested in nitric acid and analysed by inductively coupled plasma optical emission spectrometry for total silicon content. Fasting serum samples were also collected, diluted and analysed for silicon. Higher concentrations of silicon (up to 50-fold) were found associated with bone and the connective tissues compared with the non-connective tissues. Although total silicon content increased with age in all tissues, the highest connective tissue silicon concentrations (up to 9.98. μg/g wet weight) were found in young weanling rats, decreasing thereafter with age (by 2-6 fold). Fasting serum silicon concentrations reflected the pattern of connective tissue silicon concentrations and, both measures, when compared to collagen data from a prior experiment in Sprague-Dawley rats, mirrored type I collagen turnover with age. Our findings confirm the link between silicon and connective tissues and would imply that young growing rats have proportionally higher requirements for dietary silicon than mature adults, for bone and connective tissue development, although this was not formally investigated here. However, estimation of total body silicon content suggested that actual Si requirements may be substantially lower than previously estimated which could explain why absolute silicon deficiency is difficult to achieve but, when it is achieved in young growing animals, it results in stunted growth and abnormal development of bone and other connective tissues.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015394</affiliation-url><afid>60015394</afid><affilname>MRC Human Nutrition Research</affilname><name-variant>MRC Human Nutrition Research</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000891</affiliation-url><afid>60000891</afid><affilname>Loughborough University</affilname><name-variant>Loughborough University</name-variant><affiliation-city>Loughborough</affiliation-city><affiliation-country/></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603862985</author-url><authid>6603862985</authid><authname>Jugdaohsingh R.</authname><surname>Jugdaohsingh</surname><given-name>Ravin</given-name><initials>R.</initials><afid>60015394</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56506165500</author-url><authid>56506165500</authid><authname>Watson A.</authname><surname>Watson</surname><given-name>Abigail I E</given-name><initials>A.I.E.</initials><afid>60015394</afid><afid>60000891</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56506165500</author-url><authid>56506165500</authid><authname>Watson A.</authname><surname>Watson</surname><given-name>Abigail I E</given-name><initials>A.I.E.</initials><afid>60015394</afid><afid>60000891</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56522731800</author-url><authid>56522731800</authid><authname>Pedro L.</authname><surname>Pedro</surname><given-name>Liliana D.</given-name><initials>L.D.</initials><afid>60015394</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55551662400</author-url><authid>55551662400</authid><authname>Powell J.</authname><surname>Powell</surname><given-name>Jonathan J.</given-name><initials>J.J.</initials><afid>60015394</afid></author><authkeywords>Collagen | Connective tissues | Growth &amp; development | Silicon requirement | Silicon status | Whole body Si content</authkeywords><intid>534933393</intid><source-id>29551</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928815163"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928815163?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928815163&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928815163&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928815163</prism:url><dc:identifier>SCOPUS_ID:84928815163</dc:identifier><eid>2-s2.0-84928815163</eid><dc:title>Environmental heat exposure and cognitive performance in older adults: a controlled trial</dc:title><dc:creator>Trezza B.</dc:creator><prism:publicationName>Age</prism:publicationName><prism:issn>01619152</prism:issn><prism:eIssn>15744647</prism:eIssn><prism:volume>37</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11357-015-9783-z</prism:doi><dc:description>© 2015, American Aging Association. Thermal stress has a negative effect on the cognitive performance of military personnel and industry workers exposed to extreme environments. However, no studies have investigated the effects of environmental thermal stress on the cognitive functions of older adults. We carried out a controlled trial with 68 healthy older adults (mean age 73.3 years, 69 % female), each of whom has been assessed twice on the same day with selected tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB). Repeated sessions were conducted with air temperatures set at 24 °C and 32 °C in a balanced order. Our primary analyses did not show significant differences when comparing the cognitive performance of the total sample under the two experimental temperatures. However, interaction analysis has shown that humidity levels modify the effect of temperature on cognitive outcomes. The subgroup exposed to relative humidity greater than the median value (57.8 %) presented worse cognitive performance in the heat session when compared to the control session. Reported exercising frequency explained individual vulnerability to heat stress. Volunteers with lower levels of physical activity (&lt;4 times per week) were more likely to present worsened cognitive performance under heat stress. In a fully adjusted linear regression model, the performance under heat stress remained associated with relative humidity (β = −0.21; p = 0.007) and frequency of exercising (β = 0.18; p = 0.020). Our results indicate that heat stress may have detrimental effects on the cognitive functioning of some subgroups of older adults and under particular circumstances. Further research is needed for exploring a variety of potentially influential factors.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56239873400</author-url><authid>56239873400</authid><authname>Trezza B.</authname><surname>Trezza</surname><given-name>Beatriz Maria</given-name><initials>B.M.</initials><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36027913700</author-url><authid>36027913700</authid><authname>Apolinario D.</authname><surname>Apolinario</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56612807100</author-url><authid>56612807100</authid><authname>de Oliveira R.</authname><surname>de Oliveira</surname><given-name>Rafaela Sanchez</given-name><initials>R.S.</initials><afid>60008088</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35182735200</author-url><authid>35182735200</authid><authname>Busse A.</authname><surname>Busse</surname><given-name>Alexandre Leopold</given-name><initials>A.L.</initials><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006464542</author-url><authid>7006464542</authid><authname>Gonçalves F.</authname><surname>Gonçalves</surname><given-name>Fábio Luiz Teixeira</given-name><initials>F.L.T.</initials><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35379363900</author-url><authid>35379363900</authid><authname>Saldiva P.</authname><surname>Saldiva</surname><given-name>Paulo Hilário Nascimento</given-name><initials>P.H.N.</initials><afid>60008088</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55894748400</author-url><authid>55894748400</authid><authname>Jacob-Filho W.</authname><surname>Jacob-Filho</surname><given-name>Wilson</given-name><initials>W.</initials><afid>60008088</afid></author><authkeywords>Aged | Cognitive manifestations | Environmental exposure | Heat stress | Hot temperature | Neuropsychological test</authkeywords><intid>1535850713</intid><source-id>40283</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928341358"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928341358?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928341358&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928341358&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928341358</prism:url><dc:identifier>SCOPUS_ID:84928341358</dc:identifier><eid>2-s2.0-84928341358</eid><dc:title>Update on Blood Pressure Goals in Diabetes Mellitus</dc:title><dc:creator>Laffin L.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0591-y</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The most recent guideline statements by the 2014 Expert Panel of the National Institutes of Health as well as the American and International Societies of Hypertension recommend a blood pressure goal of &lt;140/90 mmHg in patients with diabetes mellitus. This follows prior guidelines that recommended lower BP treatment goals of &lt;130/80 mmHg in patients with diabetes. Reducing cardiovascular morbidity and mortality by trying to achieve recommended goals of risk factors like blood pressure, glucose, and cholesterol in patients with diabetes is paramount. Data from multiple trials demonstrates that early treatment of hypertension in people with diabetes clearly prevents both macrovascular and microvascular complications, but the goal blood pressure that should be achieved is now modified to a higher level. We address the evidence and evolution of how and why this blood pressure goal has changed in recent years.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029278</affiliation-url><afid>60029278</afid><affilname>University of Chicago</affilname><name-variant>University of Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029278</affiliation-url><afid>60029278</afid><affilname>University of Chicago</affilname><name-variant>University of Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56019218100</author-url><authid>56019218100</authid><authname>Laffin L.</authname><surname>Laffin</surname><given-name>Luke J.</given-name><initials>L.J.</initials><afid>60029278</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35371943700</author-url><authid>35371943700</authid><authname>Bakris G.</authname><surname>Bakris</surname><given-name>George L.</given-name><initials>G.L.</initials><afid>60029278</afid></author><authkeywords>Diabetes mellitus | Guidelines | Hypertension</authkeywords><intid>1785768290</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930206354"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930206354?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930206354&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930206354&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930206354</prism:url><dc:identifier>SCOPUS_ID:84930206354</dc:identifier><eid>2-s2.0-84930206354</eid><dc:title>Tailoring Ru&lt;sup&gt;II&lt;/sup&gt; pyridine/triazole oxygenation catalysts and using photoreactivity to probe their electronic properties</dc:title><dc:creator>Weisser F.</dc:creator><prism:publicationName>Chemistry - A European Journal</prism:publicationName><prism:issn>09476539</prism:issn><prism:eIssn>15213765</prism:eIssn><prism:volume>21</prism:volume><prism:issueIdentifier>24</prism:issueIdentifier><prism:pageRange>8926-8938</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1002/chem.201406441</prism:doi><dc:description>© 2015 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim. Tuning of ligand properties is at the heart of influencing chemical reactivity and generating tailor-made catalysts. Herein, three series of complexes [Ru(L)(Cl)(X)]PF&lt;inf&gt;6&lt;/inf&gt; (X=DMSO, PPh&lt;inf&gt;3&lt;/inf&gt;, or CD&lt;inf&gt;3&lt;/inf&gt;CN) with tripodal ligands (L1-L5) containing pyridine and triazole arms are presented. Triazole-for-pyridine substitution and the substituent at the triazole systematically influence the redox behavior and photoreactivity of the complexes. The mechanism of the light-driven ligand exchange of the DMSO complexes in CD&lt;inf&gt;3&lt;/inf&gt;CN could be elucidated, and two seven-coordinate intermediates were identified. Finally, tuning of the ligand framework was applied to the catalytic oxygenation of alkanes, for which the DMSO complexes were the best catalysts and the yield improved with increasing number of triazole arms. These results thus show how click-derived ligands can be tuned on demand for catalytic processes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030718</affiliation-url><afid>60030718</afid><affilname>Freie Universitat Berlin</affilname><name-variant>Freie Universität Berlin</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35073258600</author-url><authid>35073258600</authid><authname>Weisser F.</authname><surname>Weisser</surname><given-name>Fritz</given-name><initials>F.</initials><afid>60030718</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640787900</author-url><authid>56640787900</authid><authname>Stevens H.</authname><surname>Stevens</surname><given-name>Hendrik</given-name><initials>H.</initials><afid>60030718</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25321116900</author-url><authid>25321116900</authid><authname>Klein J.</authname><surname>Klein</surname><given-name>Johannes</given-name><initials>J.</initials><afid>60030718</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56303579000</author-url><authid>56303579000</authid><authname>Van Der Meer M.</authname><surname>Van Der Meer</surname><given-name>Margarethe</given-name><initials>M.</initials><afid>60030718</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:42061562400</author-url><authid>42061562400</authid><authname>Hohloch S.</authname><surname>Hohloch</surname><given-name>Stephan</given-name><initials>S.</initials><afid>60030718</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7202875667</author-url><authid>7202875667</authid><authname>Sarkar B.</authname><surname>Sarkar</surname><given-name>Biprajit</given-name><initials>B.</initials><afid>60030718</afid></author><authkeywords>N ligands | oxygenation | photochemistry | ruthenium | tripodal ligands</authkeywords><intid>1786087398</intid><source-id>23392</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928910616"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928910616?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928910616&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928910616&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928910616</prism:url><dc:identifier>SCOPUS_ID:84928910616</dc:identifier><eid>2-s2.0-84928910616</eid><dc:title>Robotic right colectomy with intracorporeal anastomosis compared with laparoscopic right colectomy with extracorporeal and intracorporeal anastomosis: a retrospective multicentre study</dc:title><dc:creator>Trastulli S.</dc:creator><prism:publicationName>Surgical Endoscopy and Other Interventional Techniques</prism:publicationName><prism:issn>09302794</prism:issn><prism:eIssn>14322218</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1512-1521</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00464-014-3835-9</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Background: Growing evidence suggests that the intracorporeal fashioning of an anastomosis after a laparoscopic right colectomy may offer several advantages. However, due to the difficulty of the intracorporeal technique, laparoscopic extracorporeal confectioning of the anastomosis remains the most widely adopted technique. Although the purpose of the robotic approach was to overcome the limitations of the laparoscopic technique and to simplify the most demanding surgical procedures, such as performing an intracorporeal anastomosis, evidence is lacking that compares the robotic right colectomy with intracorporeal anastomosis (RRCIA) technique with both the conventional laparoscopic right colectomy with extracorporeal anastomosis (LRCEA) and the laparoscopic right colectomy with intracorporeal anastomosis confectioning (LRCIA) techniques. This study aims to compare the intraoperative and postoperative outcomes of the RRCIA to those of both the LRCEA and the LRCIA. Methods: A retrospective review of a prospectively maintained database of two Italian centres was performed on the data on patients undergoing an RRCIA, LRCEA or LRCIA for cancer or adenomas. Results: Two hundred and thirty-six patients (RRCIA = 102, LRCEA = 94, LRCIA = 40) met the criteria for inclusion in the study. The three groups were comparable in their demographic and baseline characteristics. No significant differences were found in the conversion to open rates, intraoperative blood loss, 30-day morbidity and mortality, number of lymphnodes harvested and other pathological characteristics. Compared with the LRCEA, the RRCIA required a longer operative time (P &lt; 0.0001) but had better recovery outcomes, such as a shorter length of hospital stay (P &lt; 0.0001). Compared with the LRCIA, the RRCIA had a shorter time to first flatus (P &lt; 0.0001) but offered no advantages in terms of the length of the hospital stay. Conclusion: Performing the RRCIA offers significantly better perioperative recovery outcomes compared with the LRCEA, with a substantial reduction in the length of the hospital stay. The RRCIA does not offer the same advantages compared with the LRCIA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60083546</affiliation-url><afid>60083546</afid><affilname>Azienda Ospedaliera S. Maria di Terni</affilname><name-variant>Azienda Ospedaliera S. Maria</name-variant><affiliation-city>Terni</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021921</affiliation-url><afid>60021921</afid><affilname>Azienda Ospedaliera Careggi</affilname><name-variant>Azienda Ospedaliera Careggi</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60086664</affiliation-url><afid>60086664</afid><affilname>Ospedale della Misericordia, Grosseto</affilname><name-variant>Ospedale Misericordia</name-variant><affiliation-city>Grosseto</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26430097600</author-url><authid>26430097600</authid><authname>Trastulli S.</authname><surname>Trastulli</surname><given-name>Stefano</given-name><initials>S.</initials><afid>60083546</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602425555</author-url><authid>6602425555</authid><authname>Coratti A.</authname><surname>Coratti</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60021921</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25632355600</author-url><authid>25632355600</authid><authname>Guarino S.</authname><surname>Guarino</surname><given-name>Salvatore</given-name><initials>S.</initials><afid>60032350</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56123851600</author-url><authid>56123851600</authid><authname>Piagnerelli R.</authname><surname>Piagnerelli</surname><given-name>Riccardo</given-name><initials>R.</initials><afid>60086664</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6504774424</author-url><authid>6504774424</authid><authname>Annecchiarico M.</authname><surname>Annecchiarico</surname><given-name>Mario</given-name><initials>M.</initials><afid>60021921</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:26026239700</author-url><authid>26026239700</authid><authname>Coratti F.</authname><surname>Coratti</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60086664</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:12240842600</author-url><authid>12240842600</authid><authname>Di Marino M.</authname><surname>Di Marino</surname><given-name>Michele</given-name><initials>M.</initials><afid>60021921</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:18344666500</author-url><authid>18344666500</authid><authname>Ricci F.</authname><surname>Ricci</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60083546</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:50161321700</author-url><authid>50161321700</authid><authname>Desiderio J.</authname><surname>Desiderio</surname><given-name>Jacopo</given-name><initials>J.</initials><afid>60083546</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7004106437</author-url><authid>7004106437</authid><authname>Cirocchi R.</authname><surname>Cirocchi</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60083546</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55260708600</author-url><authid>55260708600</authid><authname>Parisi A.</authname><surname>Parisi</surname><given-name>Amilcare</given-name><initials>A.</initials><afid>60083546</afid></author><authkeywords>Colectomy | Colorectal surgery | Ileocolic anastomosis | Laparoscopic surgery | Right colectomy | Robotic surgery</authkeywords><intid>535862227</intid><source-id>19196</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923937270"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923937270?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923937270&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923937270&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1096495915000184"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923937270</prism:url><dc:identifier>SCOPUS_ID:84923937270</dc:identifier><eid>2-s2.0-84923937270</eid><dc:title>MicroRNA-122 targets genes related to liver metabolism in chickens</dc:title><dc:creator>Wang X.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology Part - B: Biochemistry and Molecular Biology</prism:publicationName><prism:issn>10964959</prism:issn><prism:eIssn>18791107</prism:eIssn><prism:volume>184</prism:volume><prism:pageRange>29-35</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpb.2015.02.002</prism:doi><pii>S1096495915000184</pii><dc:description>© 2015 Elsevier Inc. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by targeting mRNAs. MicroRNA-122 (miR-122) has important functions in mammalian and fish livers, but its functions in the poultry liver are largely unknown. In this study, we determined the expression patterns of miR-122 in the chicken and identified its target genes in the chicken liver. We found that chicken miR-122 was highly expressed in the liver and that its expression in the liver was up-regulated during the early posthatch life. By bioinformatics and reporter gene analyses, we identified PKM2, TGFB3, FABP5 and ARCN1 as miR-122 target genes in the chicken liver. miR-122 knockdown in primary chicken hepatocytes and expression analysis of miR-122 and predicted target mRNAs in the chicken liver suggested that the expression of PKM2 and FABP5 in the chicken liver is regulated by miR-122. Knockdown of miR-122 affected the expression of 123 genes in cultured chicken hepatocytes. Among these genes, the largest cluster, which consisted of 21 genes, was involved in liver metabolism. These findings suggest that miR-122 plays a role in liver metabolism in the chicken by directly or indirectly regulating the expression of genes involved in liver metabolism.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073496</affiliation-url><afid>60073496</afid><affilname>Changshu Institute of Technology</affilname><name-variant>Changshu Institute of Technology</name-variant><affiliation-city>Changshu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007381</affiliation-url><afid>60007381</afid><affilname>Yangzhou University</affilname><name-variant>Yangzhou University</name-variant><affiliation-city>Yangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027090</affiliation-url><afid>60027090</afid><affilname>Virginia Polytechnic Institute and State University</affilname><name-variant>Virginia Polytechnic Institute and State University</name-variant><affiliation-city>Blacksburg</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54785592200</author-url><authid>54785592200</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xingguo</given-name><initials>X.</initials><afid>60073496</afid><afid>60007381</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54785592200</author-url><authid>54785592200</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xingguo</given-name><initials>X.</initials><afid>60073496</afid><afid>60007381</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55768913600</author-url><authid>55768913600</authid><authname>Shao F.</authname><surname>Shao</surname><given-name>Fang</given-name><initials>F.</initials><afid>60073496</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55547111453</author-url><authid>55547111453</authid><authname>Yu J.</authname><surname>Yu</surname><given-name>Jianfeng</given-name><initials>J.</initials><afid>60073496</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56118322000</author-url><authid>56118322000</authid><authname>Jiang H.</authname><surname>Jiang</surname><given-name>Honglin</given-name><initials>H.</initials><afid>60027090</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35811972800</author-url><authid>35811972800</authid><authname>Gong D.</authname><surname>Gong</surname><given-name>Daoqing</given-name><initials>D.</initials><afid>60007381</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7401760588</author-url><authid>7401760588</authid><authname>Gu Z.</authname><surname>Gu</surname><given-name>Zhiliang</given-name><initials>Z.</initials><afid>60073496</afid></author><authkeywords>Chicken | Hepatocytes | Liver metabolism | MicroRNA-122 | Target genes</authkeywords><intid>1785080646</intid><source-id>9700153210</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928895503"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928895503?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928895503&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928895503&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928895503</prism:url><dc:identifier>SCOPUS_ID:84928895503</dc:identifier><eid>2-s2.0-84928895503</eid><dc:title>Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers</dc:title><dc:creator>Tinsley J.</dc:creator><prism:publicationName>Journal of Clinical Pharmacology</prism:publicationName><prism:issn>00912700</prism:issn><prism:eIssn>15524604</prism:eIssn><prism:volume>55</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>698-707</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1002/jcph.468</prism:doi><dc:description>© 2015 The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology. SMT C1100 is a small molecule utrophin modulator in development to treat Duchenne muscular dystrophy. This study evaluated the safety, tolerability, and pharmacokinetics of SMT C1100 in healthy volunteers. This double-blind, placebo-controlled Phase 1 study comprised: Part 1, an escalating, single-dose with/without fasting involving 50 mg/kg, 100 mg/kg, 200 mg/kg, and 400 mg/kg doses; and Part 2, a multiple 10 day dose evaluation involving 100 mg/kg bid and 200 mg/kg bid doses. Adverse events were recorded. SMT C1100 was absorbed rapidly following single and multiple oral doses, with median t&lt;inf&gt;max&lt;/inf&gt; attained within 2-3.5 hour across all doses. Considerable variability of pharmacokinetic parameters was noted among subjects. Following single doses, systemic exposure increased in a sub-proportional manner, with the 8.0-fold dose increment resulting in 2.7- and 2.4-fold increases in AUC&lt;inf&gt;0-∞&lt;/inf&gt; and C&lt;inf&gt;max&lt;/inf&gt;, respectively. AUC&lt;inf&gt;0-∞&lt;/inf&gt; and C&lt;inf&gt;max&lt;/inf&gt; were estimated as 4.2- and 4.8-fold greater, respectively, following food. Systemic exposure reduced upon repeat dosing with steady-state concentrations achieved within 3-5 days of multiple bid dosing. No serious or severe adverse events were reported. SMT C1100 was safe and well tolerated with plasma concentrations achieved sufficient to cause a 50% increase in concentrations of utrophin in cells in vitro.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106418922</affiliation-url><afid>106418922</afid><affilname>Summit plc</affilname><name-variant>Summit PLC</name-variant><affiliation-city>Summit</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115266255</affiliation-url><afid>115266255</afid><affilname>S.H.B. Enterprises Limited</affilname><name-variant>S.H.B. Enterprises Limited</name-variant><affiliation-city>Beaconsfield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026851</affiliation-url><afid>60026851</afid><affilname>University of Oxford</affilname><name-variant>Oxford University</name-variant><affiliation-city>Oxford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006760715</author-url><authid>7006760715</authid><authname>Tinsley J.</authname><surname>Tinsley</surname><given-name>Jon</given-name><initials>J.</initials><afid>106418922</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56533143100</author-url><authid>56533143100</authid><authname>Robinson N.</authname><surname>Robinson</surname><given-name>Neil</given-name><initials>N.</initials><afid>115266255</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35414895000</author-url><authid>35414895000</authid><authname>Davies K.</authname><surname>Davies</surname><given-name>Kay E.</given-name><initials>K.E.</initials><afid>60026851</afid></author><authkeywords>disease modifying therapy | Duchene muscular dystrophy | pharmacokinetics | Phase 1 | Utrophin</authkeywords><intid>1035857486</intid><source-id>22983</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928787690"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928787690?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928787690&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928787690&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928787690</prism:url><dc:identifier>SCOPUS_ID:84928787690</dc:identifier><eid>2-s2.0-84928787690</eid><dc:title>Non-destructive Electrical Methods for Measuring the Physical Characteristics of Porous Materials</dc:title><dc:creator>Merioua A.</dc:creator><prism:publicationName>Journal of Nondestructive Evaluation</prism:publicationName><prism:issn>01959298</prism:issn><prism:eIssn>15734862</prism:eIssn><prism:volume>34</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>1-12</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10921-015-0287-7</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The durability of reinforced concrete structures, built on the seafront, has been at the heart of recent concerns. Indeed, chloride transport across the porosity of concrete coating produces medium to long-term corrosion of reinforcements. This has a direct impact on the mechanical behavior and the ageing of the affected structures. The difficulty of in situ monitoring of these structures, continuously and non-destructively against infiltration of chlorides, is still topical. The work presented here aims mainly at correlating the electrical properties, i.e. electrical resistance, conductivity.., with the physical characteristics (porosity, tortuosity,..), of granular materials using Archie’s law. The recommended experimental program consists in placing, different granular materials, i.e. sand, mortar, bricks, and concretes saturated with electrolytic solutions, in a PVC cell fitted with a pair of stainless steel electrodes connected to an electrical circuit, in order to measure the electrical resistances. The results obtained allow one to determine durability factors, such as the connected porosity and the coefficient of chloride diffusion through a simple measurement of the EC, and estimate the tortuosity parameter that governs transport in porous media.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068756</affiliation-url><afid>60068756</afid><affilname>University of Tlemcen</affilname><name-variant>Université de Tlemcen</name-variant><affiliation-city>Tlemcen</affiliation-city><affiliation-country>Algeria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56613532300</author-url><authid>56613532300</authid><authname>Merioua A.</authname><surname>Merioua</surname><given-name>Abderrahmane</given-name><initials>A.</initials><afid>60068756</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23970322100</author-url><authid>23970322100</authid><authname>Bezzar A.</authname><surname>Bezzar</surname><given-name>AbdelIllah I.</given-name><initials>A.I.</initials><afid>60068756</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23970488400</author-url><authid>23970488400</authid><authname>Ghomari F.</authname><surname>Ghomari</surname><given-name>Fouad</given-name><initials>F.</initials><afid>60068756</afid></author><authkeywords>Chloride | Concrete | Granular material | Non-destructive testing | Porosity</authkeywords><intid>2035845254</intid><source-id>21179</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84919808075"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84919808075?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84919808075&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84919808075&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S030881461401930X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84919808075</prism:url><dc:identifier>SCOPUS_ID:84919808075</dc:identifier><eid>2-s2.0-84919808075</eid><dc:title>Peppermint antioxidants revisited</dc:title><dc:creator>Riachi L.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>176</prism:volume><prism:pageRange>72-81</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.12.028</prism:doi><pii>S030881461401930X</pii><dc:description>©2014 Elsevier Ltd. All rights reserved. This review discusses the relationship between the chemical composition and antioxidant property of peppermint tisane and essential oil. Phenolic acids (e.g. rosmarinic and caffeic acids), flavones (e.g. luteolin derivatives) and flavanones (e.g. eriocitrin derivatives) are possibly the major infusion antioxidants. Vitamin antioxidants (e.g. ascorbic acid and carotenoids) are minor contributors to the overall antioxidant potential. Unsaturated terpenes having a cyclohexadiene structure (e.g. terpinene) and minor cyclic oxygenated terpenes (e.g. thymol), may contribute to antioxidant potential whilst acyclic unsaturated oxygenated monoterpenes (e.g. linalool) may act as pro-oxidants in essential oil. Findings on the antioxidant potential of major cyclic oxygenated terpenes (menthol and menthone) are conflicting. Antioxidant behaviour of aqueous/organic solvent extracts and essential oil as well as the effect of environmental stresses on essential oil and phenolic composition are briefly discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000036</affiliation-url><afid>60000036</afid><affilname>Universidade Federal do Rio de Janeiro</affilname><name-variant>Federal University of Rio de Janeiro</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000036</affiliation-url><afid>60000036</afid><affilname>Universidade Federal do Rio de Janeiro</affilname><name-variant>Federal University of Rio de Janeiro</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55767541600</author-url><authid>55767541600</authid><authname>Riachi L.</authname><surname>Riachi</surname><given-name>Liza G.</given-name><initials>L.G.</initials><afid>60000036</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701635839</author-url><authid>6701635839</authid><authname>De Maria C.</authname><surname>De Maria</surname><given-name>Carlos A B</given-name><initials>C.A.B.</initials><afid>60000036</afid><afid>60000036</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701635839</author-url><authid>6701635839</authid><authname>De Maria C.</authname><surname>De Maria</surname><given-name>Carlos A B</given-name><initials>C.A.B.</initials><afid>60000036</afid><afid>60000036</afid></author><authkeywords>Antioxidant | Essential oil | Infusion | Peppermint | Phenolics | Terpenes</authkeywords><intid>34365301</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929648571"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929648571?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929648571&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929648571&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929648571</prism:url><dc:identifier>SCOPUS_ID:84929648571</dc:identifier><eid>2-s2.0-84929648571</eid><dc:title>Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure</dc:title><dc:creator>Liou B.</dc:creator><prism:publicationName>Antimicrobial Agents and Chemotherapy</prism:publicationName><prism:issn>00664804</prism:issn><prism:eIssn>10986596</prism:eIssn><prism:volume>59</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>3637-3640</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1128/AAC.04987-14</prism:doi><dc:description>Copyright © 2015, American Society for Microbiology. All Rights Reserved. We describe the clinical outcome of 17 patients with secondary Acinetobacter bacteremia whose isolates had a tigecycline MIC of ≤2 mg/liter and who received tigecycline within 2 days of bacteremia onset. The 14-day mortality rate of the tigecycline cohort was 41.2% (7/17), which was significantly higher than that of those receiving other appropriate antimicrobial agents (13.8%, 9/65; P = 0.018). However, the percentages of end-stage renal disease and congestive heart failure were higher in the tigecycline cohort. The efficacy of tigecycline was contingent upon the illness severity and bacterial species. Tigecycline should be applied cautiously for treatment of Acinetobacter bacteremia.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029238</affiliation-url><afid>60029238</afid><affilname>Mackay Memorial Hospital Taiwan</affilname><name-variant>Mackay Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013314</affiliation-url><afid>60013314</afid><affilname>Veterans General Hospital-Taipei</affilname><name-variant>Taipei Veterans General Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069716</affiliation-url><afid>60069716</afid><affilname>National Yang-Ming University Taiwan</affilname><name-variant>National Yang-Ming University</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013314</affiliation-url><afid>60013314</afid><affilname>Veterans General Hospital-Taipei</affilname><name-variant>Taipei Veterans General Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010037</affiliation-url><afid>60010037</afid><affilname>National Health Research Institutes Taiwan</affilname><name-variant>National Health Research Institutes</name-variant><affiliation-city>Zhunan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006121</affiliation-url><afid>60006121</afid><affilname>Veterans General Hospital-Taichung Taiwan</affilname><name-variant>Taichung Veterans General Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652001700</author-url><authid>56652001700</authid><authname>Liou B.</authname><surname>Liou</surname><given-name>Bo Huang</given-name><initials>B.H.</initials><afid>60029238</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35332473300</author-url><authid>35332473300</authid><authname>Lee Y.</authname><surname>Lee</surname><given-name>Yi Tzu</given-name><initials>Y.T.</initials><afid>60013314</afid><afid>60069716</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35332473300</author-url><authid>35332473300</authid><authname>Lee Y.</authname><surname>Lee</surname><given-name>Yi Tzu</given-name><initials>Y.T.</initials><afid>60013314</afid><afid>60069716</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35798393800</author-url><authid>35798393800</authid><authname>Kuo S.</authname><surname>Kuo</surname><given-name>Shu Chen</given-name><initials>S.C.</initials><afid>60069716</afid><afid>60013314</afid><afid>60010037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35798393800</author-url><authid>35798393800</authid><authname>Kuo S.</authname><surname>Kuo</surname><given-name>Shu Chen</given-name><initials>S.C.</initials><afid>60069716</afid><afid>60013314</afid><afid>60010037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35798393800</author-url><authid>35798393800</authid><authname>Kuo S.</authname><surname>Kuo</surname><given-name>Shu Chen</given-name><initials>S.C.</initials><afid>60069716</afid><afid>60013314</afid><afid>60010037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56651364400</author-url><authid>56651364400</authid><authname>Liu P.</authname><surname>Liu</surname><given-name>Po Yu</given-name><initials>P.Y.</initials><afid>60006121</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102443738</author-url><authid>7102443738</authid><authname>Fung C.</authname><surname>Fung</surname><given-name>Chang Phone</given-name><initials>C.P.</initials><afid>60069716</afid><afid>60013314</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102443738</author-url><authid>7102443738</authid><authname>Fung C.</authname><surname>Fung</surname><given-name>Chang Phone</given-name><initials>C.P.</initials><afid>60069716</afid><afid>60013314</afid></author><intid>2035983441</intid><source-id>19615</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209351"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209351?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209351&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209351&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209351</prism:url><dc:identifier>SCOPUS_ID:84930209351</dc:identifier><eid>2-s2.0-84930209351</eid><dc:title>Adult vocational training for migrants in North-East Italy</dc:title><dc:creator>Magnani N.</dc:creator><prism:publicationName>International Migration</prism:publicationName><prism:issn>00207985</prism:issn><prism:eIssn>14682435</prism:eIssn><prism:volume>53</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>150-167</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1111/j.1468-2435.2009.00578.x</prism:doi><dc:description>© 2009 The Author. International Migration © 2009 IOM. This article contributes to the study of policies for the integration of immigrants into the labour markets of European immigration countries by focusing on the specific issue of vocational training for immigrant workers in Italy. Vocational training has a central role in the European employment strategy. Moreover, with regard to migrants, it is also relevant to the topical issue of the governance of international labour migration. The article analyses both the demand and the supply of vocational training in north-east Italy, generally regarded as the rich and industrialised heart of the country. It draws on 30 interviews conducted with key informants and experts from local and regional governmental bodies, trade unions, employment offices, and private educational agencies in the main towns of the Veneto region. Various types of vocational training for immigrant workers are considered, from traditional full-time courses financed by the European Social Fund to new projects for the selection and pre-training of immigrants in their countries of origin. The extent to which these policy tools are able to meet the actual needs of immigrant workers and of the local business sector is investigated, as well as their problematic interaction with the national regulatory framework for immigration control.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015986</affiliation-url><afid>60015986</afid><affilname>Universita degli Studi di Trento</affilname><name-variant>Università di Trento</name-variant><affiliation-city>Trento</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25655077500</author-url><authid>25655077500</authid><authname>Magnani N.</authname><surname>Magnani</surname><given-name>Natalia</given-name><initials>N.</initials><afid>60015986</afid></author><intid>36085802</intid><source-id>26855</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928015514"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928015514?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928015514&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928015514&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1570023215002135"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928015514</prism:url><dc:identifier>SCOPUS_ID:84928015514</dc:identifier><eid>2-s2.0-84928015514</eid><dc:title>Validated high-performance liquid chromatography method for the determination of a phosphodiesterase inhibitor SK5474 in rat plasma and its application to pharmacokinetic study of SK5474</dc:title><dc:creator>Kim T.</dc:creator><prism:publicationName>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</prism:publicationName><prism:issn>15700232</prism:issn><prism:eIssn>1873376X</prism:eIssn><prism:volume>991</prism:volume><prism:pageRange>9-12</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jchromb.2015.04.010</prism:doi><pii>S1570023215002135</pii><dc:description>© 2015 Elsevier B.V.. In this study, a method for the quantitation of SK5474 in rat plasma was developed and validated using high performance liquid chromatography (HPLC). The plasma samples were prepared by deproteinization, and sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed-phase (C18) column. The mobile phase, 0.02. M ammonium acetate buffer:acetonitrile (48:52, v/v), was run at a flow rate of 1.0. mL/min, and the column eluent was monitored using an ultraviolet detector at 254. nm at room temperature. The retention times of sildenafil and SK5474 were approximately 5.8 and 7.2. min, respectively. The quantitation limit of SK5474 in rat plasma was 0.03. μg/mL. Pharmacokinetic parameters of SK5474 was evaluated after intravenous (i.v.; at doses of 15. mg/kg) and oral (p.o.; at doses of 30. mg/kg) administration of SK5474 in rats. After p.o. administration (30. mg/kg) of SK5474, F (fraction absorbed) value was approximately 46.0%.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107382884</affiliation-url><afid>107382884</afid><affilname>Jungwon University</affilname><name-variant>Jungwon University</name-variant><affiliation-city>Chungbuk</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56196885800</author-url><authid>56196885800</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tae Kon</given-name><initials>T.K.</initials><afid>107382884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56197081700</author-url><authid>56197081700</authid><authname>Ji Y.</authname><surname>Ji</surname><given-name>Young Seok</given-name><initials>Y.S.</initials><afid>107382884</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56597659500</author-url><authid>56597659500</authid><authname>Jung O.</authname><surname>Jung</surname><given-name>Oui Hyun</given-name><initials>O.H.</initials><afid>107382884</afid></author><authkeywords>Bioavailability | HPLC | Rats | Sildenafil | SK5474</authkeywords><intid>1035711545</intid><source-id>24172</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927593421"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927593421?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927593421&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927593421&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0273230015000677"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927593421</prism:url><dc:identifier>SCOPUS_ID:84927593421</dc:identifier><eid>2-s2.0-84927593421</eid><dc:title>An improved method for the isolation of rat alveolar type II lung cells: Use in the Comet assay to determine DNA damage induced by cigarette smoke</dc:title><dc:creator>Dalrymple A.</dc:creator><prism:publicationName>Regulatory Toxicology and Pharmacology</prism:publicationName><prism:issn>02732300</prism:issn><prism:eIssn>10960295</prism:eIssn><prism:volume>72</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>141-149</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yrtph.2015.03.013</prism:doi><pii>S0273230015000677</pii><dc:description>© 2015 The Authors. Smoking is a cause of serious diseases, including lung cancer, emphysema, chronic bronchitis and heart disease. DNA damage is thought to be one of the mechanisms by which cigarette smoke (CS) initiates disease in the lung. Indeed, CS induced DNA damage can be measured in vitro and in vivo. The potential of the Comet assay to measure DNA damage in isolated rat lung alveolar type II epithelial cells (AEC II) was explored as a means to include a genotoxicity end-point in rodent sub-chronic inhalation studies. In this study, published AEC II isolation methods were improved to yield viable cells suitable for use in the Comet assay. The improved method reduced the level of basal DNA damage and DNA repair in isolated AEC II. CS induced DNA damage could also be quantified in isolated cells following a single or 5. days CS exposure. In conclusion, the Comet assay has the potential to determine CS or other aerosol induced DNA damage in AEC II isolated from rodents used in sub-chronic inhalation studies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024225</affiliation-url><afid>60024225</afid><affilname>British American Tobacco</affilname><name-variant>British American Tobacco ^</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107071507</affiliation-url><afid>107071507</afid><affilname>Vivotecnia Research S.L.</affilname><name-variant>Vivotecnia Research S.L.</name-variant><affiliation-city>Tres Cantos</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56289925700</author-url><authid>56289925700</authid><authname>Dalrymple A.</authname><surname>Dalrymple</surname><given-name>Annette</given-name><initials>A.</initials><afid>60024225</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56289194000</author-url><authid>56289194000</authid><authname>Ordoñez P.</authname><surname>Ordoñez</surname><given-name>Patricia</given-name><initials>P.</initials><afid>107071507</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35273927000</author-url><authid>35273927000</authid><authname>Thorne D.</authname><surname>Thorne</surname><given-name>David</given-name><initials>D.</initials><afid>60024225</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35894032100</author-url><authid>35894032100</authid><authname>Dillon D.</authname><surname>Dillon</surname><given-name>Debbie</given-name><initials>D.</initials><afid>60024225</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006518924</author-url><authid>7006518924</authid><authname>Meredith C.</authname><surname>Meredith</surname><given-name>Clive</given-name><initials>C.</initials><afid>60024225</afid></author><authkeywords>3R4F reference cigarette | Alveolar type II cells (AEC II) | Cigarette smoke | Comet assay | DNA damage | Genotoxicity endpoint | Rat</authkeywords><intid>1035640784</intid><source-id>25176</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923919627"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923919627?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923919627&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923919627&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0889157515000575"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923919627</prism:url><dc:identifier>SCOPUS_ID:84923919627</dc:identifier><eid>2-s2.0-84923919627</eid><dc:title>Quantification of plant sterols/stanols in foods and dietary supplements containing added phytosterols</dc:title><dc:creator>Srigley C.</dc:creator><prism:publicationName>Journal of Food Composition and Analysis</prism:publicationName><prism:issn>08891575</prism:issn><prism:volume>40</prism:volume><prism:pageRange>163-176</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jfca.2015.01.008</prism:doi><pii>S0889157515000575</pii><dc:description>© 2015 . Plant sterols and plant stanols, collectively referred to as phytosterols, are currently added to conventional foods and dietary supplements for the purpose of reducing the risk of coronary heart disease (CHD). The objective of the present study was to validate a method for the determination of the content and composition of plant sterols/stanols in foods and dietary supplements containing added phytosterols. Chromatographic conditions with this method permitted the near-baseline resolution of the five major phytosterols (campesterol, campestanol, stigmasterol, β-sitosterol, sitostanol) that are the subject of the United States Food and Drug Administration's (FDA) health claim on the relationship between phytosterols and reduced risk of CHD. Analyzed samples (. n=. 25) showed total phytosterol contents that varied from 0.2 to 55.2. g/100. g, or 0.02 to 2.3. g/serving. The mean total phytosterol content was 105. ±. 14% of label declarations (range: 83-137%). Thirteen (13) products (52%) carried the FDA's health claim. This work is the first to evaluate the content and composition of phytosterols from the wide variety of products containing added phytosterols currently available in the United States and their use of the FDA's health claim for phytosterols and reduced risk of CHD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>United States Food and Drug Administration</affilname><name-variant>Center for Food Safety and Applied Nutrition</name-variant><affiliation-city>College Park</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Maryland</affilname><name-variant>Joint Institute for Food Safety and Applied Nutrition</name-variant><affiliation-city>College Park</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55914274400</author-url><authid>55914274400</authid><authname>Srigley C.</authname><surname>Srigley</surname><given-name>Cynthia T.</given-name><initials>C.T.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56533832700</author-url><authid>56533832700</authid><authname>Haile E.</authname><surname>Haile</surname><given-name>Ermias A.</given-name><initials>E.A.</initials><afid/></author><authkeywords>Campestanol (PubChem CID: 119394) | Campesterol (PubChem CID: 312822) | Cholesterol (PubChem CID: 5997) | Dietary supplement | Dihydrocholesterol (PubChem CID: 3240) | Epicoprostanol (PubChem CID: 91465) | Food analysis | Food composition | Gas chromatography | Health claim | Method validation | Phytostanol | Phytosterol | Stigmasterol (PubChem CID: 5280794) | United States Food and Drug Administration | β-Sitostanol (PubChem CID: 16219965) | β-Sitosterol (PubChem CID: 222284)</authkeywords><intid>1535075362</intid><source-id>20582</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929623818"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929623818?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929623818&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929623818&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0141933115000514"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929623818</prism:url><dc:identifier>SCOPUS_ID:84929623818</dc:identifier><eid>2-s2.0-84929623818</eid><dc:title>Cross-architecture prediction based scheduling for energy efficient execution on single-ISA heterogeneous chip-multiprocessors</dc:title><dc:creator>Zhang Y.</dc:creator><prism:publicationName>Microprocessors and Microsystems</prism:publicationName><prism:issn>01419331</prism:issn><prism:volume>39</prism:volume><prism:issueIdentifier>4-5</prism:issueIdentifier><prism:pageRange>271-285</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.micpro.2015.04.008</prism:doi><pii>S0141933115000514</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. In recent years, single-ISA heterogeneous chip multiprocessors (CMP) consisting of big high-performance cores and small power-saving cores on the same die have been proposed for the exploration of high energy-efficiency. On such heterogeneous platforms, an appropriate runtime scheduling policy lies at the heart of program executions to benefit from the processor heterogeneity. To date, most prior works addressing this problem concentrate on the performance enhancement; however, they lack detailed justification of the runtime energy consumption and do not result in the most energy-efficient execution all the time. In this work, we pay attention to reducing the energy consumption for workloads running on heterogeneous CMPs and propose a scheduling algorithm based on dynamic execution behaviors to exploit better energy-efficiency. Our strategy is capable of significantly reducing the energy consumption while delivering comparable performance to a recently proposed heterogeneous scheduler (MLP-ratio), thus improving the energy-efficiency impressively.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007566</affiliation-url><afid>60007566</afid><affilname>Louisiana State University</affilname><name-variant>Louisiana State University</name-variant><affiliation-city>Baton Rouge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003212</affiliation-url><afid>60003212</afid><affilname>University of Texas at San Antonio</affilname><name-variant>University of Texas at San Antonio</name-variant><affiliation-city>San Antonio</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007566</affiliation-url><afid>60007566</afid><affilname>Louisiana State University</affilname><name-variant>Louisiana State University</name-variant><affiliation-city>Baton Rouge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55946703800</author-url><authid>55946703800</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Ying</given-name><initials>Y.</initials><afid>60007566</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26435787800</author-url><authid>26435787800</authid><authname>Duan L.</authname><surname>Duan</surname><given-name>Lide</given-name><initials>L.</initials><afid>60003212</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55179930900</author-url><authid>55179930900</authid><authname>Li B.</authname><surname>Li</surname><given-name>Bin</given-name><initials>B.</initials><afid>60007566</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15923627700</author-url><authid>15923627700</authid><authname>Peng L.</authname><surname>Peng</surname><given-name>Lu</given-name><initials>L.</initials><afid>60007566</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56134118700</author-url><authid>56134118700</authid><authname>Sadagopan S.</authname><surname>Sadagopan</surname><given-name>Srinivasan</given-name><initials>S.</initials><afid>60003212</afid></author><authkeywords>Energy efficiency | Heterogeneous systems | Modeling techniques | Parallel processors</authkeywords><intid>1535988413</intid><source-id>15552</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926640211"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926640211?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926640211&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926640211&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1050464815001072"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926640211</prism:url><dc:identifier>SCOPUS_ID:84926640211</dc:identifier><eid>2-s2.0-84926640211</eid><dc:title>The cytosolic sensor, DDX41, activates antiviral and inflammatory immunity in response to stimulation with double-stranded DNA adherent cells of the olive flounder, paralichthys olivaceus</dc:title><dc:creator>Quynh N.</dc:creator><prism:publicationName>Fish and Shellfish Immunology</prism:publicationName><prism:issn>10504648</prism:issn><prism:eIssn>10959947</prism:eIssn><prism:volume>44</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>576-583</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.fsi.2015.03.008</prism:doi><pii>S1050464815001072</pii><dc:description>© 2015 Elsevier Ltd. DDX41, a receptor belonging to the DExD family, functions as a DNA sensor in the mammalian cytoplasm and mediates the antiviral response in host cells. Here, the olive flounder DDX41 was found to have 2267-bp long and encodes a putative protein of 614 amino acid residues. The olive flounder DDX41 mRNA was presented in all tested tissues, and was distinctly expressed in fish naturally infected with LCDV. High expression levels were observed in the heart, liver, kidney and stomach. Furthermore, the olive flounder DDX41 mRNA expression increased significantly in adherent (monocyte-like) cells following stimulation with a DNA virus. Reporter assays showed that the transcriptional activity of the IFN-I promoter was enhanced in DDX41-overexpressing HINAE cells treated with C-di-GMP (dinucleotides). Overexpression of DDX41 also induced the antiviral and inflammatory cytokine gene expression through cytoplasmic C-di-GMP treatment. These results suggest that DDX41 functions as a cytosolic DNA sensor that is capable of inducing antiviral activity and inflammatory responses in the olive flounder.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023075</affiliation-url><afid>60023075</afid><affilname>Gyeongsang National University</affilname><name-variant>Gyeongsang National University</name-variant><affiliation-city>Jinju</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001580</affiliation-url><afid>60001580</afid><affilname>University of Miyazaki</affilname><name-variant>Miyazaki University</name-variant><affiliation-city>Miyazaki</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023462</affiliation-url><afid>60023462</afid><affilname>Waseda University</affilname><name-variant>Waseda University</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115136332</affiliation-url><afid>115136332</afid><affilname>BluGen Korea</affilname><name-variant>BluGen Korea</name-variant><affiliation-city>Busan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56585808100</author-url><authid>56585808100</authid><authname>Quynh N.</authname><surname>Quynh</surname><given-name>Nhu Truong</given-name><initials>N.T.</initials><afid>60023075</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35552172100</author-url><authid>35552172100</authid><authname>Hikima J.</authname><surname>Hikima</surname><given-name>Jun ichi</given-name><initials>J.i.</initials><afid>60001580</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8282607600</author-url><authid>8282607600</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Young rim</given-name><initials>Y.r.</initials><afid>60023075</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25821709900</author-url><authid>25821709900</authid><authname>Fagutao F.</authname><surname>Fagutao</surname><given-name>Fernand F.</given-name><initials>F.F.</initials><afid>60023075</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56584941200</author-url><authid>56584941200</authid><authname>Kim M.</authname><surname>Kim</surname><given-name>Mee Sun</given-name><initials>M.S.</initials><afid>115136332</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56442797500</author-url><authid>56442797500</authid><authname>Aoki T.</authname><surname>Aoki</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60023462</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56585346500</author-url><authid>56585346500</authid><authname>Jung T.</authname><surname>Jung</surname><given-name>Tae Sung</given-name><initials>T.S.</initials><afid>60023075</afid></author><authkeywords>Bacterial cyclic dinucleotides | DDX41 | DExD/H-box helicases | Innate immunity</authkeywords><intid>1035479690</intid><source-id>15066</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359104"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359104?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359104&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359104&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359104</prism:url><dc:identifier>SCOPUS_ID:84929359104</dc:identifier><eid>2-s2.0-84929359104</eid><dc:title>Realizing all reduced syzygy sequences in the planar three-body problem</dc:title><dc:creator>Moeckel R.</dc:creator><prism:publicationName>Nonlinearity</prism:publicationName><prism:issn>09517715</prism:issn><prism:eIssn>13616544</prism:eIssn><prism:volume>28</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1919-1935</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1088/0951-7715/28/6/1919</prism:doi><dc:description>© 2015 IOP Publishing Ltd &amp; London Mathematical Society. The configuration space of the planar three-body problem, reduced by rotations and with collisions excluded, has a rich topology which supports a large set of free homotopy classes. These classes have a simple description in terms of syzygy (or eclipse) sequences. Each homotopy class corresponds to a unique 'reduced' syzygy sequence. We prove that each reduced syzygy sequence is realized by a periodic solution of the rotation-reduced Newtonian planar three-body problem. The realizing solutions have small, nonzero angular momentum, repeatedly come very close to triple collision, and have lots of 'stutters' - repeated syzygies of the same type, which cancel out up to homotopy. The heart of the proof stems from the work by one of us on symbolic dynamics arising out of the central configurations after the triple collision is blown up using McGehee's method. We end with a list of open problems.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024941</affiliation-url><afid>60024941</afid><affilname>University of California, Santa Cruz</affilname><name-variant>University of California</name-variant><affiliation-city>Santa Cruz</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602247964</author-url><authid>6602247964</authid><authname>Moeckel R.</authname><surname>Moeckel</surname><given-name>Richard</given-name><initials>R.</initials><afid>60005745</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202664997</author-url><authid>7202664997</authid><authname>Montgomery R.</authname><surname>Montgomery</surname><given-name>Richard</given-name><initials>R.</initials><afid>60024941</afid></author><authkeywords>Euler solutions | free homotopies | Lagrange solutions | McGehee blow-up | planar three-body problem | syzygy sequences | triple collisions</authkeywords><intid>35943183</intid><source-id>25696</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928557650"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928557650?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928557650&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928557650&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928557650</prism:url><dc:identifier>SCOPUS_ID:84928557650</dc:identifier><eid>2-s2.0-84928557650</eid><dc:title>Merging image databases as an example for information integration</dc:title><dc:creator>Maurer H.</dc:creator><prism:publicationName>Central European Journal of Operations Research</prism:publicationName><prism:issn>1435246X</prism:issn><prism:eIssn>16139178</prism:eIssn><prism:volume>23</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>441-458</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10100-015-0380-0</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. By integrating information we mean pulling information pieces from various sources together with as little loss of information and as little redundancy as possible. Operation Research techniques applied in many situations, like heuristic algorithms, meta-heuristics, similarity measures, use of constraints, combinatorial algorithms and collaborative efforts provide valuable tools for this process, if augmented by other techniques known from knowledge management and information retrieval. Given the huge amount of information we are confronted with, information integration is one of the biggest challenges of this century. This paper describes methods and techniques for the information integration process. It is interesting to note that in areas such as information integration, consolidation and simplification that are not usually at the heart of Operation Research, some of the most important techniques used in this field can be applied successfully. Information integration is an important topic but, in general no really convincing approaches have been discovered, so far. By limiting the domain to the integration of image databases the problem becomes tractable, by using the mentioned techniques and also applying methods ranging from image processing, knowledge management and natural language processing to feature engineering.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019663</affiliation-url><afid>60019663</afid><affilname>Technische Universitat Graz</affilname><name-variant>Technische Universität Graz</name-variant><affiliation-city>Graz</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55147247000</author-url><authid>55147247000</authid><authname>Maurer H.</authname><surname>Maurer</surname><given-name>Hermann</given-name><initials>H.</initials><afid>60019663</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55940244600</author-url><authid>55940244600</authid><authname>Mehmood R.</authname><surname>Mehmood</surname><given-name>Rizwan</given-name><initials>R.</initials><afid>60019663</afid></author><authkeywords>Constraints observation | Feature engineering | Heuristic algorithms | Human supported artificial intelligence | Information integration | Natural language processing</authkeywords><intid>535802875</intid><source-id>5000158106</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922420962"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922420962?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922420962&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922420962&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0191886915000306"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922420962</prism:url><dc:identifier>SCOPUS_ID:84922420962</dc:identifier><eid>2-s2.0-84922420962</eid><dc:title>Iowa Gambling Task performance and executive function predict low-income urban preadolescents' risky behaviors</dc:title><dc:creator>Ursache A.</dc:creator><prism:publicationName>Personality and Individual Differences</prism:publicationName><prism:issn>01918869</prism:issn><prism:volume>79</prism:volume><prism:pageRange>1-6</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.paid.2015.01.010</prism:doi><pii>S0191886915000306</pii><dc:description>© 2015. This study examines preadolescents' reports of risk-taking as predicted by two different, but related inhibitory control systems involving sensitivity to reward and loss on the one hand, and higher order processing in the context of cognitive conflict, known as executive functioning (EF), on the other. Importantly, this study examines these processes with a sample of inner-city, low-income preadolescents and as such examines the ways in which these processes may be related to risky behaviors as a function of children's levels of both concurrent and chronic exposure to household poverty. As part of a larger longitudinal study, 382 children (ages 9-11) provided a self-report of risky behaviors and participated in the Iowa Gambling Task, assessing bias for infrequent loss (preference for infrequent, high magnitude versus frequent, low magnitude loss) and the Hearts and Flowers task assessing executive functioning. Results demonstrated that a higher bias for infrequent loss was associated with higher risky behaviors for children who demonstrated lower EF. Furthermore, bias for infrequent loss was most strongly associated with higher risk-taking for children facing highest levels of poverty. Implications for early identification and prevention of risk-taking in inner-city preadolescents are discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021784</affiliation-url><afid>60021784</afid><affilname>New York University</affilname><name-variant>New York University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55177876700</author-url><authid>55177876700</authid><authname>Ursache A.</authname><surname>Ursache</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60021784</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602198382</author-url><authid>6602198382</authid><authname>Raver C.</authname><surname>Raver</surname><given-name>C. Cybele</given-name><initials>C.C.</initials><afid>60021784</afid></author><authkeywords>Executive function | Iowa Gambling Task | Preadolescents | Risk behavior</authkeywords><intid>1784811276</intid><source-id>12807</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925127658"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925127658?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925127658&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925127658&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0731708514004725"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925127658</prism:url><dc:identifier>SCOPUS_ID:84925127658</dc:identifier><eid>2-s2.0-84925127658</eid><dc:title>Application of an ultra-performance liquid chromatography method with tandem mass spectrometry to pharmacokinetics, tissue distribution and excretion in the study of DAT-230, a novel tubulin-binding agent candidate, in rats</dc:title><dc:creator>Tang J.</dc:creator><prism:publicationName>Journal of Pharmaceutical and Biomedical Analysis</prism:publicationName><prism:issn>07317085</prism:issn><prism:eIssn>1873264X</prism:eIssn><prism:volume>110</prism:volume><prism:pageRange>49-57</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jpba.2014.09.025</prism:doi><pii>S0731708514004725</pii><dc:description>© 2015 Elsevier B.V. A rapid, sensitive and high-throughput ultra-performance liquid chromatography method with tandem mass spectrometry (UPLC-MS/MS) has been developed for the determination of DAT-230 in rat plasma, urine, feces and tissues (heart, liver, spleen, lung, kidney, stomach, intestine and brain). The biological samples were prepared by protein precipitation, and separation was achieved on an ACQUITY™ UPLC BEH C18 column (50mm×2.1mm, 1.7μm) with a mobile phase that consisted of methanol - 0.2% formic acid water (80:20, v/v) at a flow rate of 0.2mL/min. The MS/MS ion transitions were monitored at m/z 372.17→357.17 for DAT-230 and m/z 406.08→345.16 for COH-203 (internal standard, IS). The calibration curve was linear in the range of 0.1-5200ng/mL for all biological matrices (r2≥0.996), and it had the same value for the lower limit of quantification. The validated method was successfully applied to the pharmacokinetics, tissue distribution and excretion study after intravenous administration of a 5mg/kg dose of DAT-230 to healthy Sprague-Dawley rats. The mean pharmacokinetic parameters of t1/2 and AUC0-12 were (1.1±0.4)h and (861.0±281.2)ngh/mL, respectively. Tissue distribution results indicated that DAT-230 exhibited rapid distribution and high liver, kidney, spleen, stomach and intestine uptake; these organs were indicated as the major target organs of the drug. In total, 5.3% of the administered DAT-230 was excreted in an unconverted form in urine, feces and bile, which implies that DAT-230 was excreted primarily in the form of metabolites.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007269</affiliation-url><afid>60007269</afid><affilname>Shenyang Pharmaceutical University</affilname><name-variant>Shenyang Pharmaceutical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007269</affiliation-url><afid>60007269</afid><affilname>Shenyang Pharmaceutical University</affilname><name-variant>Shenyang Pharmaceutical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56558983200</author-url><authid>56558983200</authid><authname>Tang J.</authname><surname>Tang</surname><given-name>Jingya</given-name><initials>J.</initials><afid>60007269</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56558978200</author-url><authid>56558978200</authid><authname>Zhang C.</authname><surname>Zhang</surname><given-name>Chungang</given-name><initials>C.</initials><afid>60007269</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56558871400</author-url><authid>56558871400</authid><authname>Sun J.</authname><surname>Sun</surname><given-name>Jun</given-name><initials>J.</initials><afid>60007269</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56558961200</author-url><authid>56558961200</authid><authname>Zhao L.</authname><surname>Zhao</surname><given-name>Longshan</given-name><initials>L.</initials><afid>60007269</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7409431624</author-url><authid>7409431624</authid><authname>Zhang W.</authname><surname>Zhang</surname><given-name>Weige</given-name><initials>W.</initials><afid>60007269</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56454612200</author-url><authid>56454612200</authid><authname>Liu Z.</authname><surname>Liu</surname><given-name>Zhenzhen</given-name><initials>Z.</initials><afid>60007269</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55700853200</author-url><authid>55700853200</authid><authname>Sun L.</authname><surname>Sun</surname><given-name>Lu</given-name><initials>L.</initials><afid>60007269</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15031413300</author-url><authid>15031413300</authid><authname>Chen X.</authname><surname>Chen</surname><given-name>Xiaohui</given-name><initials>X.</initials><afid>60007269</afid></author><authkeywords>DAT-230 | Excretion | Pharmacokinetics | Tissue distribution | UPLC/MS/MS</authkeywords><intid>535268527</intid><source-id>23061</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926630601"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926630601?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926630601&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926630601&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926630601</prism:url><dc:identifier>SCOPUS_ID:84926630601</dc:identifier><eid>2-s2.0-84926630601</eid><dc:title>Objective, comparative assessment of the penetration depth of temporal-focusing microscopy for imaging various organs</dc:title><dc:creator>Rowlands C.</dc:creator><prism:publicationName>Journal of Biomedical Optics</prism:publicationName><prism:issn>10833668</prism:issn><prism:eIssn>15602281</prism:eIssn><prism:volume>20</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1117/1.JBO.20.6.061107</prism:doi><dc:description>© The Authors. Temporal focusing is a technique for performing axially resolved widefield multiphoton microscopy with a large field of view. Despite significant advantages over conventional point-scanning multiphoton microscopy in terms of imaging speed, the need to collect the whole image simultaneously means that it is expected to achieve a lower penetration depth in common biological samples compared to point-scanning. We assess the penetration depth using a rigorous objective criterion based on the modulation transfer function, comparing it to point-scanning multiphoton microscopy. Measurements are performed in a variety of mouse organs in order to provide practical guidance as to the achievable penetration depth for both imaging techniques. It is found that two-photon scanning microscopy has approximately twice the penetration depth of temporal-focusing microscopy, and that penetration depth is organ-specific; the heart has the lowest penetration depth, followed by the liver, lungs, and kidneys, then the spleen, and finally white adipose tissue.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Biological Engineering</affilname><name-variant>Massachusetts Institute of Technology</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Chemistry</affilname><name-variant>Massachusetts Institute of Technology</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Mechanical Engineering</affilname><name-variant>Massachusetts Institute of Technology</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23986154900</author-url><authid>23986154900</authid><authname>Rowlands C.</authname><surname>Rowlands</surname><given-name>Christopher J.</given-name><initials>C.J.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12766460400</author-url><authid>12766460400</authid><authname>Bruns O.</authname><surname>Bruns</surname><given-name>Oliver T.</given-name><initials>O.T.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005959235</author-url><authid>7005959235</authid><authname>Bawendi M.</authname><surname>Bawendi</surname><given-name>Moungi G.</given-name><initials>M.G.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102823670</author-url><authid>7102823670</authid><authname>So P.</authname><surname>So</surname><given-name>Peter T C</given-name><initials>P.T.C.</initials><afid/><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102823670</author-url><authid>7102823670</authid><authname>So P.</authname><surname>So</surname><given-name>Peter T C</given-name><initials>P.T.C.</initials><afid/><afid/></author><authkeywords>biophotonics | image quality | imaging | microscopy | optical transfer functions | ultrafast phenomena</authkeywords><intid>1035480755</intid><article-number>061107</article-number><source-id>12156</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924045140"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924045140?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924045140&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924045140&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0048969715001746"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924045140</prism:url><dc:identifier>SCOPUS_ID:84924045140</dc:identifier><eid>2-s2.0-84924045140</eid><dc:title>Multiple inorganic toxic substances contaminating the groundwater of Myingyan Township, Myanmar: Arsenic, manganese, fluoride, iron, and uranium</dc:title><dc:creator>Bacquart T.</dc:creator><prism:publicationName>Science of the Total Environment</prism:publicationName><prism:issn>00489697</prism:issn><prism:eIssn>18791026</prism:eIssn><prism:volume>517</prism:volume><prism:pageRange>232-245</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.scitotenv.2015.02.038</prism:doi><pii>S0048969715001746</pii><dc:description>© 2015 Elsevier B.V. In South Asia, the technological and societal shift from drinking surface water to groundwater has resulted in a great reduction of acute diseases due to water borne pathogens. However, arsenic and other naturally occurring inorganic toxic substances present in groundwater in the region have been linked to a variety of chronic diseases, including cancers, heart disease, and neurological problems. Due to the highly specific symptoms of chronic arsenic poisoning, arsenic was the first inorganic toxic substance to be noticed at unsafe levels in the groundwater of West Bengal, India and Bangladesh. Subsequently, other inorganic toxic substances, including manganese, uranium, and fluoride have been found at unsafe levels in groundwater in South Asia. While numerous drinking water wells throughout Myanmar have been tested for arsenic, relatively little is known about the concentrations of other inorganic toxic substances in Myanmar groundwater. In this study, we analyzed samples from 18 drinking water wells (12 in Myingyan City and 6 in nearby Tha Pyay Thar Village) and 2 locations in the Ayeyarwaddy River for arsenic, boron, barium, beryllium, cadmium, cobalt, chromium, copper, fluoride, iron, mercury, manganese, molybdenum, nickel, lead, antimony, selenium, thallium, uranium, vanadium, and zinc. Concentrations of arsenic, manganese, fluoride, iron, or uranium exceeded health-based reference values in most wells. In addition, any given well usually contained more than one toxic substance at unsafe concentrations. While water testing and well sharing could reduce health risks, none of the wells sampled provide water that is entirely safe with respect to inorganic toxic substances. It is imperative that users of these wells, and users of other wells that have not been tested for multiple inorganic toxic substances throughout the region, be informed of the need for drinking water testing and the health consequences of drinking water contaminated with inorganic toxic substances.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100943694</affiliation-url><afid>100943694</afid><affilname>Better Life Laboratories</affilname><name-variant>Better Life Laboratories</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018347</affiliation-url><afid>60018347</afid><affilname>Norwich University</affilname><name-variant>Norwich University</name-variant><affiliation-city>Northfield</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018347</affiliation-url><afid>60018347</afid><affilname>Norwich University</affilname><name-variant>Norwich University</name-variant><affiliation-city>Northfield</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025047</affiliation-url><afid>60025047</afid><affilname>Vermont Department of Health</affilname><name-variant>Vermont Department of Health</name-variant><affiliation-city>Burlington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030319</affiliation-url><afid>60030319</afid><affilname>Hospital for Sick Children University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22933748800</author-url><authid>22933748800</authid><authname>Bacquart T.</authname><surname>Bacquart</surname><given-name>Thomas</given-name><initials>T.</initials><afid>100943694</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602169682</author-url><authid>6602169682</authid><authname>Frisbie S.</authname><surname>Frisbie</surname><given-name>Seth</given-name><initials>S.</initials><afid>100943694</afid><afid>60018347</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602169682</author-url><authid>6602169682</authid><authname>Frisbie S.</authname><surname>Frisbie</surname><given-name>Seth</given-name><initials>S.</initials><afid>100943694</afid><afid>60018347</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8947700400</author-url><authid>8947700400</authid><authname>Mitchell E.</authname><surname>Mitchell</surname><given-name>Erika</given-name><initials>E.</initials><afid>100943694</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56536406300</author-url><authid>56536406300</authid><authname>Grigg L.</authname><surname>Grigg</surname><given-name>Laurie</given-name><initials>L.</initials><afid>60018347</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56535994500</author-url><authid>56535994500</authid><authname>Cole C.</authname><surname>Cole</surname><given-name>Christopher</given-name><initials>C.</initials><afid>60018347</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56536133200</author-url><authid>56536133200</authid><authname>Small C.</authname><surname>Small</surname><given-name>Colleen</given-name><initials>C.</initials><afid>60025047</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35565615600</author-url><authid>35565615600</authid><authname>Sarkar B.</authname><surname>Sarkar</surname><given-name>Bibudhendra</given-name><initials>B.</initials><afid>60030319</afid><afid>60016849</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35565615600</author-url><authid>35565615600</authid><authname>Sarkar B.</authname><surname>Sarkar</surname><given-name>Bibudhendra</given-name><initials>B.</initials><afid>60030319</afid><afid>60016849</afid></author><authkeywords>Burma | Drinking water | Drinking water guidelines | Hydrogeology | South asia | Trace metals</authkeywords><intid>1785084103</intid><source-id>25349</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226120"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226120?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226120&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226120&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226120</prism:url><dc:identifier>SCOPUS_ID:84930226120</dc:identifier><eid>2-s2.0-84930226120</eid><dc:title>Haemodynamic and anatomic progression of aortic stenosis</dc:title><dc:creator>Nguyen V.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>943-947</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-307154</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Background: Aortic valve stenosis (AS) is a progressive disease, but the impact of baseline AS haemodynamic or anatomic severity on AS progression remains unclear. Methods: In 149 patients (104 mild AS, 36 moderate AS and 9 severe AS) enrolled in 2 ongoing prospective cohorts (COFRASA/GENERAC), we evaluated AS haemodynamic severity at baseline and yearly, thereafter, using echocardiography (mean pressure gradient (MPG)) and AS anatomic severity using CT (degree of aortic valve calcification (AVC)). Results: After a mean follow-up of 2.9±1.0 years, mean MGP increased from 22±11 to 30±16 mm Hg (+3±3 mm Hg/year), and mean AVC from 1108±891 to 1640±1251 AU (arbitrary units) (+188±176 AU/year). Progression of AS was strongly related to baseline haemodynamic severity (+2±3 mm Hg/year in mild AS, +4±3 mm Hg/year in moderate AS and +5±5 mm Hg/year in severe AS (p=0.01)), and baseline haemodynamic severity was an independent predictor of haemodynamic progression (p=0.0003). Annualised haemodynamic and anatomic progression rates were significantly correlated (r=0.55, p&lt;0.0001), but AVC progression rate was also significantly associated with baseline haemodynamic severity (+141±133 AU/year in mild AS, +279±189 AU/year in moderate AS and +361±293 AU/year in severe AS, p&lt;0.0001), and both baseline MPG and baseline AVC were independent determinants of AVC progression (p&lt;0.0001). Conclusions: AS progressed faster with increasing haemodynamic or anatomic severity. Our results suggest that a medical strategy aimed at preventing AVC progression may be useful in all subsets of patients with AS including those with severe AS and support the recommended closer follow-up of patients with AS as AS severity increases. Clinical trial registration: COFRASA (clinicalTrial.gov number NCT 00338676) and GENERAC (clinicalTrial.gov number NCT00647088).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005711</affiliation-url><afid>60005711</afid><affilname>Universite Paris 7- Denis Diderot</affilname><name-variant>Université Paris 7</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56245451600</author-url><authid>56245451600</authid><authname>Nguyen V.</authname><surname>Nguyen</surname><given-name>Virginia</given-name><initials>V.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56245451600</author-url><authid>56245451600</authid><authname>Nguyen V.</authname><surname>Nguyen</surname><given-name>Virginia</given-name><initials>V.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56245451600</author-url><authid>56245451600</authid><authname>Nguyen V.</authname><surname>Nguyen</surname><given-name>Virginia</given-name><initials>V.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24330930300</author-url><authid>24330930300</authid><authname>Cimadevilla C.</authname><surname>Cimadevilla</surname><given-name>Claire</given-name><initials>C.</initials><afid>60022785</afid><afid>60022785</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24330930300</author-url><authid>24330930300</authid><authname>Cimadevilla C.</authname><surname>Cimadevilla</surname><given-name>Claire</given-name><initials>C.</initials><afid>60022785</afid><afid>60022785</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:11141213900</author-url><authid>11141213900</authid><authname>Estellat C.</authname><surname>Estellat</surname><given-name>Candice</given-name><initials>C.</initials><afid>60022785</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663276600</author-url><authid>56663276600</authid><authname>Codogno I.</authname><surname>Codogno</surname><given-name>Isabelle</given-name><initials>I.</initials><afid>60022785</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506839447</author-url><authid>6506839447</authid><authname>Huart V.</authname><surname>Huart</surname><given-name>Virginie</given-name><initials>V.</initials><afid>60022785</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004526710</author-url><authid>7004526710</authid><authname>Benessiano J.</authname><surname>Benessiano</surname><given-name>Joelle</given-name><initials>J.</initials><afid>60022785</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004180081</author-url><authid>7004180081</authid><authname>Duval X.</authname><surname>Duval</surname><given-name>Xavier</given-name><initials>X.</initials><afid>60022785</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004079799</author-url><authid>7004079799</authid><authname>Pibarot P.</authname><surname>Pibarot</surname><given-name>Philippe</given-name><initials>P.</initials><afid>60032619</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:25622188700</author-url><authid>25622188700</authid><authname>Clavel M.</authname><surname>Clavel</surname><given-name>Marie Annick</given-name><initials>M.A.</initials><afid>60005558</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35445371700</author-url><authid>35445371700</authid><authname>Enriquez-Sarano M.</authname><surname>Enriquez-Sarano</surname><given-name>Maurice</given-name><initials>M.</initials><afid>60005558</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:16158858700</author-url><authid>16158858700</authid><authname>Vahanian A.</authname><surname>Vahanian</surname><given-name>Alec</given-name><initials>A.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:16158858700</author-url><authid>16158858700</authid><authname>Vahanian A.</authname><surname>Vahanian</surname><given-name>Alec</given-name><initials>A.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:16158858700</author-url><authid>16158858700</authid><authname>Vahanian A.</authname><surname>Vahanian</surname><given-name>Alec</given-name><initials>A.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6603661401</author-url><authid>6603661401</authid><authname>Messika-Zeitoun D.</authname><surname>Messika-Zeitoun</surname><given-name>David</given-name><initials>D.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6603661401</author-url><authid>6603661401</authid><authname>Messika-Zeitoun D.</authname><surname>Messika-Zeitoun</surname><given-name>David</given-name><initials>D.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6603661401</author-url><authid>6603661401</authid><authname>Messika-Zeitoun D.</authname><surname>Messika-Zeitoun</surname><given-name>David</given-name><initials>D.</initials><afid>60022785</afid><afid>60022785</afid><afid>60005711</afid></author><intid>1036082763</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928253120"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928253120?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928253120&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928253120&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015010011"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928253120</prism:url><dc:identifier>SCOPUS_ID:84928253120</dc:identifier><eid>2-s2.0-84928253120</eid><dc:title>Novel anti-inflammatory therapies for the treatment of atherosclerosis</dc:title><dc:creator>Khan R.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>497-509</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.783</prism:doi><pii>S0021915015010011</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. The underlying role of inflammation in atherosclerosis has been characterized. However, current treatment of coronary artery disease (CAD) predominantly consists of targeted reductions in serum lipoprotein levels rather than combating the deleterious effects of acute and chronic inflammation. Vascular inflammation acts by a number of different molecular and cellular pathways to contribute to atherogenesis. Over the last decades, both basic studies and clinical trials have provided evidence for the potential benefits of treatment of inflammation in CAD. During this period, development of pharmacotherapies directed towards inflammation in atherosclerosis has accelerated quickly. This review will highlight specific therapies targeting interleukin-1β (IL-1β), P-selectin and 5-lipoxygenase (5-LO). It will also aim to examine the anti-inflammatory effects of serpin administration, colchicine and intravenous HDL-directed treatment of CAD. We summarize the mechanistic rationale and evidence for these novel anti-inflammatory treatments at both the experimental and clinical levels.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009507</affiliation-url><afid>60009507</afid><affilname>Universite de Montreal</affilname><name-variant>University of Montreal</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12808636600</author-url><authid>12808636600</authid><authname>Khan R.</authname><surname>Khan</surname><given-name>Razi</given-name><initials>R.</initials><afid>60009507</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36936021600</author-url><authid>36936021600</authid><authname>Spagnoli V.</authname><surname>Spagnoli</surname><given-name>Vincent</given-name><initials>V.</initials><afid>60009507</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35399980400</author-url><authid>35399980400</authid><authname>Tardif J.</authname><surname>Tardif</surname><given-name>Jean Claude</given-name><initials>J.C.</initials><afid>60009507</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603030048</author-url><authid>6603030048</authid><authname>L'Allier P.</authname><surname>L'Allier</surname><given-name>Philippe L.</given-name><initials>P.L.</initials><afid>60009507</afid></author><authkeywords>5-Lipoxygenase | Colchicine | Interleukin-1β | Intravenous HDL | P-Selectin | Serpin</authkeywords><intid>1035749202</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928991260"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928991260?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928991260&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928991260&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928991260</prism:url><dc:identifier>SCOPUS_ID:84928991260</dc:identifier><eid>2-s2.0-84928991260</eid><dc:title>Utilizing Cardiac Biomarkers to Detect and Prevent Chemotherapy-Induced Cardiomyopathy</dc:title><dc:creator>Singh D.</dc:creator><prism:publicationName>Current Heart Failure Reports</prism:publicationName><prism:issn>15469530</prism:issn><prism:eIssn>15469549</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>255-262</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11897-015-0258-4</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The success achieved in advances in cancer therapy has been marred by development of cardiotoxicity, which causes significant morbidity and mortality. This has led to the development of surveillance protocols for cardiotoxicity utilizing multimodality imaging techniques and investigation of various drugs to treat and prevent cardiotoxicity in this subset of patients. Cardiac biomarkers hold important diagnostic and prognostic value in various cardiac diseases. In this review, we discuss the use of biomarkers in patients receiving chemotherapy, highlighting data behind the use of troponin, B-type natriuretic peptide, and myeloperoxidase. We also discuss the use of dexrazoxane, angiotensin-converting enzyme inhibitors, and beta blockers in the treatment and prevention of chemotherapy-induced cardiotoxicity. Cardiac biomarkers may serve an important role in selecting patients that are at high risk of cardiotoxicity and can potentially be used to guide the administration of drugs to treat and prevent cardiotoxicity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015615</affiliation-url><afid>60015615</afid><affilname>Stanford University Medical Center</affilname><name-variant>Stanford University Medical Center</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:43161448600</author-url><authid>43161448600</authid><authname>Singh D.</authname><surname>Singh</surname><given-name>Dhssraj</given-name><initials>D.</initials><afid>60021160</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16417660100</author-url><authid>16417660100</authid><authname>Thakur A.</authname><surname>Thakur</surname><given-name>Akanksha</given-name><initials>A.</initials><afid>60015615</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56374022800</author-url><authid>56374022800</authid><authname>Tang W.</authname><surname>Tang</surname><given-name>W. H Wilson</given-name><initials>W.H.W.</initials><afid>60021160</afid></author><authkeywords>B-type natriuretic peptide | Cardiac biomarkers | Cardiac disease | Cardiomyopathy | Chemotherapy | Diagnosis</authkeywords><intid>1035880751</intid><source-id>4000148301</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929074674"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929074674?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929074674&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929074674&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0065240714000329"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929074674</prism:url><dc:identifier>SCOPUS_ID:84929074674</dc:identifier><eid>2-s2.0-84929074674</eid><dc:title>Cellular and Extracellular Matrix Basis for Heterogeneity in Mitral Annular Contraction</dc:title><dc:creator>Stephens E.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>151-159</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-014-0209-3</prism:doi><dc:description>© 2015, Biomedical Engineering Society. Regional heterogeneity in mitral annular contraction, which is generally ascribed to the fibrous vs. muscular annular composition, ensures proper leaflet motion and timing of coaptation. It is unknown whether the fibroblast-like cells in the annulus modulate this heterogeneity, even though valvular interstitial cells (VICs) can be mechanically “activated.” Fourteen sheep underwent implantation of radiopaque markers around the mitral annulus defining four segments: septal (SEPT), lateral (LAT), and anterior (ANT-C) and posterior (POST-C) commissures. Segmental annular contraction was calculated using biplane videofluoroscopy. Immunohistochemistry of annular cross sections assessed regional matrix content, matrix turnover, and cell phenotype. Micropipette aspiration measured the effective modulus of the leaflets adjacent to the myocardial border. Whereas SEPT contained more collagen I and III, LAT demonstrated more collagen and elastin turnover as shown by greater decorin, lysyl oxidase, and matrix metalloprotease (MMP)-13 and smooth muscle alpha-actin (SMaA). This greater matrix turnover paralleled greater annular contraction in LAT vs. SEPT (22.5 vs. 4.1%). Similarly, POST-C had more SMaA and MMP13 than ANT-C, consistent with greater annular contraction in POST-C (18.8 vs. 11.1%). Interestingly, POST-C had the greatest effective modulus, significantly higher than LAT. These data suggest that matrix turnover by activated VICs relates to annular motion heterogeneity, maintains steady-state mechanical properties in the annulus, and could be a therapeutic target when annular motion is impaired. Conversely, alterations in this heterogeneous annular contraction, whether through disease or secondary to ring annuloplasty, could disrupt this normal pattern of cell-mediated matrix remodeling and further adversely impact mitral valve function.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027565</affiliation-url><afid>60027565</afid><affilname>Columbia University Medical Center</affilname><name-variant>Columbia University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020000</affiliation-url><afid>60020000</afid><affilname>Spectrum Health</affilname><name-variant>Spectrum Health</name-variant><affiliation-city>Grand Rapids</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031633</affiliation-url><afid>60031633</afid><affilname>Palo Alto Medical Foundation</affilname><name-variant>Palo Alto Medical Clinic</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16686780800</author-url><authid>16686780800</authid><authname>Stephens E.</authname><surname>Stephens</surname><given-name>Elizabeth H.</given-name><initials>E.H.</initials><afid>60005286</afid><afid>60027565</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16686780800</author-url><authid>16686780800</authid><authname>Stephens E.</authname><surname>Stephens</surname><given-name>Elizabeth H.</given-name><initials>E.H.</initials><afid>60005286</afid><afid>60027565</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37023079400</author-url><authid>37023079400</authid><authname>Fahrenholtz M.</authname><surname>Fahrenholtz</surname><given-name>Monica M.</given-name><initials>M.M.</initials><afid>60005286</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56638770200</author-url><authid>56638770200</authid><authname>Connell P.</authname><surname>Connell</surname><given-name>Patrick S.</given-name><initials>P.S.</initials><afid>60005286</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004507309</author-url><authid>7004507309</authid><authname>Timek T.</authname><surname>Timek</surname><given-name>Tomasz A.</given-name><initials>T.A.</initials><afid>60032838</afid><afid>60020000</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004507309</author-url><authid>7004507309</authid><authname>Timek T.</authname><surname>Timek</surname><given-name>Tomasz A.</given-name><initials>T.A.</initials><afid>60032838</afid><afid>60020000</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006570201</author-url><authid>7006570201</authid><authname>Daughters G.</authname><surname>Daughters</surname><given-name>George T.</given-name><initials>G.T.</initials><afid>60032838</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35102446500</author-url><authid>35102446500</authid><authname>Kuo J.</authname><surname>Kuo</surname><given-name>Joyce J.</given-name><initials>J.J.</initials><afid>60005286</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35103313700</author-url><authid>35103313700</authid><authname>Patton A.</authname><surname>Patton</surname><given-name>Aaron M.</given-name><initials>A.M.</initials><afid>60005286</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006382451</author-url><authid>7006382451</authid><authname>Ingels N.</authname><surname>Ingels</surname><given-name>Neil B.</given-name><initials>N.B.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006382451</author-url><authid>7006382451</authid><authname>Ingels N.</authname><surname>Ingels</surname><given-name>Neil B.</given-name><initials>N.B.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55662957500</author-url><authid>55662957500</authid><authname>Miller D.</authname><surname>Miller</surname><given-name>D. Craig</given-name><initials>D.C.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55662957500</author-url><authid>55662957500</authid><authname>Miller D.</authname><surname>Miller</surname><given-name>D. Craig</given-name><initials>D.C.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6602569298</author-url><authid>6602569298</authid><authname>Grande-Allen K.</authname><surname>Grande-Allen</surname><given-name>K. Jane</given-name><initials>K.J.</initials><afid>60005286</afid></author><authkeywords>Annular contraction | Collagen | Extracellular matrix | Matrix metalloproteases | Mitral annulus</authkeywords><intid>535901614</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929089868"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929089868?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929089868&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929089868&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929089868</prism:url><dc:identifier>SCOPUS_ID:84929089868</dc:identifier><eid>2-s2.0-84929089868</eid><dc:title>Open vs. Minimally Invasive Mitral Valve Surgery: Surgical Technique, Indications and Results</dc:title><dc:creator>Sündermann S.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>160-166</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-015-0210-5</prism:doi><dc:description>© 2015, Biomedical Engineering Society. Minimally invasive procedures are the standard approach in many centres but are still under debate in regards of inferiority compared to conventional mitral valve surgery through a median sternotomy. The aim of this review was to summarize the current literature comparing minimally invasive mitral valve surgery (MIVS) and conventional mitral valve surgery. In this review of the current literature, we summarize our findings from a recent meta-analysis and add information from papers that were published afterwards. There were no differences between patients treated minimally invasive or through a conventional sternotomy approach in regards of perioperative stroke rate and mortality. Procedural time, cardio-pulmonary-bypass time and cross-clamp time were longer in the MIVS group. In contrast, length of intensive care unit (ICU) stay and length of in hospital stay were significantly reduced in this group. Need for blood transfusion was lower in the MIVS group. Other outcomes like i.e., the rate of rethoracotomies or renal failure didn’t differ between the groups. Repair rates and long-term freedom from recurrence of mitral regurgitation and reoperation are similar. Newer publications underline these findings. The current literature shows that MIVS and conventional mitral valve surgery show a similar perioperative outcome. Minimally invasive mitral valve surgery is favourable with regards to ICU stay, in hospital stay as well as need for blood transfusion.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009113</affiliation-url><afid>60009113</afid><affilname>Deutsches Herzzentrum Berlin</affilname><name-variant>German Heart Institute</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110211669</affiliation-url><afid>110211669</afid><affilname>University Heart Center Freiburg-Bad Krozingen</affilname><name-variant>University Heart Center Freiburg-Bad Krozingen</name-variant><affiliation-city>Freiburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36085538600</author-url><authid>36085538600</authid><authname>Sündermann S.</authname><surname>Sündermann</surname><given-name>Simon H.</given-name><initials>S.H.</initials><afid>60009113</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36678858600</author-url><authid>36678858600</authid><authname>Czerny M.</authname><surname>Czerny</surname><given-name>Martin</given-name><initials>M.</initials><afid>110211669</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26867592300</author-url><authid>26867592300</authid><authname>Falk V.</authname><surname>Falk</surname><given-name>Volkmar</given-name><initials>V.</initials><afid>60009113</afid></author><authkeywords>Meta-analysis | Minimally invasive mitral valve surgery | Minimally invasive mitral valve surgery vs. Conventional mitral valve surgery | Mitral valve surgery | Review</authkeywords><intid>1785902756</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927778026"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927778026?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927778026&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927778026&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002166"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927778026</prism:url><dc:identifier>SCOPUS_ID:84927778026</dc:identifier><eid>2-s2.0-84927778026</eid><dc:title>Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study in a community-based cohort</dc:title><dc:creator>Fontes J.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>431-436</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.043</prism:doi><pii>S0021915015002166</pii><dc:description>© 2015 Elsevier Ireland Ltd. Introduction: Inflammation and inflammatory biomarkers have emerged as integral components and predictors of incident cardiovascular (CV) disease. Omega-3 fatty acids, particularly eicosapentaenoic and docosahexaenoic acids (EPA and DHA) have anti-inflammatory properties, and have been variably associated with lower blood pressure, favorable blood lipid changes, and reduced CV events. Methods and results: We examined the cross-sectional association of red blood cell (RBC) fatty acids, representative of body membrane fatty acid composition, with 10 biomarkers active in multiple inflammatory pathways in 2724 participants (mean age 66±9 years, 54% women, 8% minorities) from the Framingham Offspring and minority Omni Cohorts. After multivariable adjustment, the RBC EPA and DHA content was inversely correlated (all P≤0.001) with 8 biomarkers: urinary isoprostanes (r=-0.16); and soluble interleukin-6 (r=-0.10); C-reactive protein (r=-0.08); tumor necrosis factor receptor 2 (r=-0.08); intercellular adhesion molecule-1 (r=-0.08); P-selectin (r=-0.06); lipoprotein-associated phospholipase-A2 mass (r=-0.11) and activity (r=-0.08). The correlations for monocyte chemoattractant protein-1 was-0.05, P=0.006 and osteoprotegerin (r=-0.06, P=0.002) were only nominally significant. Conclusion: In our large community-based study, we observed modest inverse associations between several types of inflammatory biomarkers with RBC omega-3 fatty acid levels. Our findings are consistent with the hypothesis that omega-3 fatty acids have anti-inflammatory properties.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022386</affiliation-url><afid>60022386</afid><affilname>Framingham Heart Study</affilname><name-variant>Framingham Heart Study</name-variant><affiliation-city>Framingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006385</affiliation-url><afid>60006385</afid><affilname>Boston University School of Medicine</affilname><name-variant>Boston University School of Medicine</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006385</affiliation-url><afid>60006385</afid><affilname>Boston University School of Medicine</affilname><name-variant>Boston University School of Medicine</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003526</affiliation-url><afid>60003526</afid><affilname>Boston Medical Center</affilname><name-variant>Boston Medical Center</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019674</affiliation-url><afid>60019674</afid><affilname>Boston University</affilname><name-variant>Boston University</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018701</affiliation-url><afid>60018701</afid><affilname>Boston University School of Public Health</affilname><name-variant>Boston University School of Public Health</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018701</affiliation-url><afid>60018701</afid><affilname>Boston University School of Public Health</affilname><name-variant>Boston University School of Public Health</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028179</affiliation-url><afid>60028179</afid><affilname>University of South Dakota</affilname><name-variant>University of South Dakota</name-variant><affiliation-city>Vermillion</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">20</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37021461500</author-url><authid>37021461500</authid><authname>Fontes J.</authname><surname>Fontes</surname><given-name>João D.</given-name><initials>J.D.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37021461500</author-url><authid>37021461500</authid><authname>Fontes J.</authname><surname>Fontes</surname><given-name>João D.</given-name><initials>J.D.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37021461500</author-url><authid>37021461500</authid><authname>Fontes J.</authname><surname>Fontes</surname><given-name>João D.</given-name><initials>J.D.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56312196800</author-url><authid>56312196800</authid><authname>Rahman F.</authname><surname>Rahman</surname><given-name>Faisal</given-name><initials>F.</initials><afid>60003526</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55222239200</author-url><authid>55222239200</authid><authname>Lacey S.</authname><surname>Lacey</surname><given-name>Sean</given-name><initials>S.</initials><afid>60022386</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7203022563</author-url><authid>7203022563</authid><authname>Larson M.</authname><surname>Larson</surname><given-name>Martin G.</given-name><initials>M.G.</initials><afid>60022386</afid><afid>60019674</afid><afid>60018701</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7203022563</author-url><authid>7203022563</authid><authname>Larson M.</authname><surname>Larson</surname><given-name>Martin G.</given-name><initials>M.G.</initials><afid>60022386</afid><afid>60019674</afid><afid>60018701</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7203022563</author-url><authid>7203022563</authid><authname>Larson M.</authname><surname>Larson</surname><given-name>Martin G.</given-name><initials>M.G.</initials><afid>60022386</afid><afid>60019674</afid><afid>60018701</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35369677100</author-url><authid>35369677100</authid><authname>Vasan R.</authname><surname>Vasan</surname><given-name>Ramachandran S.</given-name><initials>R.S.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35369677100</author-url><authid>35369677100</authid><authname>Vasan R.</authname><surname>Vasan</surname><given-name>Ramachandran S.</given-name><initials>R.S.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35369677100</author-url><authid>35369677100</authid><authname>Vasan R.</authname><surname>Vasan</surname><given-name>Ramachandran S.</given-name><initials>R.S.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35369677100</author-url><authid>35369677100</authid><authname>Vasan R.</authname><surname>Vasan</surname><given-name>Ramachandran S.</given-name><initials>R.S.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55628588576</author-url><authid>55628588576</authid><authname>Benjamin E.</authname><surname>Benjamin</surname><given-name>Emelia J.</given-name><initials>E.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55628588576</author-url><authid>55628588576</authid><authname>Benjamin E.</authname><surname>Benjamin</surname><given-name>Emelia J.</given-name><initials>E.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55628588576</author-url><authid>55628588576</authid><authname>Benjamin E.</authname><surname>Benjamin</surname><given-name>Emelia J.</given-name><initials>E.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55628588576</author-url><authid>55628588576</authid><authname>Benjamin E.</authname><surname>Benjamin</surname><given-name>Emelia J.</given-name><initials>E.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid><afid>60018701</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7402163908</author-url><authid>7402163908</authid><authname>Harris W.</authname><surname>Harris</surname><given-name>William S.</given-name><initials>W.S.</initials><afid>60028179</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36808528200</author-url><authid>36808528200</authid><authname>Robins S.</authname><surname>Robins</surname><given-name>Sander J.</given-name><initials>S.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36808528200</author-url><authid>36808528200</authid><authname>Robins S.</authname><surname>Robins</surname><given-name>Sander J.</given-name><initials>S.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36808528200</author-url><authid>36808528200</authid><authname>Robins S.</authname><surname>Robins</surname><given-name>Sander J.</given-name><initials>S.J.</initials><afid>60022386</afid><afid>60006385</afid><afid>60006385</afid></author><authkeywords>Biomarkers | Cross-sectional study | Inflammation | Omega-3 fatty acids</authkeywords><intid>1035661456</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929148231"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929148231?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929148231&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929148231&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929148231</prism:url><dc:identifier>SCOPUS_ID:84929148231</dc:identifier><eid>2-s2.0-84929148231</eid><dc:title>Oxidized low-density lipoprotein alters endothelial progenitor cell populations</dc:title><dc:creator>Cui Y.</dc:creator><prism:publicationName>Frontiers in Bioscience - Landmark</prism:publicationName><prism:issn>10939946</prism:issn><prism:eIssn>10934715</prism:eIssn><prism:volume>20</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>975-988</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><dc:description>© 2015, Frontiers in Bioscience. All rights reserved. Oxidized low-density lipoprotein (ox-LDL) is critical to atherosclerosis in hyperlipidemia. Bone marrow (BM)-derived endothelial progenitor cells (EPCs) are important in preventing atherosclerosis, however these cells are significantly decreased in number in hyperlipidemia. This study aimed to determine whether ox-LDL and hyperlipidemia exert similar effects on EPC populations, and to investigate the involvement of reactive oxygen species (ROS). ROS production in BM and blood was significantly increased in male C57BL/6 mice treated with intravenous ox-LDL, and in hyperlipidemic LDL receptor knockout mice fed with a 4-month high-fat diet. ROS formation was effectively blocked by overexpression of antioxidant enzymes or N-acetylcysteine treatment. In both hyperlipidemic and ox-LDL-treated mice, the number of c-Kit&lt;sup&gt;+&lt;/sup&gt;/CD31&lt;sup&gt;+&lt;/sup&gt; cells in BM and blood and of Sca-1&lt;sup&gt;+&lt;/sup&gt; /Flk-&lt;sup&gt;1+&lt;/sup&gt; cells in blood significantly decreased, whereas the number of blood CD34&lt;sup&gt;+&lt;/sup&gt;/Flk-1&lt;sup&gt;+&lt;/sup&gt; cells increased. In contrast, the number of blood CD34&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; cells increased in ox-LDL-treated mice but decreased in hyperlipidemic mice. Only the changes in CD34&lt;sup&gt;+&lt;/sup&gt; /Flk-1&lt;sup&gt;+&lt;/sup&gt; cell number were prevented by inhibiting ROS production. These data suggested that ox-LDL produced significant changes in BM and blood EPC populations, largely similar to chronic hyperlipidemia, via predominantly ROS-independent mechanism(s).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090016</affiliation-url><afid>60090016</afid><affilname>Dorothy M. Davis Heart and Lung Research Institute</affilname><name-variant>Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022144</affiliation-url><afid>60022144</afid><affilname>University of Central Florida</affilname><name-variant>University of Central Florida</name-variant><affiliation-city>Orlando</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55260938600</author-url><authid>55260938600</authid><authname>Cui Y.</authname><surname>Cui</surname><given-name>Yuqi</given-name><initials>Y.</initials><afid>60090016</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55305651600</author-url><authid>55305651600</authid><authname>Narasimhulu C.</authname><surname>Narasimhulu</surname><given-name>Chandrakala A.</given-name><initials>C.A.</initials><afid>60022144</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56300991900</author-url><authid>56300991900</authid><authname>Liu L.</authname><surname>Liu</surname><given-name>Lingjuan</given-name><initials>L.</initials><afid>60090016</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55718334400</author-url><authid>55718334400</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xin</given-name><initials>X.</initials><afid>60090016</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55907481400</author-url><authid>55907481400</authid><authname>Xiao Y.</authname><surname>Xiao</surname><given-name>Yuan</given-name><initials>Y.</initials><afid>60090016</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36065598500</author-url><authid>36065598500</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jia</given-name><initials>J.</initials><afid>60090016</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7402761495</author-url><authid>7402761495</authid><authname>Xie X.</authname><surname>Xie</surname><given-name>Xiaoyun</given-name><initials>X.</initials><afid>60090016</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56662405000</author-url><authid>56662405000</authid><authname>Hao H.</authname><surname>Hao</surname><given-name>Hong</given-name><initials>H.</initials><afid>60090016</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56640960900</author-url><authid>56640960900</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jason Z.</given-name><initials>J.Z.</initials><afid>60090016</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56640398400</author-url><authid>56640398400</authid><authname>He G.</authname><surname>He</surname><given-name>Guanglong</given-name><initials>G.</initials><afid>60090016</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7101694348</author-url><authid>7101694348</authid><authname>Cowan P.</authname><surname>Cowan</surname><given-name>Peter J.</given-name><initials>P.J.</initials><afid>60026553</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:24447785400</author-url><authid>24447785400</authid><authname>Cui L.</authname><surname>Cui</surname><given-name>Lianqun</given-name><initials>L.</initials><afid>60031031</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56648354900</author-url><authid>56648354900</authid><authname>Zhu H.</authname><surname>Zhu</surname><given-name>Hua</given-name><initials>H.</initials><afid>60090016</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7101695320</author-url><authid>7101695320</authid><authname>Parthasarathy S.</authname><surname>Parthasarathy</surname><given-name>Sampath</given-name><initials>S.</initials><afid>60022144</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7406676747</author-url><authid>7406676747</authid><authname>Liu Z.</authname><surname>Liu</surname><given-name>Zhenguo</given-name><initials>Z.</initials></author><authkeywords>EPC | Hyperlipidemia | NAC | Ox-LDL | ROS</authkeywords><intid>1785919319</intid><source-id>27974</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929346593"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929346593?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929346593&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929346593&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929346593</prism:url><dc:identifier>SCOPUS_ID:84929346593</dc:identifier><eid>2-s2.0-84929346593</eid><dc:title>Epigenetic-Mediated Reprogramming of Pancreatic Endocrine Cells</dc:title><dc:creator>Mathiyalagan P.</dc:creator><prism:publicationName>Antioxidants and Redox Signaling</prism:publicationName><prism:issn>15230864</prism:issn><prism:eIssn>15577716</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>16</prism:issueIdentifier><prism:pageRange>1483-1495</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1089/ars.2014.6103</prism:doi><dc:description>© Copyright 2015, Mary Ann Liebert, Inc. Significance: Type 1 diabetes (T1D) results from cell-mediated autoimmune destruction of insulin-secreting pancreatic beta cells (β-cells). In the context of T1D, the scarcity of organ donors has driven research to alternate sources of functionally competent, insulin-secreting β-cells as substitute for donor islets to meet the clinical need for transplantation therapy. Recent Advances: Experimental evidence of an inherent plasticity of pancreatic cells has fuelled interest in in vivo regeneration of β-cells. Transcriptional modulation and direct reprogramming of noninsulin secreting pancreatic α-cells to functionally mimic insulin-secreting β-cells is one of the promising avenues to the treatment of diabetes. Recent studies now show that adult progenitor and glucagon&lt;sup&gt;+&lt;/sup&gt; α-cells can be converted into β-like cells in vivo, as a result of specific activation of the Pax4 gene in α-cells and curing diabetes in preclinical models. Critical Issues: The challenge now is to understand the precise developmental transitions mediated by endocrine transcription factors and co-regulatory determinants responsible for pancreatic function and repair. Future Directions: Epigenetic-mediated regulation of transcription factor binding in pancreatic α-cells by specific drugs to direct reprogramming into functional insulin producing cells could be of potential innovative therapy for the treatment of T1D.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36010738600</author-url><authid>36010738600</authid><authname>Mathiyalagan P.</authname><surname>Mathiyalagan</surname><given-name>Prabhu</given-name><initials>P.</initials><afid>60033409</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55355490100</author-url><authid>55355490100</authid><authname>Keating S.</authname><surname>Keating</surname><given-name>Samuel T.</given-name><initials>S.T.</initials><afid>60033409</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507705705</author-url><authid>6507705705</authid><authname>Al-Hasani K.</authname><surname>Al-Hasani</surname><given-name>Keith</given-name><initials>K.</initials><afid>60033409</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8966609000</author-url><authid>8966609000</authid><authname>El-Osta A.</authname><surname>El-Osta</surname><given-name>Assam</given-name><initials>A.</initials><afid>60033409</afid><afid>60026553</afid><afid>60019578</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8966609000</author-url><authid>8966609000</authid><authname>El-Osta A.</authname><surname>El-Osta</surname><given-name>Assam</given-name><initials>A.</initials><afid>60033409</afid><afid>60026553</afid><afid>60019578</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8966609000</author-url><authid>8966609000</authid><authname>El-Osta A.</authname><surname>El-Osta</surname><given-name>Assam</given-name><initials>A.</initials><afid>60033409</afid><afid>60026553</afid><afid>60019578</afid></author><intid>1035941189</intid><source-id>27514</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927729932"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927729932?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927729932&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927729932&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015001744"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927729932</prism:url><dc:identifier>SCOPUS_ID:84927729932</dc:identifier><eid>2-s2.0-84927729932</eid><dc:title>The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial</dc:title><dc:creator>Stefanutti C.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>408-414</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.014</prism:doi><pii>S0021915015001744</pii><dc:description>© 2015 The Authors. Objectives: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide. Methods: Existing lipid-lowering therapy, including apheresis, was to remain stable from Week-6 to Week 26. Lomitapide dose was escalated on the basis of individual safety/tolerability from 5mg to 60mg a day (maximum). The primary endpoint was mean percent change in LDL-C from baseline to Week 26 (efficacy phase), after which patients remained on lomitapide through Week 78 for safety assessment and further evaluation of efficacy. During this latter period, apheresis could be adjusted. We analysed the impact of apheresis on LDL-C reductions in patients receiving lomitapide. Results: Of the 29 patients that entered the efficacy phase, 18 (62%) were receiving apheresis at baseline. Twenty-three patients (13 receiving apheresis) completed the Week 26 evaluation. Of the six patients who discontinued in the first 26 weeks, five were receiving apheresis. There were no significant differences in percent change from baseline of LDL-C at Week 26 in patients treated (-48%) and not treated (-55%) with apheresis (p=0.545). Changes in Lp(a) levels were modest and not different between groups (p=0.436). Conclusion: The LDL-C lowering efficacy of lomitapide is unaffected by lipoprotein apheresis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000356</affiliation-url><afid>60000356</afid><affilname>University of Cape Town</affilname><name-variant>University of Cape Town</name-variant><affiliation-city>Cape Town</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017697</affiliation-url><afid>60017697</afid><affilname>Universita degli Studi di Palermo</affilname><name-variant>Università di Palermo</name-variant><affiliation-city>Palermo</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008371</affiliation-url><afid>60008371</afid><affilname>Netcare</affilname><name-variant>Netcare Rosebank Hospital</name-variant><affiliation-city>Sandton</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010884</affiliation-url><afid>60010884</afid><affilname>Western University</affilname><name-variant>University of Western Ontario</name-variant><affiliation-city>London</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015852</affiliation-url><afid>60015852</afid><affilname>Ospedale Niguarda Ca'Granda</affilname><name-variant>Ospedale Niguarda Ca' Granda</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016173</affiliation-url><afid>60016173</afid><affilname>Cedars-Sinai Medical Center</affilname><name-variant>Cedars-Sinai Medical Center</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009507</affiliation-url><afid>60009507</afid><affilname>Universite de Montreal</affilname><name-variant>University of Montreal</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024690</affiliation-url><afid>60024690</afid><affilname>University of Ferrara</affilname><name-variant>Università di Ferrara</name-variant><affiliation-city>Ferrara</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021902</affiliation-url><afid>60021902</afid><affilname>Universiteit van Pretoria</affilname><name-variant>University of Pretoria</name-variant><affiliation-city>Pretoria</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112724254</affiliation-url><afid>112724254</afid><affilname>Aegerion Pharmaceuticals</affilname><name-variant>Aegerion Pharmaceuticals</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110178212</affiliation-url><afid>110178212</afid><affilname>Veristat</affilname><name-variant>Veristat</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56055363600</author-url><authid>56055363600</authid><authname>Stefanutti C.</authname><surname>Stefanutti</surname><given-name>C.</given-name><initials>C.</initials><afid>60032350</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005939626</author-url><authid>7005939626</authid><authname>Blom D.</authname><surname>Blom</surname><given-name>D. J.</given-name><initials>D.J.</initials><afid>60000356</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005411173</author-url><authid>7005411173</authid><authname>Averna M.</authname><surname>Averna</surname><given-name>M. R.</given-name><initials>M.R.</initials><afid>60017697</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701789889</author-url><authid>6701789889</authid><authname>Meagher E.</authname><surname>Meagher</surname><given-name>E. A.</given-name><initials>E.A.</initials><afid>60006297</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56594775700</author-url><authid>56594775700</authid><authname>Theron H.</authname><surname>Theron</surname><given-name>H. dT</given-name><initials>H.d.</initials><afid>60008371</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005986982</author-url><authid>7005986982</authid><authname>Marais A.</authname><surname>Marais</surname><given-name>A. D.</given-name><initials>A.D.</initials><afid>60000356</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56601759200</author-url><authid>56601759200</authid><authname>Hegele R.</authname><surname>Hegele</surname><given-name>R. A.</given-name><initials>R.A.</initials><afid>60010884</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36042362900</author-url><authid>36042362900</authid><authname>Sirtori C.</authname><surname>Sirtori</surname><given-name>C. R.</given-name><initials>C.R.</initials><afid>60015852</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55546859900</author-url><authid>55546859900</authid><authname>Shah P.</authname><surname>Shah</surname><given-name>P. K.</given-name><initials>P.K.</initials><afid>60016173</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55352480800</author-url><authid>55352480800</authid><authname>Gaudet D.</authname><surname>Gaudet</surname><given-name>D.</given-name><initials>D.</initials><afid>60009507</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35273474900</author-url><authid>35273474900</authid><authname>Vigna G.</authname><surname>Vigna</surname><given-name>G. B.</given-name><initials>G.B.</initials><afid>60024690</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6603834862</author-url><authid>6603834862</authid><authname>Sachais B.</authname><surname>Sachais</surname><given-name>B. S.</given-name><initials>B.S.</initials><afid>60006297</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6602579383</author-url><authid>6602579383</authid><authname>Di Giacomo S.</authname><surname>Di Giacomo</surname><given-name>S.</given-name><initials>S.</initials><afid>60032350</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:55567880300</author-url><authid>55567880300</authid><authname>du Plessis A.</authname><surname>du Plessis</surname><given-name>A. M E</given-name><initials>A.M.E.</initials><afid>60021902</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6506410175</author-url><authid>6506410175</authid><authname>Bloedon L.</authname><surname>Bloedon</surname><given-name>L. T.</given-name><initials>L.T.</initials><afid>112724254</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:56594687700</author-url><authid>56594687700</authid><authname>Balser J.</authname><surname>Balser</surname><given-name>J.</given-name><initials>J.</initials><afid>110178212</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:35378627400</author-url><authid>35378627400</authid><authname>Rader D.</authname><surname>Rader</surname><given-name>D. J.</given-name><initials>D.J.</initials><afid>60006297</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:6602971540</author-url><authid>6602971540</authid><authname>Cuchel M.</authname><surname>Cuchel</surname><given-name>M.</given-name><initials>M.</initials><afid>60006297</afid></author><authkeywords>Homozygous familial hypercholesterolaemia | Lipoprotein apheresis | Lomitapide</authkeywords><intid>35667035</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927758941"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927758941?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927758941&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927758941&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002312"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927758941</prism:url><dc:identifier>SCOPUS_ID:84927758941</dc:identifier><eid>2-s2.0-84927758941</eid><dc:title>Insulin therapy in insulin resistance: Could it be part of a lethal pathway?</dc:title><dc:creator>Bittencourt M.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>400-401</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.013</prism:doi><pii>S0021915015002312</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>no</subtype><subtypeDescription>Note</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36117675900</author-url><authid>36117675900</authid><authname>Bittencourt M.</authname><surname>Bittencourt</surname><given-name>Márcio Sommer</given-name><initials>M.S.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36117675900</author-url><authid>36117675900</authid><authname>Bittencourt M.</authname><surname>Bittencourt</surname><given-name>Márcio Sommer</given-name><initials>M.S.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23987797600</author-url><authid>23987797600</authid><authname>Hajjar L.</authname><surname>Hajjar</surname><given-name>Ludhmila Abrahao</given-name><initials>L.A.</initials><afid>60008088</afid></author><authkeywords>Cardiovascular disease | Diabetes | Insulin resistance | Insulin therapy | Mortality</authkeywords><intid>35666286</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929175928"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929175928?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929175928&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929175928&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929175928</prism:url><dc:identifier>SCOPUS_ID:84929175928</dc:identifier><eid>2-s2.0-84929175928</eid><dc:title>Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury</dc:title><dc:creator>Duthie K.</dc:creator><prism:publicationName>British Journal of Pharmacology</prism:publicationName><prism:issn>00071188</prism:issn><prism:eIssn>14765381</prism:eIssn><prism:volume>172</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:pageRange>2827-2837</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bph.13086</prism:doi><dc:description>© 2015 The British Pharmacological Society. Background and Purpose Endothelin (ET) receptor antagonism reduces neointimal lesion formation in animal models. This investigation addressed the hypothesis that the selective ET&lt;inf&gt;A&lt;/inf&gt; receptor antagonist sitaxentan would be more effective than mixed ET&lt;inf&gt;A&lt;/inf&gt;&lt;inf&gt;/&lt;/inf&gt;&lt;inf&gt;B&lt;/inf&gt; receptor antagonism at inhibiting neointimal proliferation in a mouse model of intraluminal injury. Experimental Approach Antagonism of ET&lt;inf&gt;A&lt;/inf&gt; receptors by sitaxentan (1-100 nM) was assessed in femoral arteries isolated from adult, male C57Bl6 mice using isometric wire myography. Neointimal lesion development was induced by intraluminal injury in mice receiving sitaxentan (ET&lt;inf&gt;A&lt;/inf&gt; antagonist; 15 mg·kg&lt;sup&gt;-1&lt;/sup&gt;·day&lt;sup&gt;-1&lt;/sup&gt;), A192621 (ET&lt;inf&gt;B&lt;/inf&gt; antagonist; 30 mg·kg&lt;sup&gt;-1&lt;/sup&gt;·day&lt;sup&gt;-1&lt;/sup&gt;), the combination of both antagonists or vehicle. Treatment began 1 week before, and continued for 28 days after, surgery. Femoral arteries were then harvested for analysis of lesion size and composition. Key Results Sitaxentan produced a selective, concentration-dependent parallel rightward shift of ET-1-mediated contraction in isolated femoral arteries. Sitaxentan reduced neointimal lesion size, whereas ET&lt;inf&gt;B&lt;/inf&gt; and combined ET&lt;inf&gt;A&lt;/inf&gt;&lt;inf&gt;/&lt;/inf&gt;&lt;inf&gt;B&lt;/inf&gt; receptor antagonism did not. Macrophage and α-smooth muscle actin content were unaltered by ET receptor antagonism but sitaxentan reduced the amount of collagen in lesions. Conclusions and Implications These results suggest that ET&lt;inf&gt;A&lt;/inf&gt; receptor antagonism would be more effective than combined ET&lt;inf&gt;A&lt;/inf&gt;/ET&lt;inf&gt;B&lt;/inf&gt; receptor antagonism at reducing neointimal lesion formation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027272</affiliation-url><afid>60027272</afid><affilname>University of Edinburgh</affilname><name-variant>University of Edinburgh</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010719</affiliation-url><afid>60010719</afid><affilname>National Heart and Lung Institute</affilname><name-variant>National Heart and Lung Institute</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115234515</affiliation-url><afid>115234515</afid><affilname>Drax Power Station North Yorkshire</affilname><name-variant>Drax Power Station North Yorkshire</name-variant><affiliation-city/><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55263375300</author-url><authid>55263375300</authid><authname>Duthie K.</authname><surname>Duthie</surname><given-name>Karolina M.</given-name><initials>K.M.</initials><afid>60027272</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701389748</author-url><authid>6701389748</authid><authname>Hadoke P.</authname><surname>Hadoke</surname><given-name>Patrick W F</given-name><initials>P.W.F.</initials><afid>60027272</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35083717000</author-url><authid>35083717000</authid><authname>Kirkby N.</authname><surname>Kirkby</surname><given-name>Nicholas S.</given-name><initials>N.S.</initials><afid>60027272</afid><afid>60010719</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35083717000</author-url><authid>35083717000</authid><authname>Kirkby N.</authname><surname>Kirkby</surname><given-name>Nicholas S.</given-name><initials>N.S.</initials><afid>60027272</afid><afid>60010719</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7404491514</author-url><authid>7404491514</authid><authname>Miller E.</authname><surname>Miller</surname><given-name>Eileen</given-name><initials>E.</initials><afid>60027272</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55902920400</author-url><authid>55902920400</authid><authname>Ivy J.</authname><surname>Ivy</surname><given-name>Jessica R.</given-name><initials>J.R.</initials><afid>60027272</afid><afid>115234515</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55902920400</author-url><authid>55902920400</authid><authname>Ivy J.</authname><surname>Ivy</surname><given-name>Jessica R.</given-name><initials>J.R.</initials><afid>60027272</afid><afid>115234515</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56604834200</author-url><authid>56604834200</authid><authname>McShane J.</authname><surname>McShane</surname><given-name>John F.</given-name><initials>J.F.</initials><afid>60027272</afid><afid>60022148</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56604834200</author-url><authid>56604834200</authid><authname>McShane J.</authname><surname>McShane</surname><given-name>John F.</given-name><initials>J.F.</initials><afid>60027272</afid><afid>60022148</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56272418100</author-url><authid>56272418100</authid><authname>Lim W.</authname><surname>Lim</surname><given-name>Win Gel</given-name><initials>W.G.</initials><afid>60027272</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35432554600</author-url><authid>35432554600</authid><authname>Webb D.</authname><surname>Webb</surname><given-name>David J.</given-name><initials>D.J.</initials><afid>60027272</afid></author><intid>535918251</intid><source-id>20084</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928633234"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928633234?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928633234&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928633234&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928633234</prism:url><dc:identifier>SCOPUS_ID:84928633234</dc:identifier><eid>2-s2.0-84928633234</eid><dc:title>New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?</dc:title><dc:creator>Paulis L.</dc:creator><prism:publicationName>Current Hypertension Reports</prism:publicationName><prism:issn>15226417</prism:issn><prism:eIssn>15343111</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11906-015-0557-x</prism:doi><dc:description>© 2015, The Author(s). Arterial hypertension is the most prevalent controllable disease world-wide. Yet, we still need to further improve blood pressure control, deal with resistant hypertension, and we hope to reduce risk “beyond blood pressure.” The number of candidate molecules aspiring for these aims is constantly declining. The new possible approaches to combat high blood pressure include neprilysin/neutral endopeptidase (NEP) inhibition, particularly when combined with an angiotensin receptor blockade (such as the ARNI, LCZ696), phosphodiesterase 5 (PDE5) inhibition (KD027/Slx-2101), natriuretic agents (PL3994), or a long-lasting vasointestinal peptide (VIP) analogue (PB1046). Other options exploit the protective arm of the renin-angiotensin-aldosterone system by stimulating the angiotensin AT2 receptor (compound 21), the Mas receptor (AVE-0991), or the angiotensin converting enzyme 2. Finally, we review the possibilities how to optimize the use of the available treatment options by using drug combinations or by tailoring therapy to each patient’s angiotensin peptide profile.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001987</affiliation-url><afid>60001987</afid><affilname>Comenius University</affilname><name-variant>Comenius University</name-variant><affiliation-city>Bratislava</affiliation-city><affiliation-country>Slovakia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010330</affiliation-url><afid>60010330</afid><affilname>Slovak Academy of Sciences</affilname><name-variant>Slovak Academy of Sciences</name-variant><affiliation-city>Bratislava</affiliation-city><affiliation-country>Slovakia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013083</affiliation-url><afid>60013083</afid><affilname>Institute of Experimental Endocrinology Slovak Academy of Sciences</affilname><name-variant>Slovak Acad. Sci.</name-variant><affiliation-city>Bratislava</affiliation-city><affiliation-country>Slovakia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14032104600</author-url><authid>14032104600</authid><authname>Paulis L.</authname><surname>Paulis</surname><given-name>Ludovit</given-name><initials>L.</initials><afid>60001987</afid><afid>60010330</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14032104600</author-url><authid>14032104600</authid><authname>Paulis L.</authname><surname>Paulis</surname><given-name>Ludovit</given-name><initials>L.</initials><afid>60001987</afid><afid>60010330</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55986018100</author-url><authid>55986018100</authid><authname>Rajkovicova R.</authname><surname>Rajkovicova</surname><given-name>Romana</given-name><initials>R.</initials><afid>60001987</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006176257</author-url><authid>7006176257</authid><authname>Simko F.</authname><surname>Simko</surname><given-name>Fedor</given-name><initials>F.</initials><afid>60001987</afid><afid>60013083</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006176257</author-url><authid>7006176257</authid><authname>Simko F.</authname><surname>Simko</surname><given-name>Fedor</given-name><initials>F.</initials><afid>60001987</afid><afid>60013083</afid></author><authkeywords>Angiotensin AT2 receptor | Angiotensin peptides | Drug combination | Hypertension | Neprilysin | Renin-angiotensin-aldosterone system</authkeywords><intid>1535813294</intid><source-id>23135</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929104265"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929104265?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929104265&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929104265&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929104265</prism:url><dc:identifier>SCOPUS_ID:84929104265</dc:identifier><eid>2-s2.0-84929104265</eid><dc:title>Acute effect of static exercise on the cardiovascular system: assessment by cardiovascular magnetic resonance</dc:title><dc:creator>Alegret J.</dc:creator><prism:publicationName>European Journal of Applied Physiology</prism:publicationName><prism:issn>14396319</prism:issn><prism:volume>115</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1195-1203</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00421-015-3101-4</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. Purpose: The acute effect of static exercise on the global dynamics of the cardiovascular system is poorly understood. The use of cardiovascular magnetic resonance (CMR) may be useful for evaluating this effect. Methods: A total of 12 healthy individuals underwent CMR imaging at rest and while performing a maximal sustained static exercise (weight elevation with both legs). We analyzed the effects on left and right ventricular function, ascending aorta dynamics, and venous capacitance using standard cine and phase-contrast sequences. Results: We observed excellent reproducibility in the measurements of the images obtained at rest as well as during static exercise. During exercise, we observed reduced left (−35 ± 8 %, p &lt; 0.001) and right (−44 ± 9 %, p &lt; 0.001) ventricle end-diastolic volumes, reduced left (−35 ± 16 %, p &lt; 0.001) and right (−43 ± 8 %, p &lt; 0.001) ventricle end-systolic volumes (both with a significantly greater reduction in the right ventricle), a reduced superior vena cava cross-sectional area (−20 ± 17 %, p = 0.003), and increased left ventricle wall thickness. We estimated that there was an increase in left ventricle contractility. There were no significant changes in the left and right ventricular ejection fractions. During exercise, we noted a tendency toward decreased aortic distensibility and a reduction of ascending aorta systolic expansion. Conclusions: In healthy individuals, an acute maximal static exercise produced a reduction in the left ventricle, right ventricle, and superior vena cava volumes as well as signs of increased aortic stiffness without increasing left ventricular systolic wall stress. CMR is feasible and useful in evaluating the hemodynamic effects of static exercise.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010347</affiliation-url><afid>60010347</afid><affilname>Hospital Sant Joan de Deu</affilname><name-variant>Hospital Sant Joan de Déu</name-variant><affiliation-city>Esplugas de Llobregat</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010347</affiliation-url><afid>60010347</afid><affilname>Hospital Sant Joan de Deu</affilname><name-variant>Hospital Sant Joan de Déu</name-variant><affiliation-city>Esplugas de Llobregat</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010347</affiliation-url><afid>60010347</afid><affilname>Hospital Sant Joan de Deu</affilname><name-variant>Hospital Sant Joan de Déu</name-variant><affiliation-city>Esplugas de Llobregat</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35510362100</author-url><authid>35510362100</authid><authname>Alegret J.</authname><surname>Alegret</surname><given-name>Josep M.</given-name><initials>J.M.</initials><afid>60010347</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35486532500</author-url><authid>35486532500</authid><authname>Beltrán-Debón R.</authname><surname>Beltrán-Debón</surname><given-name>Raúl</given-name><initials>R.</initials><afid>60010347</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23501677000</author-url><authid>23501677000</authid><authname>La Gerche A.</authname><surname>La Gerche</surname><given-name>Andre</given-name><initials>A.</initials><afid>60026553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507800667</author-url><authid>6507800667</authid><authname>Franco-Bonafonte L.</authname><surname>Franco-Bonafonte</surname><given-name>Luis</given-name><initials>L.</initials><afid>60010347</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56638508700</author-url><authid>56638508700</authid><authname>Rubio-Pérez F.</authname><surname>Rubio-Pérez</surname><given-name>Francisco</given-name><initials>F.</initials><afid>60010347</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:12786425600</author-url><authid>12786425600</authid><authname>Calvo N.</authname><surname>Calvo</surname><given-name>Nahum</given-name><initials>N.</initials><afid>60010347</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102553476</author-url><authid>7102553476</authid><authname>Montero M.</authname><surname>Montero</surname><given-name>Manuel</given-name><initials>M.</initials><afid>60010347</afid></author><authkeywords>Cardiovascular magnetic resonance imaging | Static exercise | Ventricles</authkeywords><intid>1785901477</intid><source-id>23402</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923217555"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923217555?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923217555&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923217555&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0195666315000471"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923217555</prism:url><dc:identifier>SCOPUS_ID:84923217555</dc:identifier><eid>2-s2.0-84923217555</eid><dc:title>What menu changes do restaurants make after joining a voluntary restaurant recognition program?</dc:title><dc:creator>Gase L.</dc:creator><prism:publicationName>Appetite</prism:publicationName><prism:issn>01956663</prism:issn><prism:eIssn>10958304</prism:eIssn><prism:volume>89</prism:volume><prism:pageRange>131-135</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.appet.2015.01.026</prism:doi><pii>S0195666315000471</pii><dc:description>© 2015 Elsevier Ltd. Programs that recognize restaurants for offering healthful options have emerged as a popular strategy to address the obesity epidemic; however, program fidelity and business responses to such programs are rarely assessed. This study sought to examine how retail restaurants in Los Angeles County chose to comply with participation criteria required by the Choose Health LA Restaurants initiative in the region; the program recognizes restaurants for offering reduced-size portions and healthy children's meals. Menus of all restaurants that joined within 1 year of program launch (n = 17 restaurant brands) were assessed for changes. Nine of the 17 brands made changes to their menus to meet participation criteria for reduced-size portions while 8 of the 10 restaurant brands that offered children's menus made changes to improve the healthfulness of children's meals. Results of this comparative assessment lend support to restaurant compliance with program criteria and menu improvements, even though they are voluntary, representing an important step toward implementing this strategy in the retail environment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105599866</affiliation-url><afid>105599866</afid><affilname>Division of Chronic Disease and Injury Prevention</affilname><name-variant>Division of Chronic Disease and Injury Prevention</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005247</affiliation-url><afid>60005247</afid><affilname>David Geffen School of Medicine at UCLA</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027550</affiliation-url><afid>60027550</afid><affilname>University of California, Los Angeles</affilname><name-variant>UCLA</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26535858000</author-url><authid>26535858000</authid><authname>Gase L.</authname><surname>Gase</surname><given-name>Lauren N.</given-name><initials>L.N.</initials><afid>105599866</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56523988800</author-url><authid>56523988800</authid><authname>Kaur M.</authname><surname>Kaur</surname><given-name>Mandip</given-name><initials>M.</initials><afid>105599866</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55247412600</author-url><authid>55247412600</authid><authname>Dunning L.</authname><surname>Dunning</surname><given-name>Lauren</given-name><initials>L.</initials><afid>105599866</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56524148300</author-url><authid>56524148300</authid><authname>Montes C.</authname><surname>Montes</surname><given-name>Christine</given-name><initials>C.</initials><afid>105599866</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56437784300</author-url><authid>56437784300</authid><authname>Kuo T.</authname><surname>Kuo</surname><given-name>Tony</given-name><initials>T.</initials><afid>105599866</afid><afid>60005247</afid><afid>60027550</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56437784300</author-url><authid>56437784300</authid><authname>Kuo T.</authname><surname>Kuo</surname><given-name>Tony</given-name><initials>T.</initials><afid>105599866</afid><afid>60005247</afid><afid>60027550</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56437784300</author-url><authid>56437784300</authid><authname>Kuo T.</authname><surname>Kuo</surname><given-name>Tony</given-name><initials>T.</initials><afid>105599866</afid><afid>60005247</afid><afid>60027550</afid></author><authkeywords>Eating | Food industry | Obesity | Portion size | Restaurant program</authkeywords><intid>1534938267</intid><source-id>29994</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928994749"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928994749?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928994749&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928994749&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928994749</prism:url><dc:identifier>SCOPUS_ID:84928994749</dc:identifier><eid>2-s2.0-84928994749</eid><dc:title>Erratum: MuRF1 activity is present in cardiac mitochondria and regulates reactive oxygen species production in vivo [J Bioenerg Biomembr, 46, (2014), (173-187), DOI 10.1007/s10863-014-9549-9]</dc:title><dc:creator>Mattox T.</dc:creator><prism:publicationName>Journal of Bioenergetics and Biomembranes</prism:publicationName><prism:issn>0145479X</prism:issn><prism:eIssn>15736881</prism:eIssn><prism:volume>47</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>281</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10863-014-9597-1</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016280</affiliation-url><afid>60016280</afid><affilname>East Carolina University</affilname><name-variant>East Carolina University</name-variant><affiliation-city>Greenville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025111</affiliation-url><afid>60025111</afid><affilname>The University of North Carolina at Chapel Hill</affilname><name-variant>University of North Carolina at Chapel Hill</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025111</affiliation-url><afid>60025111</afid><affilname>The University of North Carolina at Chapel Hill</affilname><name-variant>University of North Carolina at Chapel Hill</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025111</affiliation-url><afid>60025111</afid><affilname>The University of North Carolina at Chapel Hill</affilname><name-variant>University of North Carolina at Chapel Hill</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011520</affiliation-url><afid>60011520</afid><affilname>King's College London</affilname><name-variant>King's College London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011715</affiliation-url><afid>60011715</afid><affilname>Tianjin Medical University</affilname><name-variant>Tianjin Medical University General Hospital</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025111</affiliation-url><afid>60025111</afid><affilname>The University of North Carolina at Chapel Hill</affilname><name-variant>University of North Carolina at Chapel Hill</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025111</affiliation-url><afid>60025111</afid><affilname>The University of North Carolina at Chapel Hill</affilname><name-variant>University of North Carolina at Chapel Hill</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>er</subtype><subtypeDescription>Erratum</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56053363500</author-url><authid>56053363500</authid><authname>Mattox T.</authname><surname>Mattox</surname><given-name>Taylor A.</given-name><initials>T.A.</initials><afid>60016280</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56625451100</author-url><authid>56625451100</authid><authname>Young M.</authname><surname>Young</surname><given-name>Martin E.</given-name><initials>M.E.</initials><afid>60027086</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56638786800</author-url><authid>56638786800</authid><authname>Rubel C.</authname><surname>Rubel</surname><given-name>Carrie E.</given-name><initials>C.E.</initials><afid>60025111</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54934523200</author-url><authid>54934523200</authid><authname>Spaniel C.</authname><surname>Spaniel</surname><given-name>Carolyn</given-name><initials>C.</initials><afid>60025111</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26032258400</author-url><authid>26032258400</authid><authname>Rodríguez J.</authname><surname>Rodríguez</surname><given-name>Jessica E.</given-name><initials>J.E.</initials><afid>60025111</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56637165600</author-url><authid>56637165600</authid><authname>Grevengoed T.</authname><surname>Grevengoed</surname><given-name>Trisha J.</given-name><initials>T.J.</initials><afid>60025111</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:26643603500</author-url><authid>26643603500</authid><authname>Gautel M.</authname><surname>Gautel</surname><given-name>Mathias</given-name><initials>M.</initials><afid>60011520</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56182662000</author-url><authid>56182662000</authid><authname>Xu Z.</authname><surname>Xu</surname><given-name>Zhelong</given-name><initials>Z.</initials><afid>60011715</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:12798292600</author-url><authid>12798292600</authid><authname>Anderson E.</authname><surname>Anderson</surname><given-name>Ethan J.</given-name><initials>E.J.</initials><afid>60016280</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56638728800</author-url><authid>56638728800</authid><authname>Willis M.</authname><surname>Willis</surname><given-name>Monte S.</given-name><initials>M.S.</initials><afid>60025111</afid><afid>60025111</afid><afid>60025111</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56638728800</author-url><authid>56638728800</authid><authname>Willis M.</authname><surname>Willis</surname><given-name>Monte S.</given-name><initials>M.S.</initials><afid>60025111</afid><afid>60025111</afid><afid>60025111</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56638728800</author-url><authid>56638728800</authid><authname>Willis M.</authname><surname>Willis</surname><given-name>Monte S.</given-name><initials>M.S.</initials><afid>60025111</afid><afid>60025111</afid><afid>60025111</afid></author><intid>2035878578</intid><source-id>17590</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928168945"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928168945?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928168945&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928168945&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0379073815001528"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928168945</prism:url><dc:identifier>SCOPUS_ID:84928168945</dc:identifier><eid>2-s2.0-84928168945</eid><dc:title>Donepezil distribution in postmortem cases and potential for redistribution</dc:title><dc:creator>Nagasawa S.</dc:creator><prism:publicationName>Forensic Science International</prism:publicationName><prism:issn>03790738</prism:issn><prism:eIssn>18726283</prism:eIssn><prism:volume>251</prism:volume><prism:pageRange>132-138</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.forsciint.2015.04.006</prism:doi><pii>S0379073815001528</pii><dc:description>© 2015. Donepezil (DPZ) is an acetylcholine-esterase inhibitor currently used as the frontline drug to treat Alzheimer's disease. The aim of this study was to investigate the possibility of postmortem redistribution (PMR) of DPZ, which could complicate the determination of cause of death in medico-legal cases. Additionally, metabolic enzyme DNA polymorphism, drug-drug interaction and the presence of lesions in metabolic and egestion organs were examined to eliminate the possibility of a high antemortem DPZ concentration. Subsequently, the average DPZ concentration of four sites of peripheral blood (right and left femoral artery and vein) was compared with central blood and liver DPZ concentrations in seven postmortem cases. DPZ concentrations ranged from 0.02 to 0.45. μg/mL in the peripheral blood, 0.09-0.4. μg/mL in central blood, and from 1.2 to 6.7. μg/kg in the liver. In most specimens, the concentrations were higher than the therapeutic range (approximately 0.030-0.075. μg/mL). DPZ central blood to peripheral blood (C/P) ratios averaged 1.73. ±. 1.02 (±standard deviation) while liver to peripheral blood (L/P) ratios were higher and averaged 17.5. ±. 7.25. It is documented that a C/P ratio of less than (or about) 1.0 and an L/P ratio less than 5 are not indicative of PMR, whereas a C/P ratio exceeding 2 and L/P ratio exceeding 20 highlight a propensity for significant PMR. Our data suggest that DPZ exhibits a moderate degree of PMR. Additionally, a lowered pH was found in all blood specimens (&lt;6-6.75 in the peripheral blood and &lt;6-6.66 in the central blood). This postmortem reduction in blood pH may increase the ionic forms of DPZ, resulting in a high blood DPZ concentration.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002787</affiliation-url><afid>60002787</afid><affilname>Chiba University</affilname><name-variant>Chiba University</name-variant><affiliation-city>Chiba</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002354</affiliation-url><afid>60002354</afid><affilname>University of Tokyo Faculty of Medicine</affilname><name-variant>University of Tokyo</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26429946900</author-url><authid>26429946900</authid><authname>Nagasawa S.</authname><surname>Nagasawa</surname><given-name>Sayaka</given-name><initials>S.</initials><afid>60002787</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55350602200</author-url><authid>55350602200</authid><authname>Torimitsu S.</authname><surname>Torimitsu</surname><given-name>Suguru</given-name><initials>S.</initials><afid>60002787</afid><afid>60002354</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55350602200</author-url><authid>55350602200</authid><authname>Torimitsu S.</authname><surname>Torimitsu</surname><given-name>Suguru</given-name><initials>S.</initials><afid>60002787</afid><afid>60002354</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55236347900</author-url><authid>55236347900</authid><authname>Chiba F.</authname><surname>Chiba</surname><given-name>Fumiko</given-name><initials>F.</initials><afid>60002787</afid><afid>60002354</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55236347900</author-url><authid>55236347900</authid><authname>Chiba F.</authname><surname>Chiba</surname><given-name>Fumiko</given-name><initials>F.</initials><afid>60002787</afid><afid>60002354</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55912338300</author-url><authid>55912338300</authid><authname>Kubo Y.</authname><surname>Kubo</surname><given-name>Yuko</given-name><initials>Y.</initials><afid>60002787</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55873877200</author-url><authid>55873877200</authid><authname>Yajima D.</authname><surname>Yajima</surname><given-name>Daisuke</given-name><initials>D.</initials><afid>60002787</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102085129</author-url><authid>7102085129</authid><authname>Iwase H.</authname><surname>Iwase</surname><given-name>Hirotaro</given-name><initials>H.</initials><afid>60002787</afid><afid>60002354</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102085129</author-url><authid>7102085129</authid><authname>Iwase H.</authname><surname>Iwase</surname><given-name>Hirotaro</given-name><initials>H.</initials><afid>60002787</afid><afid>60002354</afid></author><authkeywords>Central blood | Donepezil | LC/MS/MS | Liver | Peripheral blood | Postmortem redistribution</authkeywords><intid>1035728577</intid><source-id>27743</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928989726"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928989726?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928989726&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928989726&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928989726</prism:url><dc:identifier>SCOPUS_ID:84928989726</dc:identifier><eid>2-s2.0-84928989726</eid><dc:title>Banking of cryopreserved iliac artery and vein homografts: clinical uses in transplantation</dc:title><dc:creator>Heng W.</dc:creator><prism:publicationName>Cell and Tissue Banking</prism:publicationName><prism:issn>13899333</prism:issn><prism:volume>16</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>235-242</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10561-014-9469-2</prism:doi><dc:description>© 2014, The Author(s). Iliac artery and vein homografts are critical for revascularization in living-donor liver transplantation. Since 2010, National Cardiovascular Homograft Bank and National University Hospital have collaborated in the pioneer endeavor of banking iliac vessel homografts for such surgeries in Singapore. This article aims to demonstrate that the processing, decontamination and cryopreservation techniques that our bank follow, help preserve iliac vessel homografts for a longer duration as compared to homografts preserved using short-term preservation techniques. This paper reports the first 4 years of post-operative outcome for recipients as a preliminary report for a longer-term outcome study. Criteria for donor assessment, techniques of iliac vessel homograft recovery, processing, decontamination, cryopreservation and storage according to the American Association of Tissue Banks standards are also described. From 2010 until 2013, we discovered of the iliac vessel homografts processed, 17 (94.4 %) were suitable for clinical use. Nine iliac artery grafts (64 %) and one iliac vein graft (14 %) were implanted. Irrespective of vessel type, homografts &lt;90 mm in length were of little use. Of the nine current iliac vessel homograft recipients, eight patients (89 %) had living-donor liver transplantation and one patient (11 %) had reconstruction of the right internal carotid artery after resection of an aneurysm. Our preliminary results supports existing literatures that suggest cryopreserved iliac vessel homografts can be successfully used for revascularization in liver transplantation and reconstruction of carotid artery. Encouraging short-term post-operative patient outcomes have been achieved, with no report of adverse event attributed to implanted homografts. We believe that our processing, decontamination and cryopreservation techniques have helped preserve the homografts for longer duration as compared to homografts preserved using short-term preservation techniques.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004409</affiliation-url><afid>60004409</afid><affilname>National Heart Centre, Singapore</affilname><name-variant>National Heart Centre Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031325</affiliation-url><afid>60031325</afid><affilname>National University Hospital, Singapore</affilname><name-variant>National University Hospital</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55195380500</author-url><authid>55195380500</authid><authname>Heng W.</authname><surname>Heng</surname><given-name>Wee Ling</given-name><initials>W.L.</initials><afid>60004409</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55406288300</author-url><authid>55406288300</authid><authname>Madhavan K.</authname><surname>Madhavan</surname><given-name>Krishnakumar</given-name><initials>K.</initials><afid>60031325</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56329506300</author-url><authid>56329506300</authid><authname>Wee P.</authname><surname>Wee</surname><given-name>Priscilla</given-name><initials>P.</initials><afid>60031325</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55194936000</author-url><authid>55194936000</authid><authname>Seck T.</authname><surname>Seck</surname><given-name>Tracy</given-name><initials>T.</initials><afid>60004409</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23091196600</author-url><authid>23091196600</authid><authname>Lim Y.</authname><surname>Lim</surname><given-name>Yeong Phang</given-name><initials>Y.P.</initials><afid>60004409</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403654448</author-url><authid>7403654448</authid><authname>Lim C.</authname><surname>Lim</surname><given-name>Chong Hee</given-name><initials>C.H.</initials><afid>60004409</afid></author><authkeywords>Allografts | Artery | Cryopreservation | Liver transplantation | Vein</authkeywords><intid>1785884652</intid><source-id>18439</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928251706"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928251706?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928251706&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928251706&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015001999"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928251706</prism:url><dc:identifier>SCOPUS_ID:84928251706</dc:identifier><eid>2-s2.0-84928251706</eid><dc:title>The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial</dc:title><dc:creator>Emami H.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>490-496</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.039</prism:doi><pii>S0021915015001999</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objectives: This study evaluated the effect of p38 mitogen-activated protein kinase (p38MAPK) inhibitor, BMS-582949, on atherosclerotic plaque inflammation, using &lt;sup&gt;18&lt;/sup&gt;FDG-PET imaging. p38MAPK is an important element of inflammatory pathways in atherothrombosis and its inhibition may lead to reduced inflammation within atherosclerotic plaques. Methods: Subjects with documented atherosclerosis (n=72) on stable low-dose statin therapy and having at least one lesion with active atherosclerotic plaque inflammation in either aorta or carotid arteries were randomized to BMS-582949 (100mg once daily), placebo, or atorvastatin (80mg once daily), for 12 weeks. Arterial inflammation was assessed using &lt;sup&gt;18&lt;/sup&gt;FDG-PET/CT imaging of the carotid arteries and aorta. Uptake of arterial &lt;sup&gt;18&lt;/sup&gt;FDG was assessed as target-to-background ratio (TBR): 1) as a mean of all slices of the index vessel, and 2) within active slices of all vessels (AS: which includes only slices with significant inflammation (TBR≥1.6) at the baseline). Results: Treatment with BMS-582949 did not reduce arterial inflammation relative to placebo, (δTBR &lt;inf&gt;index:&lt;/inf&gt; 0.10 [95% CI: -0.11, 0.30], p=0.34; δTBR &lt;inf&gt;AS&lt;/inf&gt;: -0.01 [-0.31, 0.28], p=0.93) or hs-CRP (median %δCRP [IQR]: 33.83% [153.91] vs. 16.71% [133.45], p=0.61). In contrast, relative to placebo, statin intensification was associated with significant reduction of hs-CRP (%δCRP [IQR]: -17.44% [54.68] vs. 16.71% [133.45], p=0.04) and arterial inflammation in active slices (δTBR&lt;inf&gt;AS&lt;/inf&gt;=-0.24 [95% CI: -0.46, -0.01], p=0.04). Conclusions: The findings of this study demonstrates that in stable atherosclerosis, 12 weeks of treatment with BMS-582949 did not reduce arterial inflammation or hs-CRP compared to placebo, whereas intensification of statin therapy significantly decreased arterial inflammation. •We evaluated the effect of p38MAPK inhibitor, BMS-582949, on arterial inflammation.•Subjects with known ASCVD were randomized to BMS-582949, placebo, or atorvastatin.•We demonstrate that treatment with BMS-582949 did not reduce arterial inflammation.•Intensification of statin therapy (positive control) reduced arterial inflammation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020999</affiliation-url><afid>60020999</afid><affilname>Massachusetts General Hospital and Harvard Medical School</affilname><name-variant>Massachusetts General Hospital and Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001149</affiliation-url><afid>60001149</afid><affilname>Bristol-Myers Squibb Research and Development</affilname><name-variant>Bristol-Myers Squibb</name-variant><affiliation-city>Princeton</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017412</affiliation-url><afid>60017412</afid><affilname>University of Cincinnati College of Medicine</affilname><name-variant>Univ. of Cincinnati Coll. of Med.</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002441</affiliation-url><afid>60002441</afid><affilname>Baylor College of Medicine</affilname><name-variant>Baylor College of Medicine</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023009</affiliation-url><afid>60023009</afid><affilname>University of Pennsylvania, Health System</affilname><name-variant>Hospital of the University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55970892300</author-url><authid>55970892300</authid><authname>Emami H.</authname><surname>Emami</surname><given-name>Hamed</given-name><initials>H.</initials><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15125276600</author-url><authid>15125276600</authid><authname>Vucic E.</authname><surname>Vucic</surname><given-name>Esad</given-name><initials>E.</initials><afid>60029929</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35811235900</author-url><authid>35811235900</authid><authname>Subramanian S.</authname><surname>Subramanian</surname><given-name>Sharath</given-name><initials>S.</initials><afid>60029929</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:52263239500</author-url><authid>52263239500</authid><authname>Abdelbaky A.</authname><surname>Abdelbaky</surname><given-name>Amr</given-name><initials>A.</initials><afid>60029929</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006629064</author-url><authid>7006629064</authid><authname>Fayad Z.</authname><surname>Fayad</surname><given-name>Zahi A.</given-name><initials>Z.A.</initials><afid>60012981</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56602209200</author-url><authid>56602209200</authid><authname>Du S.</authname><surname>Du</surname><given-name>Shuyan</given-name><initials>S.</initials><afid>60001149</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7202767952</author-url><authid>7202767952</authid><authname>Roth E.</authname><surname>Roth</surname><given-name>Eli</given-name><initials>E.</initials><afid>60017412</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101711066</author-url><authid>7101711066</authid><authname>Ballantyne C.</authname><surname>Ballantyne</surname><given-name>Christie M.</given-name><initials>C.M.</initials><afid>60002441</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35370495800</author-url><authid>35370495800</authid><authname>Mohler E.</authname><surname>Mohler</surname><given-name>Emile R.</given-name><initials>E.R.</initials><afid>60023009</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701811527</author-url><authid>6701811527</authid><authname>Farkouh M.</authname><surname>Farkouh</surname><given-name>Michael E.</given-name><initials>M.E.</initials><afid>60016849</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35102508700</author-url><authid>35102508700</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Joonyoung</given-name><initials>J.</initials><afid>60001149</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56556189300</author-url><authid>56556189300</authid><authname>Farmer M.</authname><surname>Farmer</surname><given-name>Matthew</given-name><initials>M.</initials><afid>60001149</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:42561537800</author-url><authid>42561537800</authid><authname>Li L.</authname><surname>Li</surname><given-name>Li</given-name><initials>L.</initials><afid>60001149</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:6506541935</author-url><authid>6506541935</authid><authname>Ehlgen A.</authname><surname>Ehlgen</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60001149</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603186013</author-url><authid>6603186013</authid><authname>Langenickel T.</authname><surname>Langenickel</surname><given-name>Thomas H.</given-name><initials>T.H.</initials><afid>60001149</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:36830850800</author-url><authid>36830850800</authid><authname>Velasquez L.</authname><surname>Velasquez</surname><given-name>Linda</given-name><initials>L.</initials><afid>60001149</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:35185064500</author-url><authid>35185064500</authid><authname>Hayes W.</authname><surname>Hayes</surname><given-name>Wendy</given-name><initials>W.</initials><afid>60001149</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:6603090252</author-url><authid>6603090252</authid><authname>Tawakol A.</authname><surname>Tawakol</surname><given-name>Ahmed</given-name><initials>A.</initials><afid>60029929</afid><afid>60020999</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:6603090252</author-url><authid>6603090252</authid><authname>Tawakol A.</authname><surname>Tawakol</surname><given-name>Ahmed</given-name><initials>A.</initials><afid>60029929</afid><afid>60020999</afid></author><authkeywords>&lt;sup&gt;18&lt;/sup&gt;FDG | Atherosclerosis | FDG | Hs-CRP | Imaging | Inflammation | MAPK | MAPK | PET | ROI | SUV | TBR</authkeywords><intid>1535752196</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922974563"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922974563?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922974563&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922974563&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0952791515000291"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922974563</prism:url><dc:identifier>SCOPUS_ID:84922974563</dc:identifier><eid>2-s2.0-84922974563</eid><dc:title>Epithelial cytokines and pulmonary allergic inflammation</dc:title><dc:creator>Lloyd C.</dc:creator><prism:publicationName>Current Opinion in Immunology</prism:publicationName><prism:issn>09527915</prism:issn><prism:eIssn>18790372</prism:eIssn><prism:volume>34</prism:volume><prism:pageRange>52-58</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.coi.2015.02.001</prism:doi><pii>S0952791515000291</pii><dc:description>© 2015 Elsevier Ltd. The triad of epithelial derived cytokines, IL-25, IL-33 and TSLP are important for the initiation and development of pulmonary immune responses to environmental stimuli. Data from experiments using mouse models provide compelling evidence for their involvement in both innate and adaptive immunity to drive type-2 responses, allergic inflammation and airway remodelling. These cytokines are known to be expressed in human lung tissue and immune cells, however their involvement in mediating allergic pulmonary responses in patients is less clear than in murine models of disease. This article focuses on evidence for the role of IL-25, IL-33 and TSLP in human allergic disease and discusses their potential as therapeutic targets for severe asthma.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010719</affiliation-url><afid>60010719</afid><affilname>National Heart and Lung Institute</affilname><name-variant>National Heart and Lung Institute</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009009</affiliation-url><afid>60009009</afid><affilname>Royal Brompton Hospital</affilname><name-variant>Brompton Hospital</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202193210</author-url><authid>7202193210</authid><authname>Lloyd C.</authname><surname>Lloyd</surname><given-name>Clare M.</given-name><initials>C.M.</initials><afid>60010719</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603099922</author-url><authid>6603099922</authid><authname>Saglani S.</authname><surname>Saglani</surname><given-name>Sejal</given-name><initials>S.</initials><afid>60010719</afid><afid>60009009</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603099922</author-url><authid>6603099922</authid><authname>Saglani S.</authname><surname>Saglani</surname><given-name>Sejal</given-name><initials>S.</initials><afid>60010719</afid><afid>60009009</afid></author><intid>1534904352</intid><source-id>18797</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925744323"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925744323?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925744323&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925744323&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1053811915002153"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925744323</prism:url><dc:identifier>SCOPUS_ID:84925744323</dc:identifier><eid>2-s2.0-84925744323</eid><dc:title>Which motor cortical region best predicts imagined movement?</dc:title><dc:creator>Park C.</dc:creator><prism:publicationName>NeuroImage</prism:publicationName><prism:issn>10538119</prism:issn><prism:eIssn>10959572</prism:eIssn><prism:volume>113</prism:volume><prism:pageRange>101-110</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroimage.2015.03.033</prism:doi><pii>S1053811915002153</pii><dc:description>© 2015 Elsevier Inc. In brain-computer interfacing (BCI), motor imagery is used to provide a gateway to an effector action or behavior. However, in contrast to the main functional role of the primary motor cortex (M1) in motor execution, the M1's involvement in motor imagery has been debated, while the roles of secondary motor areas such as the premotor cortex (PMC) and supplementary motor area (SMA) in motor imagery have been proposed. We examined which motor cortical region had the greatest predictive ability for imagined movement among the primary and secondary motor areas. For two modes of motor performance, executed movement and imagined movement, in 12 healthy subjects who performed two types of motor task, hand grasping and hand rotation, we used the multivariate Bayes method to compare predictive ability between the primary and secondary motor areas (M1, PMC, and SMA) contralateral to the moved hand. With the distributed representation of activation, executed movement was best predicted from the M1 while imagined movement from the SMA, among the three motor cortical regions, in both types of motor task. In addition, the most predictive information about the distinction between executed movement and imagined movement was contained in the M1. The greater predictive ability of the SMA for imagined movement suggests its functional role that could be applied to motor imagery-based BCI.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016329</affiliation-url><afid>60016329</afid><affilname>SungKyunKwan University, School of Medicine</affilname><name-variant>Sungkyunkwan University School of Medicine</name-variant><affiliation-city>Suwon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010484</affiliation-url><afid>60010484</afid><affilname>Samsung Group</affilname><name-variant>Samsung Group</name-variant><affiliation-city>Seongnam</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024872</affiliation-url><afid>60024872</afid><affilname>Hanyang University</affilname><name-variant>Hanyang University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025960</affiliation-url><afid>60025960</afid><affilname>Korea Institute of Science and Technology</affilname><name-variant>Korea Inst. of Sci. and Technology</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016329</affiliation-url><afid>60016329</afid><affilname>SungKyunKwan University, School of Medicine</affilname><name-variant>Sungkyunkwan University School of Medicine</name-variant><affiliation-city>Suwon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56201473700</author-url><authid>56201473700</authid><authname>Park C.</authname><surname>Park</surname><given-name>Chang hyun</given-name><initials>C.h.</initials><afid>60016329</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35301717900</author-url><authid>35301717900</authid><authname>Chang W.</authname><surname>Chang</surname><given-name>Won Hyuk</given-name><initials>W.H.</initials><afid>60016329</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56449516800</author-url><authid>56449516800</authid><authname>Lee M.</authname><surname>Lee</surname><given-name>Minji</given-name><initials>M.</initials><afid>60010484</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56504793500</author-url><authid>56504793500</authid><authname>Kwon G.</authname><surname>Kwon</surname><given-name>Gyu Hyun</given-name><initials>G.H.</initials><afid>60024872</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56504640000</author-url><authid>56504640000</authid><authname>Kim L.</authname><surname>Kim</surname><given-name>Laehyun</given-name><initials>L.</initials><afid>60025960</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56201824500</author-url><authid>56201824500</authid><authname>Kim S.</authname><surname>Kim</surname><given-name>Sung Tae</given-name><initials>S.T.</initials><afid>60016329</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:25960819900</author-url><authid>25960819900</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Yun Hee</given-name><initials>Y.H.</initials><afid>60016329</afid><afid>60010484</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:25960819900</author-url><authid>25960819900</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Yun Hee</given-name><initials>Y.H.</initials><afid>60016329</afid><afid>60010484</afid></author><authkeywords>FMRI | Motor cortex | Motor execution | Motor imagery | Multivariate Bayes</authkeywords><intid>1535347581</intid><source-id>17495</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929169376"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929169376?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929169376&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929169376&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929169376</prism:url><dc:identifier>SCOPUS_ID:84929169376</dc:identifier><eid>2-s2.0-84929169376</eid><dc:title>Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition</dc:title><dc:creator>Tortorella S.</dc:creator><prism:publicationName>Antioxidants and Redox Signaling</prism:publicationName><prism:issn>15230864</prism:issn><prism:eIssn>15577716</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>16</prism:issueIdentifier><prism:pageRange>1382-1424</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1089/ars.2014.6097</prism:doi><dc:description>© Copyright 2015, Mary Ann Liebert, Inc. Significance: Sulforaphane, produced by the hydrolytic conversion of glucoraphanin after ingestion of cruciferous vegetables, particularly broccoli and broccoli sprouts, has been extensively studied due to its apparent health-promoting properties in disease and limited toxicity in normal tissue. Recent Studies: Recent identification of a sub-population of tumor cells with stem cell-like self-renewal capacity that may be responsible for relapse, metastasis, and resistance, as a potential target of the dietary compound, may be an important aspect of sulforaphane chemoprevention. Evidence also suggests that sulforaphane may target the epigenetic alterations observed in specific cancers, reversing aberrant changes in gene transcription through mechanisms of histone deacetylase inhibition, global demethylation, and microRNA modulation. Critical Issues: In this review, we discuss the biochemical and biological properties of sulforaphane with a particular emphasis on the anticancer properties of the dietary compound. Sulforaphane possesses the capacity to intervene in multistage carcinogenesis through the modulation and/or regulation of important cellular mechanisms. The inhibition of phase I enzymes that are responsible for the activation of pro-carcinogens, and the induction of phase II enzymes that are critical in mutagen elimination are well-characterized chemopreventive properties. Furthermore, sulforaphane mediates a number of anticancer pathways, including the activation of apoptosis, induction of cell cycle arrest, and inhibition of NFκB. Future Directions: Further characterization of the chemopreventive properties of sulforaphane and its capacity to be selectively toxic to malignant cells are warranted to potentially establish the clinical utility of the dietary compound as an anti-cancer compound alone, and in combination with clinically relevant therapeutic and management strategies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009102</affiliation-url><afid>60009102</afid><affilname>Murdoch Children's Research Institute</affilname><name-variant>Murdoch Childrens Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55990294100</author-url><authid>55990294100</authid><authname>Tortorella S.</authname><surname>Tortorella</surname><given-name>Stephanie M.</given-name><initials>S.M.</initials><afid>60033409</afid><afid>60026553</afid><afid>60026553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55990294100</author-url><authid>55990294100</authid><authname>Tortorella S.</authname><surname>Tortorella</surname><given-name>Stephanie M.</given-name><initials>S.M.</initials><afid>60033409</afid><afid>60026553</afid><afid>60026553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55990294100</author-url><authid>55990294100</authid><authname>Tortorella S.</authname><surname>Tortorella</surname><given-name>Stephanie M.</given-name><initials>S.M.</initials><afid>60033409</afid><afid>60026553</afid><afid>60026553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701708825</author-url><authid>6701708825</authid><authname>Royce S.</authname><surname>Royce</surname><given-name>Simon G.</given-name><initials>S.G.</initials><afid>60026553</afid><afid>60019578</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701708825</author-url><authid>6701708825</authid><authname>Royce S.</authname><surname>Royce</surname><given-name>Simon G.</given-name><initials>S.G.</initials><afid>60026553</afid><afid>60019578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35181516800</author-url><authid>35181516800</authid><authname>Licciardi P.</authname><surname>Licciardi</surname><given-name>Paul V.</given-name><initials>P.V.</initials><afid>60009102</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602867137</author-url><authid>6602867137</authid><authname>Karagiannis T.</authname><surname>Karagiannis</surname><given-name>Tom C.</given-name><initials>T.C.</initials><afid>60033409</afid><afid>60026553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602867137</author-url><authid>6602867137</authid><authname>Karagiannis T.</authname><surname>Karagiannis</surname><given-name>Tom C.</given-name><initials>T.C.</initials><afid>60033409</afid><afid>60026553</afid></author><intid>1785919243</intid><source-id>27514</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925016034"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925016034?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925016034&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925016034&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0964569115000617"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925016034</prism:url><dc:identifier>SCOPUS_ID:84925016034</dc:identifier><eid>2-s2.0-84925016034</eid><dc:title>Ship-wake induced sediment remobilization: Effects and proposed management strategies for the Venice Lagoon</dc:title><dc:creator>Rapaglia J.</dc:creator><prism:publicationName>Ocean and Coastal Management</prism:publicationName><prism:issn>09645691</prism:issn><prism:volume>110</prism:volume><prism:pageRange>1-11</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ocecoaman.2015.03.002</prism:doi><pii>S0964569115000617</pii><dc:description>© 2015 Elsevier Ltd. More than 3000 commercial vessels navigate through the Malamocco-Marghera Industrial Canal in Venice Lagoon, Italy in a given year, leading to an estimated annual resuspension of 1.2×106metrictons of sediment. Hence, ship wakes contribute to the significant erosion of shoals in the central lagoon which has occurred over the last 30 years. Drawdown associated with the surface depression wave from successive ships induces sediment transport towards the shipping canal, where the cost of dredging amounts to tens of millions of Euro per year. Most ship traffic occurs near an industrial zone, resulting in substantial potential for resuspension of contaminated sediment. Thus, sediment resuspension by ship traffic in the Venice Lagoon has the potential for detrimental economic and environmental impacts.This paper illustrates the impacts of ship induced depression waves and discusses management options for mitigating those impacts, based on extensive observational data and analysis conducted in Venice Lagoon, Italy. This article helps to further the understanding of the processes that govern sediment transport along the shipping channel and employ this knowledge to develop specific management recommendations.A reduction in the navigation speed of ships, an increase in the distance between successive ships, and limiting navigation to tidal levels above 0.3m from the local 1897 reference mean sea level can help to minimize these problems.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012345</affiliation-url><afid>60012345</afid><affilname>Christian-Albrechts-Universitat zu Kiel</affilname><name-variant>University of Kiel</name-variant><affiliation-city>Kiel</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022249</affiliation-url><afid>60022249</afid><affilname>Sacred Heart University Fairfield</affilname><name-variant>Sacred Heart University</name-variant><affiliation-city>Fairfield</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021199</affiliation-url><afid>60021199</afid><affilname>Consiglio Nazionale delle Ricerche</affilname><name-variant>CNR</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108117654</affiliation-url><afid>108117654</afid><affilname>James Cook University</affilname><name-variant>James Cook University</name-variant><affiliation-city>Douglas</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9740646200</author-url><authid>9740646200</authid><authname>Rapaglia J.</authname><surname>Rapaglia</surname><given-name>John</given-name><initials>J.</initials><afid>60012345</afid><afid>60022249</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9740646200</author-url><authid>9740646200</authid><authname>Rapaglia J.</authname><surname>Rapaglia</surname><given-name>John</given-name><initials>J.</initials><afid>60012345</afid><afid>60022249</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55986367000</author-url><authid>55986367000</authid><authname>Zaggia L.</authname><surname>Zaggia</surname><given-name>Luca</given-name><initials>L.</initials><afid>60021199</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602861712</author-url><authid>6602861712</authid><authname>Parnell K.</authname><surname>Parnell</surname><given-name>Kevin</given-name><initials>K.</initials><afid>108117654</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55794082900</author-url><authid>55794082900</authid><authname>Lorenzetti G.</authname><surname>Lorenzetti</surname><given-name>Giuliano</given-name><initials>G.</initials><afid>60021199</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8508362000</author-url><authid>8508362000</authid><authname>Vafeidis A.</authname><surname>Vafeidis</surname><given-name>Athanasios T.</given-name><initials>A.T.</initials><afid>60012345</afid></author><authkeywords>Depression waves | Dredging | Ports | Sediment resuspension | Shipping</authkeywords><intid>535235722</intid><source-id>28333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929192551"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929192551?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929192551&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929192551&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929192551</prism:url><dc:identifier>SCOPUS_ID:84929192551</dc:identifier><eid>2-s2.0-84929192551</eid><dc:title>The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia</dc:title><dc:creator>Tortorella S.</dc:creator><prism:publicationName>Antioxidants and Redox Signaling</prism:publicationName><prism:issn>15230864</prism:issn><prism:eIssn>15577716</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>16</prism:issueIdentifier><prism:pageRange>1425-1462</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1089/ars.2014.6096</prism:doi><dc:description>© Copyright 2015, Mary Ann Liebert, Inc. Significance: Chronic myeloid leukemia (CML) involves the malignant transformation of hematopoietic stem cells, defined largely by the Philadelphia chromosome and expression of the breakpoint cluster region-Abelson (BCR-ABL) oncoprotein. Pharmacological tyrosine kinase inhibitors (TKIs), including imatinib mesylate, have overcome limitations in conventional treatment for the improved clinical management of CML. Recent Advances: Accumulated evidence has led to the identification of a subpopulation of quiescent leukemia progenitor cells with stem-like self renewal properties that may initiate leukemogenesis, which are also shown to be present in residual disease due to their insensitivity to tyrosine kinase inhibition. Critical Issues: The characterization of quiescent leukemia progenitor cells as a unique cell population in CML pathogenesis has become critical with the complete elucidation of mechanisms involved in their survival independent of BCR-ABL that is important in the development of novel anticancer strategies. Understanding of these functional pathways in CML progenitor cells will allow for their selective therapeutic targeting. In addition, disease pathogenesis and drug responsiveness is also thought to be modulated by epigenetic regulatory mechanisms such as DNA methylation, histone acetylation, and microRNA expression, with a capacity to control CML-associated gene transcription. Future Directions: A number of compounds in combination with TKIs are under preclinical and clinical investigation to assess their synergistic potential in targeting leukemic progenitor cells and/or the epigenome in CML. Despite the collective promise, further research is required in order to refine understanding, and, ultimately, advance antileukemic therapeutic strategies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011362</affiliation-url><afid>60011362</afid><affilname>Royal Melbourne Institute of Technology University</affilname><name-variant>RMIT University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55990294100</author-url><authid>55990294100</authid><authname>Tortorella S.</authname><surname>Tortorella</surname><given-name>Stephanie M.</given-name><initials>S.M.</initials><afid>60033409</afid><afid>60026553</afid><afid>60026553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55990294100</author-url><authid>55990294100</authid><authname>Tortorella S.</authname><surname>Tortorella</surname><given-name>Stephanie M.</given-name><initials>S.M.</initials><afid>60033409</afid><afid>60026553</afid><afid>60026553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55990294100</author-url><authid>55990294100</authid><authname>Tortorella S.</authname><surname>Tortorella</surname><given-name>Stephanie M.</given-name><initials>S.M.</initials><afid>60033409</afid><afid>60026553</afid><afid>60026553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640903300</author-url><authid>56640903300</authid><authname>Hung A.</authname><surname>Hung</surname><given-name>Andrew</given-name><initials>A.</initials><afid>60011362</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602867137</author-url><authid>6602867137</authid><authname>Karagiannis T.</authname><surname>Karagiannis</surname><given-name>Tom C.</given-name><initials>T.C.</initials><afid>60033409</afid><afid>60026553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602867137</author-url><authid>6602867137</authid><authname>Karagiannis T.</authname><surname>Karagiannis</surname><given-name>Tom C.</given-name><initials>T.C.</initials><afid>60033409</afid><afid>60026553</afid></author><intid>535917219</intid><source-id>27514</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930179618"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930179618?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930179618&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930179618&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0927776515002155"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930179618</prism:url><dc:identifier>SCOPUS_ID:84930179618</dc:identifier><eid>2-s2.0-84930179618</eid><dc:title>Athrombogenic hydrogel coatings for medical devices - Examination of biological properties</dc:title><dc:creator>Butruk-Raszeja B.</dc:creator><prism:publicationName>Colloids and Surfaces B: Biointerfaces</prism:publicationName><prism:issn>09277765</prism:issn><prism:eIssn>18734367</prism:eIssn><prism:volume>130</prism:volume><prism:pageRange>192-198</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.colsurfb.2015.04.008</prism:doi><pii>S0927776515002155</pii><dc:description>© 2015 Elsevier B.V. In the article the authors present hydrogel coatings prepared from polyvinylpyrrolidone (PVP) macromolecules, which are chemically bonded to polyurethane (PU) substrate. The coating is designed to improve the surface hemocompatibility of blood-contacting medical devices.The coating was characterized in terms of physical properties (swelling ratio, hydrogel density, surface morphology, coating thickness, coating durability). In order to examine surface hemocompatibility, the materials were contacted with whole human blood under arterial flow simulated conditions followed by calculation of platelet consumption and the number of platelet aggregates. Samples were also contacted with platelet-poor plasma; the number of surface-adsorbed fibrinogen molecules was measured using ELISA assay. Finally, the inflammatory reaction after implantation was assessed, using New Zealand rabbits.The designed coating is characterized by high water content and excellent durability in aqueous environment - over a 35-day period, no significant changes in coating thickness were observed. Experiments with blood proved twice the reduction in adsorption of serum-derived fibrinogen together with a moderate reduction in the number of platelet aggregates formed during the contact of the material with blood. The analysis of an inflammatory reaction after the implantation confirmed high biocompatibility of the fabricated materials - studies have shown no toxic effects of the implanted material on the surrounding animal tissues.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003675</affiliation-url><afid>60003675</afid><affilname>Politechnika Warszawska</affilname><name-variant>Warsaw University of Technology</name-variant><affiliation-city>Warsaw</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114989006</affiliation-url><afid>114989006</afid><affilname>Foundation for Cardiac Surgery Development</affilname><name-variant>Foundation for Cardiac Surgery Development</name-variant><affiliation-city/><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56601363000</author-url><authid>56601363000</authid><authname>Butruk-Raszeja B.</authname><surname>Butruk-Raszeja</surname><given-name>Beata A.</given-name><initials>B.A.</initials><afid>60003675</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56601358300</author-url><authid>56601358300</authid><authname>Łojszczyk I.</authname><surname>Łojszczyk</surname><given-name>Ilona</given-name><initials>I.</initials><afid>60003675</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603738196</author-url><authid>6603738196</authid><authname>Ciach T.</authname><surname>Ciach</surname><given-name>Tomasz</given-name><initials>T.</initials><afid>60003675</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36174081200</author-url><authid>36174081200</authid><authname>Kościelniak-Ziemniak M.</authname><surname>Kościelniak-Ziemniak</surname><given-name>Magdalena</given-name><initials>M.</initials><afid>114989006</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56601450800</author-url><authid>56601450800</authid><authname>Janiczak K.</authname><surname>Janiczak</surname><given-name>Karolina</given-name><initials>K.</initials><afid>114989006</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:13104312700</author-url><authid>13104312700</authid><authname>Kustosz R.</authname><surname>Kustosz</surname><given-name>Roman</given-name><initials>R.</initials><afid>114989006</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55212606000</author-url><authid>55212606000</authid><authname>Gonsior M.</authname><surname>Gonsior</surname><given-name>Małgorzata</given-name><initials>M.</initials><afid>114989006</afid></author><authkeywords>Blood compatibility | Fibrinogen | Hydrogel | Platelet | Polyurethane | Surface modification</authkeywords><intid>536079642</intid><source-id>26590</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924968835"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924968835?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924968835&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924968835&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0147651315001116"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924968835</prism:url><dc:identifier>SCOPUS_ID:84924968835</dc:identifier><eid>2-s2.0-84924968835</eid><dc:title>Efficacy of the hatching event in assessing the embryo toxicity of the nano-sized TiO2 particles in zebrafish: A comparison between two different classes of hatching-derived variables</dc:title><dc:creator>Samaee S.</dc:creator><prism:publicationName>Ecotoxicology and Environmental Safety</prism:publicationName><prism:issn>01476513</prism:issn><prism:eIssn>10902414</prism:eIssn><prism:volume>116</prism:volume><prism:pageRange>121-128</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ecoenv.2015.03.012</prism:doi><pii>S0147651315001116</pii><dc:description>© 2015 Elsevier Inc. The aim of the present study was to evaluate the nano-TiO2 toxicity to zebrafish embryos through evaluating the success in hatching in relationship with hours post-exposure instead of considering just the total hatching rate. Zebrafish embryos 4h post-fertilization were exposed to nTiO2 (0, 0.01, 10, and 1000μgmL-1) for 130h. The hatching rate (HR) was calculated for each concentration (treatment). The HR magnitude was significantly (p&lt;0.001) correlated (using simple regression) to hours post-exposure time interval (hpe; 34, 58, 82, 106, and 130), noted as HR.hpe. The HR descriptive statistics (HRds) and the parameters of the regression models (i.e., constant, x, F, and r2) were recruited to define 15 HRds- and 4 h.hpe-derived variables, respectively. The efficacy of the variables was evaluated. Exposure to nTiO2 led to a significant: premature hatching and general decrease in time required for normal hatching; and change in HR and hpe interrelations in a dose-dependent manner. The major change in hatchability between the treatment and control occurred at 58 hpe (62 hpf), when the treatment with nTiO2 induced significant premature hatching compared to only 6% of the hatched embryos in the control at the same time point. EC10 and EC50 values that cause premature hatching at 58 hpe for nTiO2 are 0.073μgmL-1 and 107.2μgmL-1 respectively. In general, this study shows multivariate differences among exposure concentrations of nTiO2 recruiting hatching-derived endpoints.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000627</affiliation-url><afid>60000627</afid><affilname>Urmia University</affilname><name-variant>University of Urmia</name-variant><affiliation-city>Urmia</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027708</affiliation-url><afid>60027708</afid><affilname>Tehran University of Medical Sciences</affilname><name-variant>Tehran University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028717</affiliation-url><afid>60028717</afid><affilname>Ludwig-Maximilians-Universitat Munchen</affilname><name-variant>University of Munich</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027708</affiliation-url><afid>60027708</afid><affilname>Tehran University of Medical Sciences</affilname><name-variant>Tehran University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15048716200</author-url><authid>15048716200</authid><authname>Samaee S.</authname><surname>Samaee</surname><given-name>Seyed Mohammadreza</given-name><initials>S.M.</initials><afid>60000627</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56556291800</author-url><authid>56556291800</authid><authname>Rabbani S.</authname><surname>Rabbani</surname><given-name>Shahram</given-name><initials>S.</initials><afid>60027708</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36598601000</author-url><authid>36598601000</authid><authname>Jovanović B.</authname><surname>Jovanović</surname><given-name>Boris</given-name><initials>B.</initials><afid>60028717</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15728245200</author-url><authid>15728245200</authid><authname>Mohajeri-Tehrani M.</authname><surname>Mohajeri-Tehrani</surname><given-name>Mohammad Reza</given-name><initials>M.R.</initials><afid>60027708</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55967760500</author-url><authid>55967760500</authid><authname>Haghpanah V.</authname><surname>Haghpanah</surname><given-name>Vahid</given-name><initials>V.</initials><afid>60027708</afid></author><authkeywords>Embryos | Hatching | Nanoparticles | NM-105 | Titanium dioxide | Zebrafish</authkeywords><intid>1785233013</intid><source-id>25076</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929191539"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929191539?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929191539&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929191539&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0165247815000644"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929191539</prism:url><dc:identifier>SCOPUS_ID:84929191539</dc:identifier><eid>2-s2.0-84929191539</eid><dc:title>The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-β1 pathway in human lung fibroblasts</dc:title><dc:creator>Schilter H.</dc:creator><prism:publicationName>Immunology Letters</prism:publicationName><prism:issn>01652478</prism:issn><prism:eIssn>18790542</prism:eIssn><prism:volume>165</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>90-101</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.imlet.2015.04.003</prism:doi><pii>S0165247815000644</pii><dc:description>© 2015 The Authors. Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterised by a progressive decline in lung function which can be attributed to excessive scarring, inflammation and airway remodelling. Mannose-6-phosphate (M6P) is a strong inhibitor of fibrosis and its administration has been associated with beneficial effects in tendon repair surgery as well as nerve repair after injury. Given this promising therapeutic approach we developed an improved analogue of M6P, namely PXS64, and explored its anti-fibrotic effects in vitro. Normal human lung fibroblasts (NHLF) and human lung fibroblast 19 cells (HF19) were exposed to active recombinant human TGF-β1 to induce increases in fibrotic markers. rhTGF-β1 increased constitutive protein levels of fibronectin and collagen in the NHLF cells, whereas HF19 cells showed increased levels of fibronectin, collagen as well as αSMA (alpha smooth muscle actin). PXS64 demonstrated a robust inhibitory effect on all proteins analysed. IPF patient fibroblasts treated with PXS64 presented an improved phenotype in terms of their morphological appearance, as well as a decrease in fibrotic markers (collagen, CTGF, TGF-β3, tenascin C, αSMA and THBS1). To explore the cell signalling pathways involved in the anti-fibrotic effects of PXS64, proteomics analysis with iTRAQ labelling was performed and the data demonstrated a specific antagonistic effect on the TGF-β1 pathway. This study shows that PXS64 effectively inhibits the production of extracellular matrix, as well as myofibroblast differentiation during fibrosis. These results suggest that PXS64 influences tissue remodelling by inhibiting TGF-β1 signalling in NHLF and HF19 cell lines, as well as in IPF patient fibroblasts. Thus PXS64 is a potential candidate for preclinical application in pulmonary fibrosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Drug Discovery</affilname><affiliation-city>Pharmaxis</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090016</affiliation-url><afid>60090016</afid><affilname>Dorothy M. Davis Heart and Lung Research Institute</affilname><name-variant>Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011394</affiliation-url><afid>60011394</afid><affilname>Medizinische Universitat Wien</affilname><name-variant>Medical University of Vienna</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010330</affiliation-url><afid>60010330</afid><affilname>Slovak Academy of Sciences</affilname><name-variant>Slovak Academy of Sciences</name-variant><affiliation-city>Bratislava</affiliation-city><affiliation-country>Slovakia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019544</affiliation-url><afid>60019544</afid><affilname>Macquarie University</affilname><name-variant>Macquarie University</name-variant><affiliation-city>North Ryde</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023932</affiliation-url><afid>60023932</afid><affilname>University of Technology Sydney</affilname><name-variant>University of Technology</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23480284500</author-url><authid>23480284500</authid><authname>Schilter H.</authname><surname>Schilter</surname><given-name>Heidi</given-name><initials>H.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:34970828900</author-url><authid>34970828900</authid><authname>Cantemir-Stone C.</authname><surname>Cantemir-Stone</surname><given-name>Carmen Z.</given-name><initials>C.Z.</initials><afid>60090016</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6508290072</author-url><authid>6508290072</authid><authname>Leksa V.</authname><surname>Leksa</surname><given-name>Vladimir</given-name><initials>V.</initials><afid>60011394</afid><afid>60010330</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6508290072</author-url><authid>6508290072</authid><authname>Leksa V.</authname><surname>Leksa</surname><given-name>Vladimir</given-name><initials>V.</initials><afid>60011394</afid><afid>60010330</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54791561600</author-url><authid>54791561600</authid><authname>Ohradanova-Repic A.</authname><surname>Ohradanova-Repic</surname><given-name>Anna</given-name><initials>A.</initials><afid>60011394</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55893275600</author-url><authid>55893275600</authid><authname>Findlay A.</authname><surname>Findlay</surname><given-name>Alison D.</given-name><initials>A.D.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55635622900</author-url><authid>55635622900</authid><authname>Deodhar M.</authname><surname>Deodhar</surname><given-name>Mandar</given-name><initials>M.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7007051269</author-url><authid>7007051269</authid><authname>Stockinger H.</authname><surname>Stockinger</surname><given-name>Hannes</given-name><initials>H.</initials><afid>60011394</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56512813900</author-url><authid>56512813900</authid><authname>Song X.</authname><surname>Song</surname><given-name>Xiaomin</given-name><initials>X.</initials><afid>60019544</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7102425914</author-url><authid>7102425914</authid><authname>Molloy M.</authname><surname>Molloy</surname><given-name>Mark</given-name><initials>M.</initials><afid>60019544</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56640773200</author-url><authid>56640773200</authid><authname>Marsh C.</authname><surname>Marsh</surname><given-name>Clay B.</given-name><initials>C.B.</initials><afid>60090016</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56581890000</author-url><authid>56581890000</authid><authname>Jarolimek W.</authname><surname>Jarolimek</surname><given-name>Wolfgang</given-name><initials>W.</initials><afid/><afid>60023932</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56581890000</author-url><authid>56581890000</authid><authname>Jarolimek W.</authname><surname>Jarolimek</surname><given-name>Wolfgang</given-name><initials>W.</initials><afid/><afid>60023932</afid></author><authkeywords>Fibroblasts | Idiopathic pulmonary fibrosis | M6P | Mannose-6-phosphate | PXS64 | TGF-β1</authkeywords><intid>1535918320</intid><source-id>20825</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928982704"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928982704?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928982704&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928982704&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0277953615002701"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928982704</prism:url><dc:identifier>SCOPUS_ID:84928982704</dc:identifier><eid>2-s2.0-84928982704</eid><dc:title>Rationalising prescribing: Evidence, marketing and practice-relevant knowledge</dc:title><dc:creator>Wadmann S.</dc:creator><prism:publicationName>Social Science and Medicine</prism:publicationName><prism:issn>02779536</prism:issn><prism:eIssn>18735347</prism:eIssn><prism:volume>135</prism:volume><prism:pageRange>109-116</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.socscimed.2015.04.032</prism:doi><pii>S0277953615002701</pii><dc:description>© 2015 Elsevier Ltd. Initiatives in the name of 'rational pharmacotherapy' have been launched to alter what is seen as 'inappropriate' prescribing practices of physicians. Based on observations and interviews with 20 general practitioners (GPs) in 2009-2011, we explored how attempts to rationalise prescribing interact with chronic care management in Denmark. We demonstrate how attempts to rationalise prescribing by informing GPs about drug effects, adverse effects and price do not satisfy GPs' knowledge needs. We argue that, for GPs, 'rational' prescribing cannot be understood in separation from the processes that enable patients to use medication. Therefore, GPs do much more to obtain knowledge about medications than seek advice on 'rational pharmacotherapy'. For instance, GPs also seek opportunities to acquaint themselves with the material objects of medication and medical devices. We conceptualise the knowledge needs of GPs as a need for practice-relevant knowledge and argue that industry sales representatives are granted opportunity to access general practice because they understand this need of GPs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015199</affiliation-url><afid>60015199</afid><affilname>Copenhagen University Hospital</affilname><name-variant>University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55240220500</author-url><authid>55240220500</authid><authname>Wadmann S.</authname><surname>Wadmann</surname><given-name>Sarah</given-name><initials>S.</initials><afid>60030840</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56567788800</author-url><authid>56567788800</authid><authname>Bang L.</authname><surname>Bang</surname><given-name>Lia E.</given-name><initials>L.E.</initials><afid>60015199</afid></author><authkeywords>Clinical decision-making | Denmark | Evidence-based medicine (EBM) | Governance | Medical marketing | Practice-relevant knowledge | Prescribing | Rational pharmacotherapy</authkeywords><intid>1535883905</intid><source-id>18983</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925699343"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925699343?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925699343&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925699343&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167701215000986"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925699343</prism:url><dc:identifier>SCOPUS_ID:84925699343</dc:identifier><eid>2-s2.0-84925699343</eid><dc:title>Evaluation of peptide nucleic acid-mediated multiplex real-time PCR kits for rapid detection of carbapenemase genes in gram-negative clinical isolates</dc:title><dc:creator>Jeong S.</dc:creator><prism:publicationName>Journal of Microbiological Methods</prism:publicationName><prism:issn>01677012</prism:issn><prism:eIssn>18728359</prism:eIssn><prism:volume>113</prism:volume><prism:pageRange>4-9</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.mimet.2015.03.019</prism:doi><pii>S0167701215000986</pii><dc:description>© 2015 Elsevier B.V. The emergence of clinical isolates of carbapenemase-producing microbes confers multidrug-resistance to these bacteria and renders them difficult to treat. This study was performed to evaluate peptide nucleic acid (PNA) probe-based multiplex real-time PCR kits used to detect carbapenemase genes. In total, 324 carbapenemase genes, collected from 318 gram-negative clinical isolates in 36 different hospital laboratories, were assayed to evaluate multiplex real-time PCR kits (PANAGENE; Daejeon, Korea). The nine most prevalent carbapenemase genes (. KPC, OXA-48, GES, IMP, VIM, NDM, IS. Aba1-OXA-51, OXA-23, and OXA-58) were included in this study. The sensitivity and specificity of the multiplex real-time PCR assay to all of the carbapenemase genes were above 99.0%, except for IS. Aba1-OXA-51. The detection limit of the assay was 100 target copies per 25. μL of reaction volume for all of the nine genetic types of carbapenemases, and the genes were all detected in a single three-hour PCR. The assay also showed considerable efficiency (above 80.0%), stable reproducibility (coefficient of variation, below 5.0%) and a long shelf-life (more than eight months) with no cross reactivity. The developed PNA-mediated multiplex real-time PCR assay was useful for the rapid, accurate and simultaneous identification of nine carbapenemase genes in gram-negative clinical isolates, suggesting its potential to help choose the appropriate antibiotics and aid the control of carbapenemase genes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012736</affiliation-url><afid>60012736</afid><affilname>Kosin University, College of Medicine</affilname><name-variant>Kosin University College of Medicine</name-variant><affiliation-city>Busan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016728</affiliation-url><afid>60016728</afid><affilname>Yonsei University College of Medicine</affilname><name-variant>Yonsei University College of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002296</affiliation-url><afid>60002296</afid><affilname>Silla University</affilname><name-variant>Silla University</name-variant><affiliation-city>Busan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006034</affiliation-url><afid>60006034</afid><affilname>Hallym University, College of Medicine</affilname><name-variant>Hallym University College of Medicine</name-variant><affiliation-city>Chuncheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56573214400</author-url><authid>56573214400</authid><authname>Jeong S.</authname><surname>Jeong</surname><given-name>Seri</given-name><initials>S.</initials><afid>60012736</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56573317300</author-url><authid>56573317300</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jung Ok</given-name><initials>J.O.</initials><afid>60016728</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56573211700</author-url><authid>56573211700</authid><authname>Jeong S.</authname><surname>Jeong</surname><given-name>Seok Hoon</given-name><initials>S.H.</initials><afid>60016728</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004882608</author-url><authid>7004882608</authid><authname>Bae I.</authname><surname>Bae</surname><given-name>Il Kwon</given-name><initials>I.K.</initials><afid>60002296</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401655376</author-url><authid>7401655376</authid><authname>Song W.</authname><surname>Song</surname><given-name>Wonkeun</given-name><initials>W.</initials><afid>60006034</afid></author><authkeywords>Carbapenemase | Gene | Multiplex real-time PCR | Peptide nucleic acid</authkeywords><intid>1785348420</intid><source-id>20235</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927937828"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927937828?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927937828&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927937828&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1537511015000537"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927937828</prism:url><dc:identifier>SCOPUS_ID:84927937828</dc:identifier><eid>2-s2.0-84927937828</eid><dc:title>LED measurement for development of a non-destructive detector of unsuitable chicken eggs in influenza vaccine production</dc:title><dc:creator>Kimura K.</dc:creator><prism:publicationName>Biosystems Engineering</prism:publicationName><prism:issn>15375110</prism:issn><prism:volume>134</prism:volume><prism:pageRange>68-73</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.biosystemseng.2015.03.011</prism:doi><pii>S1537511015000537</pii><dc:description>© 2015 IAgrE. In Japan, fertilised chicken eggs are used to produce influenza vaccines; however, some eggs die and then contaminate the vaccine stock solution, which causes large economic losses and raises health concerns. Therefore, a non-destructive test that allows distinction of normal and unsuitable chicken eggs was developed, first using visible and near-infrared (VNIR) spectroscopy and subsequently a light-emitting diode (LED) light source. Eggs were sampled from an egg farm, and each of the eggs categorised as either normal or unsuitable using candling. Linear discriminant analysis was applied using wavelength absorbance data to distinguish between normal and unsuitable eggs. All of the optical absorbance values of the normal eggs were found to be higher than those of unsuitable eggs. To reduce the production cost, LED lights and photodiodes were used as the light source and light receptors, respectively. A discrimination rate of 92.9% was obtained when LED was used as the light source.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022313</affiliation-url><afid>60022313</afid><affilname>Niigata University</affilname><name-variant>Niigata University</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012567</affiliation-url><afid>60012567</afid><affilname>Kagoshima Immaculate Heart University</affilname><name-variant>Kagoshima Immaculate Heart Univ.</name-variant><affiliation-city>Satsumasendai</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56152872000</author-url><authid>56152872000</authid><authname>Kimura K.</authname><surname>Kimura</surname><given-name>Kohei</given-name><initials>K.</initials><afid>60022313</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7402011670</author-url><authid>7402011670</authid><authname>Nakano K.</authname><surname>Nakano</surname><given-name>Kazuhiro</given-name><initials>K.</initials><afid>60022313</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55186855600</author-url><authid>55186855600</authid><authname>Ohashi S.</authname><surname>Ohashi</surname><given-name>Shintaroh</given-name><initials>S.</initials><afid>60022313</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56596220600</author-url><authid>56596220600</authid><authname>Takizawa K.</authname><surname>Takizawa</surname><given-name>Kenichi</given-name><initials>K.</initials><afid>60022313</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56152527100</author-url><authid>56152527100</authid><authname>Nakano T.</authname><surname>Nakano</surname><given-name>Takayuki</given-name><initials>T.</initials><afid>60012567</afid></author><authkeywords>Fertilised chicken egg | Influenza vaccine | Linear discriminant analysis | Non-destructive detection | VNIR spectroscopy</authkeywords><intid>1785702739</intid><source-id>61490</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924116950"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924116950?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924116950&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924116950&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2214647415000069"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924116950</prism:url><dc:identifier>SCOPUS_ID:84924116950</dc:identifier><eid>2-s2.0-84924116950</eid><dc:title>High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk</dc:title><dc:creator>Hafiane A.</dc:creator><prism:publicationName>BBA Clinical</prism:publicationName><prism:issn>22146474</prism:issn><prism:volume>3</prism:volume><prism:pageRange>175-188</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbacli.2015.01.005</prism:doi><pii>S2214647415000069</pii><dc:description>© 2015. Plasma high density lipoprotein cholesterol (HDL) comprises a heterogeneous family of lipoprotein species, differing in surface charge, size and lipid and protein compositions. While HDL cholesterol (C) mass is a strong, graded and coherent biomarker of cardiovascular risk, genetic and clinical trial data suggest that the simple measurement of HDL-C may not be causal in preventing atherosclerosis nor reflect HDL functionality. Indeed, the measurement of HDL-C may be a biomarker of cardiovascular health. To assess the issue of HDL function as a potential therapeutic target, robust and simple analytical methods are required. The complex pleiotropic effects of HDL make the development of a single measurement challenging. Development of laboratory assays that accurately HDL function must be developed validated and brought to high-throughput for clinical purposes. This review discusses the limitations of current laboratory technologies for methods that separate and quantify HDL and potential application to predict CVD, with an emphasis on emergent approaches as potential biomarkers in clinical practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006558</affiliation-url><afid>60006558</afid><affilname>McGill University Health Centre, Montreal</affilname><name-variant>McGill University Health Centre</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23094305100</author-url><authid>23094305100</authid><authname>Hafiane A.</authname><surname>Hafiane</surname><given-name>Anouar</given-name><initials>A.</initials><afid>60006558</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56537849600</author-url><authid>56537849600</authid><authname>Genest J.</authname><surname>Genest</surname><given-name>Jacques</given-name><initials>J.</initials><afid>60006558</afid></author><authkeywords>Apolipoprotein A-I | Atherosclerosis | Biomarkers of cardiovascular risk | Cellular cholesterol efflux | Coronary artery disease | High density lipoproteins | Vascular endothelial function</authkeywords><intid>535086217</intid><source-id>21100317907</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928622236"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928622236?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928622236&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928622236&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928622236</prism:url><dc:identifier>SCOPUS_ID:84928622236</dc:identifier><eid>2-s2.0-84928622236</eid><dc:title>Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention</dc:title><dc:creator>Savoia C.</dc:creator><prism:publicationName>Current Hypertension Reports</prism:publicationName><prism:issn>15226417</prism:issn><prism:eIssn>15343111</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11906-015-0553-1</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Hypertension is one of the major risk factors for atrial fibrillation which in turn is the most prevalent concomitant condition in hypertensive patients. While both these pathological conditions are independent risk factors for stroke, the association of hypertension and atrial fibrillation increases the incidence of disabling strokes. Moreover, documented or silent atrial fibrillation doubles the rate of cardiovascular death. Lowering blood pressure is strongly recommended, particularly for primary stroke prevention. However, a relatively small percentage of hypertensive patients still achieve the recommended blood pressure goals. The management of atrial fibrillation with respect to stroke prevention is changing. New oral anticoagulants represent a major advancement in long-term anticoagulation therapy in non valvular atrial fibrillation. They have several benefits over warfarin, including improved adherence to the anticoagulation therapy. This is an important issue since non-adherence to stroke prevention medications is a risk factor for first and recurrent strokes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60084996</affiliation-url><afid>60084996</afid><affilname>Azienda Ospedaliera Sant'Andrea</affilname><name-variant>Sapienza University of Rome</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602739152</author-url><authid>6602739152</authid><authname>Savoia C.</authname><surname>Savoia</surname><given-name>Carmine</given-name><initials>C.</initials><afid>60084996</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55445072800</author-url><authid>55445072800</authid><authname>Sada L.</authname><surname>Sada</surname><given-name>Lidia</given-name><initials>L.</initials><afid>60084996</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102295300</author-url><authid>7102295300</authid><authname>Volpe M.</authname><surname>Volpe</surname><given-name>Massimo</given-name><initials>M.</initials><afid>60084996</afid><afid>60032350</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102295300</author-url><authid>7102295300</authid><authname>Volpe M.</authname><surname>Volpe</surname><given-name>Massimo</given-name><initials>M.</initials><afid>60084996</afid><afid>60032350</afid></author><authkeywords>Antihypertensive drugs | ARBs | Blood pressure control | NOACs | Oral anticoagulants</authkeywords><intid>1035808773</intid><source-id>23135</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929336905"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929336905?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929336905&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929336905&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929336905</prism:url><dc:identifier>SCOPUS_ID:84929336905</dc:identifier><eid>2-s2.0-84929336905</eid><dc:title>Ranolazine for the treatment of Atrial fibrillation</dc:title><dc:creator>Rosa G.</dc:creator><prism:publicationName>Expert Opinion on Investigational Drugs</prism:publicationName><prism:issn>13543784</prism:issn><prism:eIssn>17447658</prism:eIssn><prism:volume>24</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>825-836</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1517/13543784.2015.1036984</prism:doi><dc:description>© 2015 Informa UK, Ltd. Introduction: Atrial fibrillation (AF) is a frequent occurrence with advancing age and is associated with increased morbidity and mortality. Unfortunately, the currently available AF therapies have a great deal of side effects. Areas covered: In this review, the authors discuss the evidence upon which the use of Ranolazine as an anti-arrhythmic drug is based. Specifically, the authors review the Phase I-III trials that studied ranolazine as potential treatment for AF. They also discuss the efficacy, safety, tolerability and side effects and compare the MERLIN TIMI 36, HARMONY and ROLE trials. Expert opinion: Although ranolazine is considered an anti-angina drug, it may also be, according to the available data, used in patients with AF. Ranolazine has anti-AF efficacy, both alone or in combination with other drugs such as amiodarone and dronedarone. Indeed, its efficacy has been demonstrated in various settings such as the termination of paroxysmal AF, the facilitation of AF electrical cardioversion, and postoperative AF prevention. Although there is a great deal of evidence from pioneering experimental studies, the clinical evidence of the AF-suppressing effect of ranolazine is derived from studies with small sample size or from secondary analyses. A better understanding of the role of ranolazine as an anti-AF drug will be obtained through larger, prospective, placebo-controlled clinical trials in different populations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025153</affiliation-url><afid>60025153</afid><affilname>Universita degli Studi di Genova</affilname><name-variant>University of Genova</name-variant><affiliation-city>Genoa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025153</affiliation-url><afid>60025153</afid><affilname>Universita degli Studi di Genova</affilname><name-variant>University of Genova</name-variant><affiliation-city>Genoa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56530246100</author-url><authid>56530246100</authid><authname>Rosa G.</authname><surname>Rosa</surname><given-name>Gian Marco</given-name><initials>G.M.</initials><afid>60025153</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56225617700</author-url><authid>56225617700</authid><authname>Dorighi U.</authname><surname>Dorighi</surname><given-name>Ulrico</given-name><initials>U.</initials><afid>60025153</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16678617000</author-url><authid>16678617000</authid><authname>Ferrero S.</authname><surname>Ferrero</surname><given-name>Simone</given-name><initials>S.</initials><afid>60025153</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644679700</author-url><authid>56644679700</authid><authname>Brunacci M.</authname><surname>Brunacci</surname><given-name>Michele</given-name><initials>M.</initials><afid>60025153</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003394096</author-url><authid>7003394096</authid><authname>Bertero G.</authname><surname>Bertero</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60025153</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006082728</author-url><authid>7006082728</authid><authname>Brunelli C.</authname><surname>Brunelli</surname><given-name>Claudio</given-name><initials>C.</initials><afid>60025153</afid></author><authkeywords>Amiodarone | Anti-arrhythmic therapy | Atrial fibrillation | Dronedarone | Electrical cardioversion | Ranolazine</authkeywords><intid>1035939021</intid><source-id>21351</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929190981"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929190981?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929190981&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929190981&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929190981</prism:url><dc:identifier>SCOPUS_ID:84929190981</dc:identifier><eid>2-s2.0-84929190981</eid><dc:title>The presentation of respiratory failure in elderly individuals</dc:title><dc:creator>Britto R.</dc:creator><prism:publicationName>Current Geriatrics Reports</prism:publicationName><prism:eIssn>21967865</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>166-173</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13670-015-0130-0</prism:doi><dc:description>© 2015 Springer Science+Business Media New York. Respiratory failure (RF) is a prevalent condition whose presence in elderly patients may be complex and require specific and specialized intervention. A multidimensional evaluation is necessary to choose the best treatment, taking into consideration functional capacity and frailty. Cardiogenic pulmonary edema, community-acquired pneumonia, pulmonary embolism, bronchitis, and acute asthma are the main causes of RF in this patient population. Despite the limited availability of studies and data, including systematic reviews, regarding RF treatment in elderly patients, in this update, we synthesize data to guide diagnosis, treatment, and health care decision making.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017609</affiliation-url><afid>60017609</afid><affilname>Universidade Federal de Santa Catarina</affilname><name-variant>Universidade Federal de Santa Catarina</name-variant><affiliation-city>Florianopolis</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115234723</affiliation-url><afid>115234723</afid><affilname>Hospital Universitario Risoleta Tolentino Neves</affilname><name-variant>Hospital Universitario Risoleta Tolentino Neves</name-variant><affiliation-city/><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:102027727</affiliation-url><afid>102027727</afid><affilname>Prefeitura Municipal de Belo Horizonte</affilname><name-variant>Prefeitura Municipal de Belo Horizonte</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100521024</affiliation-url><afid>100521024</afid><affilname>Hospital Nossa Senhora de Lourdes</affilname><name-variant>Hospital Nossa Sra. de Lourdes</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8954470500</author-url><authid>8954470500</authid><authname>Britto R.</authname><surname>Britto</surname><given-name>Raquel R.</given-name><initials>R.R.</initials><afid>60030074</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14066660300</author-url><authid>14066660300</authid><authname>Vieira D.</authname><surname>Vieira</surname><given-name>Danielle S R</given-name><initials>D.S.R.</initials><afid>60017609</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16047263200</author-url><authid>16047263200</authid><authname>Botoni F.</authname><surname>Botoni</surname><given-name>Fernando A.</given-name><initials>F.A.</initials><afid>60030074</afid><afid>60030074</afid><afid>115234723</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16047263200</author-url><authid>16047263200</authid><authname>Botoni F.</authname><surname>Botoni</surname><given-name>Fernando A.</given-name><initials>F.A.</initials><afid>60030074</afid><afid>60030074</afid><afid>115234723</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16047263200</author-url><authid>16047263200</authid><authname>Botoni F.</authname><surname>Botoni</surname><given-name>Fernando A.</given-name><initials>F.A.</initials><afid>60030074</afid><afid>60030074</afid><afid>115234723</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56641606400</author-url><authid>56641606400</authid><authname>Botoni A.</authname><surname>Botoni</surname><given-name>Adriana L A S</given-name><initials>A.L.A.S.</initials><afid>102027727</afid><afid>100521024</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56641606400</author-url><authid>56641606400</authid><authname>Botoni A.</authname><surname>Botoni</surname><given-name>Adriana L A S</given-name><initials>A.L.A.S.</initials><afid>102027727</afid><afid>100521024</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602560090</author-url><authid>6602560090</authid><authname>Velloso M.</authname><surname>Velloso</surname><given-name>Marcelo</given-name><initials>M.</initials><afid>60030074</afid></author><authkeywords>Diagnosis | Elderly | Intensive care | Invasive ventilation | Noninvasive ventilation | Oxygen therapy | Pulmonary rehabilitation | Respiratory failure | Treatment</authkeywords><intid>2035911648</intid><source-id>21100358312</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928473692"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928473692?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928473692&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928473692&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928473692</prism:url><dc:identifier>SCOPUS_ID:84928473692</dc:identifier><eid>2-s2.0-84928473692</eid><dc:title>Excess Cardiovascular Risk in Diabetic Women: A Case for Intensive Treatment</dc:title><dc:creator>Recarti C.</dc:creator><prism:publicationName>Current Hypertension Reports</prism:publicationName><prism:issn>15226417</prism:issn><prism:eIssn>15343111</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11906-015-0554-0</prism:doi><dc:description>© 2015, The Author(s). Diabetes is a common and rapidly growing disease that affects more than 380 million people worldwide and is an established risk factor for cardiovascular disease with differential effects on women compared to men. While the general population of women, particularly young women, has more favourable cardiovascular risk profiles than men, this protective effect has been shown to be lost or even reversed in diabetic women. Several studies have demonstrated a significant diabetes-associated excess risk of cardiovascular disease in women. Sex-specific differences in risk factors associated with diabetes and their management may be responsible for the relative excess cardiovascular risk in women with diabetes. Diabetic women need intensive treatment in order to optimize management of cardiovascular risk factors. Further studies are needed to elucidate the mechanisms underlying the excess cardiovascular risk in diabetic women in order to tailor prevention and treatment strategies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018869</affiliation-url><afid>60018869</afid><affilname>Maastricht University</affilname><name-variant>University of Limburg</name-variant><affiliation-city>Maastricht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35559517100</author-url><authid>35559517100</authid><authname>Recarti C.</authname><surname>Recarti</surname><given-name>C.</given-name><initials>C.</initials><afid>60018869</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25927601100</author-url><authid>25927601100</authid><authname>Sep S.</authname><surname>Sep</surname><given-name>S. J S</given-name><initials>S.J.S.</initials><afid>60018869</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56463616500</author-url><authid>56463616500</authid><authname>Stehouwer C.</authname><surname>Stehouwer</surname><given-name>C. D A</given-name><initials>C.D.A.</initials><afid>60018869</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36045821100</author-url><authid>36045821100</authid><authname>Unger T.</authname><surname>Unger</surname><given-name>T.</given-name><initials>T.</initials><afid>60018869</afid></author><authkeywords>Cardiovascular risk | Diabetes | Sex differences | Women</authkeywords><intid>535794580</intid><source-id>23135</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926432178"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926432178?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926432178&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926432178&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015001872"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926432178</prism:url><dc:identifier>SCOPUS_ID:84926432178</dc:identifier><eid>2-s2.0-84926432178</eid><dc:title>Ethnic differences in the association between lipid metabolism genes and lipid levels in black and white South African women</dc:title><dc:creator>Ellman N.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>311-317</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.027</prism:doi><pii>S0021915015001872</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. Objective: Dyslipidaemia can lead to the development of atherosclerosis and cardiovascular disease (CVD), however its prevalence has been shown to differ between ethnic groups in South Africa (SA). Therefore the aim of this study was to investigate ethnic differences in the association between serum lipid levels and polymorphisms within genes involved in lipid metabolism in black and white SA women. Methods: In a convenient sample of 234 white and 209 black SA women of Xhosa ancestry, body composition (DXA) and fasting serum lipids were measured. Participants were genotyped for the cholesteryl ester transfer protein (CETP, rs708272, B1/B2), lipoprotein lipase (LPL, rs328, S/X), hepatic lipase (LIPC, rs1800588, C/T) and proprotein convertase subtilisin/kexin type 9 (PCSK9, rs28362286, C/X) polymorphisms. Results: Compared to white women, black women had lower concentrations of serum total cholesterol (TC, P&lt;0.001), low density lipoprotein cholesterol (LDL-C, P&lt;0.001), high density lipoprotein cholesterol (HDL-C, P&lt;0.001) and triglycerides (TG, P&lt;0.001). There were significant differences in the genotype and allele frequency distributions between black and white women for the LPL S/X (P&lt;0.001), PCSK9 C679X (P=0.002) and LIPC 514C/T (P&lt;0.001) polymorphisms. In black women only, there were genotype effects on serum lipid levels. Specifically, women with the LPL SX genotype had lower TC and LDL-C and higher HDL-C concentrations than those with the SS genotype and women with the CETP B2 allele had lower LDL-C concentrations than those with the B1B1 genotype. Conclusion: Polymorphisms within the LPL and CETP genes were associated with a more protective lipid profile in black, but not white SA women. This supports the hypothesis that the more favorable lipid profile of black compared to white SA women is associated with polymorphisms in lipid metabolism genes, specifically the LPL and CETP genes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000356</affiliation-url><afid>60000356</afid><affilname>University of Cape Town</affilname><name-variant>University of Cape Town</name-variant><affiliation-city>Cape Town</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028973</affiliation-url><afid>60028973</afid><affilname>South African Medical Research Council</affilname><name-variant>Medical Research Council</name-variant><affiliation-city>Tygerberg</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55579303200</author-url><authid>55579303200</authid><authname>Ellman N.</authname><surname>Ellman</surname><given-name>Nicole</given-name><initials>N.</initials><afid>60000356</afid><afid>60028973</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55579303200</author-url><authid>55579303200</authid><authname>Ellman N.</authname><surname>Ellman</surname><given-name>Nicole</given-name><initials>N.</initials><afid>60000356</afid><afid>60028973</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54583650500</author-url><authid>54583650500</authid><authname>Keswell D.</authname><surname>Keswell</surname><given-name>Dheshnie</given-name><initials>D.</initials><afid>60000356</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7404083910</author-url><authid>7404083910</authid><authname>Collins M.</authname><surname>Collins</surname><given-name>Malcolm</given-name><initials>M.</initials><afid>60000356</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55580972600</author-url><authid>55580972600</authid><authname>Tootla M.</authname><surname>Tootla</surname><given-name>Mehreen</given-name><initials>M.</initials><afid>60000356</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602562279</author-url><authid>6602562279</authid><authname>Goedecke J.</authname><surname>Goedecke</surname><given-name>Julia H.</given-name><initials>J.H.</initials><afid>60000356</afid><afid>60028973</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602562279</author-url><authid>6602562279</authid><authname>Goedecke J.</authname><surname>Goedecke</surname><given-name>Julia H.</given-name><initials>J.H.</initials><afid>60000356</afid><afid>60028973</afid></author><authkeywords>CETP | LIPC | Lipid profile | LPL | PCSK9</authkeywords><intid>535455534</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198881"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198881?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198881&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198881&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198881</prism:url><dc:identifier>SCOPUS_ID:84930198881</dc:identifier><eid>2-s2.0-84930198881</eid><dc:title>Biomarkers of world trade center particulate matter exposure: Physiology of distal airway and blood biomarkers that predict FEV&lt;inf&gt;1&lt;/inf&gt; decline</dc:title><dc:creator>Weiden M.</dc:creator><prism:publicationName>Seminars in Respiratory and Critical Care Medicine</prism:publicationName><prism:issn>10693424</prism:issn><prism:eIssn>10989048</prism:eIssn><prism:volume>36</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>323-333</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1547349</prism:doi><dc:description>Copyright © 2015 by Thieme Medical Publishers, Inc. Biomarkers can be important predictors of disease severity and progression. The intense exposure to particulates and other toxins from the destruction of the World Trade Center (WTC) overwhelmed the lung's normal protective barriers. The Fire Department of New York (FDNY) cohort not only had baseline pre-exposure lung function measures but also had serum samples banked soon after their WTC exposure. This well-phenotyped group of highly exposed first responders is an ideal cohort for biomarker discovery and eventual validation. Disease progression was heterogeneous in this group in that some individuals subsequently developed abnormal lung function while others recovered. Airflow obstruction predominated in WTC-exposed patients who were symptomatic. Multiple independent disease pathways may cause this abnormal FEV&lt;inf&gt;1&lt;/inf&gt; after irritant exposure. WTC exposure activates one or more of these pathways causing abnormal FEV&lt;inf&gt;1&lt;/inf&gt; in an individual. Our hypothesis was that serum biomarkers expressed within 6 months after WTC exposure reflect active disease pathways and predict subsequent development or protection from abnormal FEV&lt;inf&gt;1&lt;/inf&gt; below the lower limit of normal known as WTC-Lung Injury (WTC-LI). We utilized a nested case-cohort control design of previously healthy never smokers who sought subspecialty pulmonary evaluation to explore predictive biomarkers of WTC-LI. We have identified biomarkers of inflammation, metabolic derangement, protease/antiprotease balance, and vascular injury expressed in serum within 6 months of WTC exposure that were predictive of their FEV&lt;inf&gt;1&lt;/inf&gt; up to 7 years after their WTC exposure. Predicting future risk of airway injury after particulate exposures can focus monitoring and early treatment on a subset of patients in greatest need of these services.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024541</affiliation-url><afid>60024541</afid><affilname>New York University School of Medicine</affilname><name-variant>New York Univ. School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60098019</affiliation-url><afid>60098019</afid><affilname>Government of New york</affilname><name-variant>Government of New york</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021784</affiliation-url><afid>60021784</afid><affilname>New York University</affilname><name-variant>New York University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002388</affiliation-url><afid>60002388</afid><affilname>Albert Einstein College of Medicine of Yeshiva University</affilname><name-variant>Albert Einstein College of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005725007</author-url><authid>7005725007</authid><authname>Weiden M.</authname><surname>Weiden</surname><given-name>Michael D.</given-name><initials>M.D.</initials><afid>60024541</afid><afid>60098019</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005725007</author-url><authid>7005725007</authid><authname>Weiden M.</authname><surname>Weiden</surname><given-name>Michael D.</given-name><initials>M.D.</initials><afid>60024541</afid><afid>60098019</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55674891700</author-url><authid>55674891700</authid><authname>Kwon S.</authname><surname>Kwon</surname><given-name>Sophia</given-name><initials>S.</initials><afid>60024541</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663126900</author-url><authid>56663126900</authid><authname>Caraher E.</authname><surname>Caraher</surname><given-name>Erin</given-name><initials>E.</initials><afid>60024541</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103356417</author-url><authid>7103356417</authid><authname>Berger K.</authname><surname>Berger</surname><given-name>Kenneth I.</given-name><initials>K.I.</initials><afid>60024541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004389253</author-url><authid>7004389253</authid><authname>Reibman J.</authname><surname>Reibman</surname><given-name>Joan</given-name><initials>J.</initials><afid>60024541</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:34573666300</author-url><authid>34573666300</authid><authname>Rom W.</authname><surname>Rom</surname><given-name>William N.</given-name><initials>W.N.</initials><afid>60024541</afid><afid>60021784</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:34573666300</author-url><authid>34573666300</authid><authname>Rom W.</authname><surname>Rom</surname><given-name>William N.</given-name><initials>W.N.</initials><afid>60024541</afid><afid>60021784</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003745546</author-url><authid>7003745546</authid><authname>Prezant D.</authname><surname>Prezant</surname><given-name>David J.</given-name><initials>D.J.</initials><afid>60098019</afid><afid>60002388</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003745546</author-url><authid>7003745546</authid><authname>Prezant D.</authname><surname>Prezant</surname><given-name>David J.</given-name><initials>D.J.</initials><afid>60098019</afid><afid>60002388</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006539837</author-url><authid>7006539837</authid><authname>Nolan A.</authname><surname>Nolan</surname><given-name>Anna</given-name><initials>A.</initials><afid>60024541</afid><afid>60098019</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006539837</author-url><authid>7006539837</authid><authname>Nolan A.</authname><surname>Nolan</surname><given-name>Anna</given-name><initials>A.</initials><afid>60024541</afid><afid>60098019</afid></author><authkeywords>lung injury | obstructive airway disease | predictive biomarkers | World Trade Center</authkeywords><intid>36086271</intid><source-id>19086</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929119501"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929119501?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929119501&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929119501&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929119501</prism:url><dc:identifier>SCOPUS_ID:84929119501</dc:identifier><eid>2-s2.0-84929119501</eid><dc:title>Capillary Dysfunction: Its Detection and Causative Role in Dementias and Stroke</dc:title><dc:creator>Østergaard L.</dc:creator><prism:publicationName>Current Neurology and Neuroscience Reports</prism:publicationName><prism:issn>15284042</prism:issn><prism:eIssn>15346293</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11910-015-0557-x</prism:doi><dc:description>© 2015, The Author(s). In acute ischemic stroke, critical hypoperfusion is a frequent cause of hypoxic tissue injury: As cerebral blood flow (CBF) falls below the ischemic threshold of 20 mL/100 mL/min, neurological symptoms develop and hypoxic tissue injury evolves within minutes or hours unless the oxygen supply is restored. But is ischemia the only hemodynamic source of hypoxic tissue injury? Reanalyses of the equations we traditionally use to describe the relation between CBF and tissue oxygenation suggest that capillary flow patterns are crucial for the efficient extraction of oxygen: without close capillary flow control, “functional shunts” tend to form and some of the blood’s oxygen content in effect becomes inaccessible to tissue. This phenomenon raises several questions: Are there in fact two hemodynamic causes of tissue hypoxia: Limited blood supply (ischemia) and limited oxygen extraction due to capillary dysfunction? If so, how do we distinguish the two, experimentally and in patients? Do flow-metabolism coupling mechanisms adjust CBF to optimize tissue oxygenation when capillary dysfunction impairs oxygen extraction downstream? Cardiovascular risk factors such as age, hypertension, diabetes, hypercholesterolemia, and smoking increase the risk of both stroke and dementia. The capillary dysfunction phenomenon therefore forces us to consider whether changes in capillary morphology or blood rheology may play a role in the etiology of some stroke subtypes and in Alzheimer’s disease. Here, we discuss whether certain disease characteristics suggest capillary dysfunction rather than primary flow-limiting vascular pathology and how capillary dysfunction may be imaged and managed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029616</affiliation-url><afid>60029616</afid><affilname>Aarhus Universitet</affilname><name-variant>University of Aarhus</name-variant><affiliation-city>Aarhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023882</affiliation-url><afid>60023882</afid><affilname>Arhus Universitetshospital</affilname><name-variant>Aarhus University Hospital</name-variant><affiliation-city>Arhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029616</affiliation-url><afid>60029616</afid><affilname>Aarhus Universitet</affilname><name-variant>University of Aarhus</name-variant><affiliation-city>Aarhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006084217</author-url><authid>7006084217</authid><authname>Østergaard L.</authname><surname>Østergaard</surname><given-name>Leif</given-name><initials>L.</initials><afid>60029616</afid><afid>60023882</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006084217</author-url><authid>7006084217</authid><authname>Østergaard L.</authname><surname>Østergaard</surname><given-name>Leif</given-name><initials>L.</initials><afid>60029616</afid><afid>60023882</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56442796000</author-url><authid>56442796000</authid><authname>Jespersen S.</authname><surname>Jespersen</surname><given-name>Sune Nørhøj</given-name><initials>S.N.</initials><afid>60029616</afid><afid>60029616</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56442796000</author-url><authid>56442796000</authid><authname>Jespersen S.</authname><surname>Jespersen</surname><given-name>Sune Nørhøj</given-name><initials>S.N.</initials><afid>60029616</afid><afid>60029616</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56638584200</author-url><authid>56638584200</authid><authname>Engedahl T.</authname><surname>Engedahl</surname><given-name>Thorbjørn</given-name><initials>T.</initials><afid>60029616</afid><afid>60023882</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56638584200</author-url><authid>56638584200</authid><authname>Engedahl T.</authname><surname>Engedahl</surname><given-name>Thorbjørn</given-name><initials>T.</initials><afid>60029616</afid><afid>60023882</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55949968200</author-url><authid>55949968200</authid><authname>Jiménez E.</authname><surname>Jiménez</surname><given-name>Eugenio Gutiérrez</given-name><initials>E.G.</initials><afid>60029616</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8724327300</author-url><authid>8724327300</authid><authname>Ashkanian M.</authname><surname>Ashkanian</surname><given-name>Mahmoud</given-name><initials>M.</initials><afid>60029616</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24075704400</author-url><authid>24075704400</authid><authname>Hansen M.</authname><surname>Hansen</surname><given-name>Mikkel Bo</given-name><initials>M.B.</initials><afid>60029616</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8686943600</author-url><authid>8686943600</authid><authname>Eskildsen S.</authname><surname>Eskildsen</surname><given-name>Simon</given-name><initials>S.</initials><afid>60029616</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:12769803800</author-url><authid>12769803800</authid><authname>Mouridsen K.</authname><surname>Mouridsen</surname><given-name>Kim</given-name><initials>K.</initials><afid>60029616</afid></author><authkeywords>Alzheimer’s disease | Capillary dysfunction | Cardiovascular risk factors | Perfusion imaging | Reperfusion injury | Stroke | Vascular dementia</authkeywords><intid>535903557</intid><source-id>14989</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929965588"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929965588?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929965588&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929965588&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009912015000399"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929965588</prism:url><dc:identifier>SCOPUS_ID:84929965588</dc:identifier><eid>2-s2.0-84929965588</eid><dc:title>Relationship between serum cytokine and growth factor concentrations and coronary artery disease</dc:title><dc:creator>Mirhafez S.</dc:creator><prism:publicationName>Clinical Biochemistry</prism:publicationName><prism:issn>00099120</prism:issn><prism:eIssn>18732933</prism:eIssn><prism:volume>48</prism:volume><prism:issueIdentifier>9</prism:issueIdentifier><prism:pageRange>575-580</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.clinbiochem.2015.02.002</prism:doi><pii>S0009912015000399</pii><dc:description>© 2015 The Canadian Society of Clinical Chemists. Background: We have assessed the association between serum concentrations of 12 cytokines/growth factors and angiographically-defined coronary artery disease, comparing the concentrations in four groups (one control group and three case groups). Methods: We studied a total of 426 subjects including; 98 control subjects and 3 case groups. The patient groups consisted of: coronary artery bypass graft (CABG) candidates (. n=. 48) and patients undergoing coronary angiography, with, or without obstructive coronary artery disease. Twelve cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, MCP-1, IFN-γ, EGF, and VEGF) were measured using a sandwich chemi-luminescence assays, on the Evidence Investigator® system. Results: The four groups were well matched for demographic and clinical characteristics, except waist circumference, fasting blood glucose (FBG), total and LDL cholesterol and diastolic blood pressure that were significantly higher in case groups compared to the control group (. P&lt;. 0.05 for all). There were significant differences between control group and the other three groups regarding the measured cytokines, such as IL-1α, IL-8, MCP-1, and VEGF (. P&lt;. 0.01). Furthermore, IL-4, IL-6 and EGF were also significantly different between the control, obstructive coronary disease and CABG candidate groups (. P&lt;. 0.01). Analysis of the ROC curve showed 92.1% sensitivity, 99.2% specificity and 100% positive predictive value (PPV) for VEGF in its ability to distinguish the CABG group at the cut-off point of 37.18. pg/ml. Conclusion: The results of this study suggest that cytokines such as IL-1α, IL-4, IL-8, IL-10 and VEGF may play major roles in pathogenesis of CAD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113871175</affiliation-url><afid>113871175</afid><affilname>Neyshabur University of Medical Sciences</affilname><name-variant>Neyshabur University of Medical Sciences</name-variant><affiliation-city/><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60100018</affiliation-url><afid>60100018</afid><affilname>Brighton and Sussex Medical School</affilname><name-variant>Brighton and Sussex Medical School</name-variant><affiliation-city>Brighton</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001500</affiliation-url><afid>60001500</afid><affilname>Mashhad University of Medical Sciences</affilname><name-variant>Mashhad University of Medical Sciences</name-variant><affiliation-city>Mashad</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55321847300</author-url><authid>55321847300</authid><authname>Mirhafez S.</authname><surname>Mirhafez</surname><given-name>Seyed Reza</given-name><initials>S.R.</initials><afid>60001500</afid><afid>113871175</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55321847300</author-url><authid>55321847300</authid><authname>Mirhafez S.</authname><surname>Mirhafez</surname><given-name>Seyed Reza</given-name><initials>S.R.</initials><afid>60001500</afid><afid>113871175</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56120971300</author-url><authid>56120971300</authid><authname>Zarifian A.</authname><surname>Zarifian</surname><given-name>Ahmadreza</given-name><initials>A.</initials><afid>60001500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15847776000</author-url><authid>15847776000</authid><authname>Ebrahimi M.</authname><surname>Ebrahimi</surname><given-name>Mahmoud</given-name><initials>M.</initials><afid>60001500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56537734500</author-url><authid>56537734500</authid><authname>Ali R.</authname><surname>Ali</surname><given-name>Ramin Fakhre Ale</given-name><initials>R.F.A.</initials><afid>60001500</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55332977800</author-url><authid>55332977800</authid><authname>Avan A.</authname><surname>Avan</surname><given-name>Amir</given-name><initials>A.</initials><afid>60001500</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55921385900</author-url><authid>55921385900</authid><authname>Tajfard M.</authname><surname>Tajfard</surname><given-name>Mohammad</given-name><initials>M.</initials><afid>60001500</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36114824700</author-url><authid>36114824700</authid><authname>Mohebati M.</authname><surname>Mohebati</surname><given-name>Mohsen</given-name><initials>M.</initials><afid>60001500</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56524236300</author-url><authid>56524236300</authid><authname>Eslami S.</authname><surname>Eslami</surname><given-name>Saeid</given-name><initials>S.</initials><afid>60001500</afid><afid>60001500</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56524236300</author-url><authid>56524236300</authid><authname>Eslami S.</authname><surname>Eslami</surname><given-name>Saeid</given-name><initials>S.</initials><afid>60001500</afid><afid>60001500</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:34067787700</author-url><authid>34067787700</authid><authname>Rahsepar A.</authname><surname>Rahsepar</surname><given-name>Amir Ali</given-name><initials>A.A.</initials><afid>60001500</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36893463900</author-url><authid>36893463900</authid><authname>Rahimi H.</authname><surname>Rahimi</surname><given-name>Hamid Reza</given-name><initials>H.R.</initials><afid>60001500</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56538710600</author-url><authid>56538710600</authid><authname>Mehrad-Majd H.</authname><surname>Mehrad-Majd</surname><given-name>Hassan</given-name><initials>H.</initials><afid>113871175</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7005674972</author-url><authid>7005674972</authid><authname>Ferns G.</authname><surname>Ferns</surname><given-name>Gordon A.</given-name><initials>G.A.</initials><afid>60100018</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:15848304500</author-url><authid>15848304500</authid><authname>Ghayour-Mobarhan M.</authname><surname>Ghayour-Mobarhan</surname><given-name>Majid</given-name><initials>M.</initials><afid>60001500</afid><afid>60001500</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:15848304500</author-url><authid>15848304500</authid><authname>Ghayour-Mobarhan M.</authname><surname>Ghayour-Mobarhan</surname><given-name>Majid</given-name><initials>M.</initials><afid>60001500</afid><afid>60001500</afid></author><authkeywords>Coronary artery diseases | Cytokines | Growth factors | Inflammation</authkeywords><intid>1786042923</intid><source-id>16954</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927772829"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927772829?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927772829&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927772829&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002221"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927772829</prism:url><dc:identifier>SCOPUS_ID:84927772829</dc:identifier><eid>2-s2.0-84927772829</eid><dc:title>Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - A systematic review and meta-analysis</dc:title><dc:creator>Gerards M.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>415-423</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.004</prism:doi><pii>S0021915015002221</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objective: To verify the safety and effectiveness of traditional Chinese red yeast rice-extract (RYR) for reduction of LDL cholesterol. Methods: Systematic literature review and meta-analysis. Medline and EMBASE were searched until November 2014. We selected randomized studies in which RYR with a known content of the active substance monacolin K was tested against placebo or an active control group. Outcome measures were the effect of RYR on LDL cholesterol and incidence of adverse reactions with emphasis on liver and kidney injury and muscle symptoms. Results: Twenty studies were analyzed. Quality of safety assessment was low in the majority of studies. RYR lowered LDL cholesterol with 1.02mmol/L [-1.20;-0.83] compared to placebo. Effect of RYR on LDL was not different from statin therapy (0.03mmol/L [-0.36; 0.41]). The incidence of liver and kidney injury was 0-5% and the risk was not different between treatment and control groups (risk difference-0.01 [-0.01; 0.0] and 0.0 [-0.01; 0.02]). Conclusions: RYR exerts a clinically and statistically significant reduction of 1.02mmol/L LDL cholesterol. Only when the mild profile of adverse reactions can be affirmed in studies with adequate methodology for safety assessment, RYR might be a safe and effective treatment option for dyslipidemia and cardiovascular risk reduction in statin intolerant patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009374</affiliation-url><afid>60009374</afid><affilname>Slotervaart Hospital</affilname><name-variant>Slotervaart Hospital</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070177</affiliation-url><afid>60070177</afid><affilname>Antoni van Leeuwenhoek Ziekenhuis</affilname><name-variant>Antoni van Leeuwenhoek Hospital</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:44761005900</author-url><authid>44761005900</authid><authname>Gerards M.</authname><surname>Gerards</surname><given-name>Maaike C.</given-name><initials>M.C.</initials><afid>60009374</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56595184200</author-url><authid>56595184200</authid><authname>Terlou R.</authname><surname>Terlou</surname><given-name>Ruben J.</given-name><initials>R.J.</initials><afid>60001157</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593826100</author-url><authid>56593826100</authid><authname>Yu H.</authname><surname>Yu</surname><given-name>Huixin</given-name><initials>H.</initials><afid>60070177</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56594652200</author-url><authid>56594652200</authid><authname>Koks C.</authname><surname>Koks</surname><given-name>C. H W</given-name><initials>C.H.W.</initials><afid>60070177</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701370173</author-url><authid>6701370173</authid><authname>Gerdes V.</authname><surname>Gerdes</surname><given-name>V. E A</given-name><initials>V.E.A.</initials><afid>60009374</afid></author><authkeywords>Cardiovascular risk reduction | Cholesterol | Complementary and alternative medicine | Drug safety</authkeywords><intid>2035660390</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923336555"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923336555?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923336555&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923336555&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2352250X15000871"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923336555</prism:url><dc:identifier>SCOPUS_ID:84923336555</dc:identifier><eid>2-s2.0-84923336555</eid><dc:title>Respiratory sinus arrhythmia: A transdiagnostic biomarker of emotion dysregulation and psychopathology</dc:title><dc:creator>Beauchaine T.</dc:creator><prism:publicationName>Current Opinion in Psychology</prism:publicationName><prism:issn>2352250X</prism:issn><prism:volume>3</prism:volume><prism:pageRange>43-47</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.copsyc.2015.01.017</prism:doi><pii>S2352250X15000871</pii><dc:description>© 2015 Elsevier Ltd. In the past two decades, respiratory sinus arrhythmia (RSA)-an index of parasympathetic nervous system (PNS)-mediated cardiac control-has emerged as a reliable peripheral biomarker of emotion regulation (ER). Reduced RSA and excessive RSA reactivity (i.e., withdrawal) to emotional challenge are observed consistently among individuals with poor ER capabilities, including those with various forms of internalizing and externalizing psychopathology, and those with specific psychopathological syndromes, including anxiety, phobias, attention problems, autism, callousness, conduct disorder, depression, non-suicidal self-injury, panic disorder, and trait hostility. Emerging evidence suggests that low RSA and excessive RSA reactivity index poor ER because they are downstream peripheral markers of prefrontal cortex (PFC) dysfunction. Poorly modulated inhibitory efferent pathways from the medial PFC to the PNS result in reduced RSA and excessive RSA reactivity. According to this perspective, RSA is a non-invasive proxy for poor executive control over behavior, which characterizes most forms of psychopathology.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602689754</author-url><authid>6602689754</authid><authname>Beauchaine T.</authname><surname>Beauchaine</surname><given-name>Theodore P.</given-name><initials>T.P.</initials><afid>60003500</afid></author><intid>534963230</intid><source-id>21100372442</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928630292"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928630292?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928630292&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928630292&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928630292</prism:url><dc:identifier>SCOPUS_ID:84928630292</dc:identifier><eid>2-s2.0-84928630292</eid><dc:title>Management of Aortic Dissection: Medical Therapy and Intervention. Is There a Growing Role for Endovascular Techniques?</dc:title><dc:creator>Orion K.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0386-x</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Historically, type B aortic dissection was managed as a medical condition with limited surgical intervention unless aortic rupture occurred. Today, however, evidence is building that highlights the importance of strict medical management, timely surveillance, and windows of opportunity for surgical intervention to address both early and late aortic-based morbidities.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001555</affiliation-url><afid>60001555</afid><affilname>Johns Hopkins Hospital</affilname><name-variant>Johns Hopkins Hospital</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35273426000</author-url><authid>35273426000</authid><authname>Orion K.</authname><surname>Orion</surname><given-name>Kristine C.</given-name><initials>K.C.</initials><afid>60001555</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7402767055</author-url><authid>7402767055</authid><authname>Black J.</authname><surname>Black</surname><given-name>James H.</given-name><initials>J.H.</initials><afid>60001555</afid></author><authkeywords>Aortic-based morbidities | Surgical intervention | Therapy | Type B aortic dissection</authkeywords><intid>1035809356</intid><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226854"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226854?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226854&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226854&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226854</prism:url><dc:identifier>SCOPUS_ID:84930226854</dc:identifier><eid>2-s2.0-84930226854</eid><dc:title>Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy</dc:title><dc:creator>Italiano D.</dc:creator><prism:publicationName>Journal of Neural Transmission</prism:publicationName><prism:issn>03009564</prism:issn><prism:eIssn>14351463</prism:eIssn><prism:volume>122</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>799-808</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00702-014-1314-z</prism:doi><dc:description>© 2014, Springer-Verlag Wien. On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we retrospectively reviewed medical charts of patients with degenerative Parkinsonism treated with cabergoline in three large Italian clinics between January 2006 and June 2012. The prevalence and the severity of cardiac valve regurgitation were assessed in patients who stopped cabergoline therapy prior to June 2008 or continued therapy after that date. In addition, the proportion of patients undergoing echocardiographic examination in each cohort was evaluated. A total of 61 patients were available for evaluation. The proportion of patients who underwent a baseline echocardiographic examination increased from 64 % in the period before the 2008 SPC changes to 71 % among those who continued treatment after that date. However, only 18 and 29 % of patients underwent at least two echocardiographic examinations during the pre-SPC and cross-SPC change period, respectively. No severe cardiac valve regurgitation was documented in any of the study patients using cabergoline either prior or after 26th June 2008. Our findings show that the 2008 changes to the SPC resulted in an increase in physicians’ awareness of cabergoline-induced valvulopathy risk in Italy. However, only a small percentage of patients underwent serial echocardiography. Further efforts are needed to achieve better compliance with the prescribing guidelines for cabergoline treated patients in clinical practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011576</affiliation-url><afid>60011576</afid><affilname>Universita degli Studi di Messina</affilname><name-variant>Università di Messina</name-variant><affiliation-city>Messina</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113363288</affiliation-url><afid>113363288</afid><affilname>Genomedics</affilname><name-variant>Genomedics</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293716</affiliation-url><afid>115293716</afid><affilname>BOTO Healthcare Services Provider</affilname><name-variant>BOTO Healthcare Services Provider</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073829</affiliation-url><afid>60073829</afid><affilname>Istituti Clinici di Perfezionamento</affilname><name-variant>Istituti Clinici di Perfezionamento</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103767</affiliation-url><afid>60103767</afid><affilname>IRCCS San Raffaele Pisana</affilname><name-variant>IRCCS San Raffaele Pisana</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60083082</affiliation-url><afid>60083082</afid><affilname>IRCCS Centro Neurolesi Bonino Pulejo</affilname><name-variant>IRCCS Centro Neurolesi Bonino-Pulejo</name-variant><affiliation-city>Messina</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006989</affiliation-url><afid>60006989</afid><affilname>Pfizer</affilname><name-variant>Pfizer</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006989</affiliation-url><afid>60006989</afid><affilname>Pfizer</affilname><name-variant>Pfizer</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032114</affiliation-url><afid>60032114</afid><affilname>Erasmus University Medical Center</affilname><name-variant>Erasmus Medical Center</name-variant><affiliation-city>Rotterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22634569800</author-url><authid>22634569800</authid><authname>Italiano D.</authname><surname>Italiano</surname><given-name>Domenico</given-name><initials>D.</initials><afid>60011576</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662852500</author-url><authid>56662852500</authid><authname>Bianchini E.</authname><surname>Bianchini</surname><given-name>Elisa</given-name><initials>E.</initials><afid>113363288</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56635600100</author-url><authid>56635600100</authid><authname>Ilardi M.</authname><surname>Ilardi</surname><given-name>Maura</given-name><initials>M.</initials><afid>115293716</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:12800792900</author-url><authid>12800792900</authid><authname>Cilia R.</authname><surname>Cilia</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60073829</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005329243</author-url><authid>7005329243</authid><authname>Pezzoli G.</authname><surname>Pezzoli</surname><given-name>Gianni</given-name><initials>G.</initials><afid>60073829</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56470606900</author-url><authid>56470606900</authid><authname>Zanettini R.</authname><surname>Zanettini</surname><given-name>Renzo</given-name><initials>R.</initials><afid>60073829</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006568170</author-url><authid>7006568170</authid><authname>Vacca L.</authname><surname>Vacca</surname><given-name>Laura</given-name><initials>L.</initials><afid>60103767</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005546848</author-url><authid>7005546848</authid><authname>Stocchi F.</authname><surname>Stocchi</surname><given-name>Fabrizio</given-name><initials>F.</initials><afid>60103767</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7005112597</author-url><authid>7005112597</authid><authname>Bramanti P.</authname><surname>Bramanti</surname><given-name>Placido</given-name><initials>P.</initials><afid>60083082</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:16432751600</author-url><authid>16432751600</authid><authname>Ciurleo R.</authname><surname>Ciurleo</surname><given-name>Rosella</given-name><initials>R.</initials><afid>60083082</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35918265300</author-url><authid>35918265300</authid><authname>Di Lorenzo G.</authname><surname>Di Lorenzo</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60083082</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6602720375</author-url><authid>6602720375</authid><authname>Polimeni G.</authname><surname>Polimeni</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60011576</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6504356911</author-url><authid>6504356911</authid><authname>de Luise C.</authname><surname>de Luise</surname><given-name>Cynthia</given-name><initials>C.</initials><afid>60006989</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7404449612</author-url><authid>7404449612</authid><authname>Ross D.</authname><surname>Ross</surname><given-name>Douglas</given-name><initials>D.</initials><afid>60006989</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603033335</author-url><authid>6603033335</authid><authname>Rijnbeek P.</authname><surname>Rijnbeek</surname><given-name>Peter</given-name><initials>P.</initials><afid>60032114</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:56506702700</author-url><authid>56506702700</authid><authname>Sturkenboom M.</authname><surname>Sturkenboom</surname><given-name>Miriam</given-name><initials>M.</initials><afid>60032114</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:10140803400</author-url><authid>10140803400</authid><authname>Trifirò G.</authname><surname>Trifirò</surname><given-name>Gianluca</given-name><initials>G.</initials><afid>60011576</afid><afid>60032114</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:10140803400</author-url><authid>10140803400</authid><authname>Trifirò G.</authname><surname>Trifirò</surname><given-name>Gianluca</given-name><initials>G.</initials><afid>60011576</afid><afid>60032114</afid></author><authkeywords>Cabergoline | Dopamine agonists | Italy | Valvulopathy</authkeywords><intid>2036081666</intid><source-id>15300154855</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927128087"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927128087?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927128087&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927128087&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015001914"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927128087</prism:url><dc:identifier>SCOPUS_ID:84927128087</dc:identifier><eid>2-s2.0-84927128087</eid><dc:title>The association of metabolic syndrome and its components with brachial-ankle pulse wave velocity in south China</dc:title><dc:creator>Chen L.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>345-350</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.031</prism:doi><pii>S0021915015001914</pii><dc:description>© 2015 Elsevier Ireland Ltd. Background: Brachial-ankle pulse wave velocity (baPWV) can reflect both central and peripheral arterial stiffness. Metabolic syndrome (MS) and its components may increase arterial stiffness and the risks of cardiovascular diseases. However, the correlation of MS and its components with arterial stiffness has not been not well studied. The aim of this study was to investigate the correlation between MS/its components and arterial stiffness by the measurement of baPWV in south China population. Methods: A total of 8599 subjects were selected from those who underwent health examination in our hospital. MS was defined by Joint Scientific Statement. BaPWV, waist circumference, blood pressure (BP), fasting plasma glucose (FPG), lipid profile and serum uric acid (UA) were measured. The relationship between baPWV and MS/its components was analyzed. Results: BaPWV was significantly higher in the subjects with MS than in those without MS (P&lt;0.001 for both genders). By multivariate regression analysis, all the metabolic components were correlated to baPWV in the male and female subjects except low HDL-C and high UA in the male group. BP and FPG had the strongest correlation factors. The values of baPWV were positively correlated with the advanced age (P&lt;0.001) and the values of the MS components, and this correlation was stronger in the females than in the males (P&lt;0.001). Conclusion: Metabolic syndrome and its individual components were positively correlated with baPWV. Monitoring baPWV is helpful to identify early stage of arterial stiffness in those people with MS.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003970</affiliation-url><afid>60003970</afid><affilname>Zhejiang University</affilname><name-variant>Zhejiang University</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115142168</affiliation-url><afid>115142168</afid><affilname>Shajing People's Hospital</affilname><name-variant>Shajing People's Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56587012800</author-url><authid>56587012800</authid><authname>Chen L.</authname><surname>Chen</surname><given-name>Liying</given-name><initials>L.</initials><afid>60003970</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56587160400</author-url><authid>56587160400</authid><authname>Zhu W.</authname><surname>Zhu</surname><given-name>Wenhua</given-name><initials>W.</initials><afid>60003970</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56587557200</author-url><authid>56587557200</authid><authname>Mai L.</authname><surname>Mai</surname><given-name>Linhe</given-name><initials>L.</initials><afid>115142168</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56587286600</author-url><authid>56587286600</authid><authname>Fang L.</authname><surname>Fang</surname><given-name>Lizheng</given-name><initials>L.</initials><afid>60003970</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56587554900</author-url><authid>56587554900</authid><authname>Ying K.</authname><surname>Ying</surname><given-name>Kejing</given-name><initials>K.</initials><afid>60003970</afid></author><authkeywords>Arterial stiffness | Brachial-ankle pulse wave velocity | Cardiovascular diseases | Metabolic syndrome</authkeywords><intid>35568894</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927719217"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927719217?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927719217&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927719217&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927719217</prism:url><dc:identifier>SCOPUS_ID:84927719217</dc:identifier><eid>2-s2.0-84927719217</eid><dc:title>Number of teeth and 5-year mortality in an elderly population</dc:title><dc:creator>Hirotomi T.</dc:creator><prism:publicationName>Community Dentistry and Oral Epidemiology</prism:publicationName><prism:issn>03015661</prism:issn><prism:eIssn>16000528</prism:eIssn><prism:volume>43</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>226-231</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/cdoe.12146</prism:doi><dc:description>© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd. Objectives Several epidemiological studies have shown the association between tooth loss and mortality. However, the impact of number of teeth on mortality has not yet been fully addressed in an elderly population with many teeth. Thus, the purpose of this cohort study was to assess the possible role of number of teeth as a predictor of mortality in the elderly. Methods The subjects included in this study were generated from a cohort study started in 1998. Oral examinations and the completion of a questionnaire were carried out. A total of 600 subjects aged 70 years were enrolled at baseline. All the subjects were in good general health and did not require any special care for their daily activities. The 5-year mortality data were collected after the baseline survey. After excluding those with incomplete data, 569 subjects were analyzed. The Kaplan-Meier method was used to analyze survival curves and a Cox regression model to clarify the impact of the number of remaining teeth on the 5-year mortality. Results During the follow-up period, 25 (4.4%) subjects died. Subjects with 20 teeth or more had a significantly lower mortality rate (2.5%) than those with 19 teeth or fewer (6.1%, log-rank test, P = 0.036). Even after adjusting for confounders including gender, BMI, serum albumin level, current smoking status, education, number of family members living together and a history of chronic diseases, the risk of all-cause mortality was significantly associated with the number of remaining teeth (P = 0.047) with a hazard ratio of 0.96, indicating that there was a 4% point increase in the 5-year survival rate per additional tooth retained at the age of 70. Conclusion The findings of this study suggest that retaining more teeth might be a useful indicator for longevity of older people.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022313</affiliation-url><afid>60022313</afid><affilname>Niigata University</affilname><name-variant>Niigata University</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022313</affiliation-url><afid>60022313</afid><affilname>Niigata University</affilname><name-variant>Niigata University</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6505868188</author-url><authid>6505868188</authid><authname>Hirotomi T.</authname><surname>Hirotomi</surname><given-name>Toshinobu</given-name><initials>T.</initials><afid>60022313</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55552183400</author-url><authid>55552183400</authid><authname>Yoshihara A.</authname><surname>Yoshihara</surname><given-name>Akihiro</given-name><initials>A.</initials><afid>60022313</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56594131400</author-url><authid>56594131400</authid><authname>Ogawa H.</authname><surname>Ogawa</surname><given-name>Hiroshi</given-name><initials>H.</initials><afid>60022313</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56482741200</author-url><authid>56482741200</authid><authname>Miyazaki H.</authname><surname>Miyazaki</surname><given-name>Hideo</given-name><initials>H.</initials><afid>60022313</afid></author><authkeywords>epidemiology | geriatrics | risk assessment | tooth loss</authkeywords><intid>535668457</intid><source-id>24413</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927135122"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927135122?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927135122&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927135122&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0273230015000562"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927135122</prism:url><dc:identifier>SCOPUS_ID:84927135122</dc:identifier><eid>2-s2.0-84927135122</eid><dc:title>Providing perspective for interpreting cardiovascular mortality risks associated with ozone exposures</dc:title><dc:creator>Petito Boyce C.</dc:creator><prism:publicationName>Regulatory Toxicology and Pharmacology</prism:publicationName><prism:issn>02732300</prism:issn><prism:eIssn>10960295</prism:eIssn><prism:volume>72</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>107-116</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yrtph.2015.03.009</prism:doi><pii>S0273230015000562</pii><dc:description>© 2015 The Authors. When identifying standards for air pollutants based on uncertain evidence, both science and policy judgments play critical roles. Consequently, critical contextual factors are important for understanding the strengths, limitations, and appropriate interpretation of available science, and potential benefits of risk mitigation alternatives. These factors include the relative magnitude and certainty of the risks posed by various factors and the impacts of other risk factors on air pollutant epidemiology study findings. This commentary explores ozone's status as a risk factor for cardiovascular mortality in contrast with decades of strong and consistent evidence for other established risk factors. By comparison, the ozone evidence is less conclusive, more heterogeneous, and subject to substantial uncertainty; ozone's potential effects, if any, are small and challenging to discern. Moreover, the absence of a demonstrated causal relationship calls into question efforts to quantify cardiovascular mortality risks attributed to ozone exposures on a population level and highlights the need to explicitly acknowledge this uncertainty if such calculations are performed. These concerns are relevant for other similar policy contexts - where multiple established risk factors contribute to the health impact of interest; exposure-effect associations are relatively small, weak, and uncertain; and a causal relationship has not been clearly established.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112587567</affiliation-url><afid>112587567</afid><affilname>Gradient</affilname><name-variant>Gradient</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107990362</affiliation-url><afid>107990362</afid><affilname>Gradient</affilname><name-variant>Gradient</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507398562</author-url><authid>6507398562</authid><authname>Petito Boyce C.</authname><surname>Petito Boyce</surname><given-name>Catherine</given-name><initials>C.</initials><afid>112587567</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7402289343</author-url><authid>7402289343</authid><authname>Goodman J.</authname><surname>Goodman</surname><given-name>Julie E.</given-name><initials>J.E.</initials><afid>107990362</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8242374500</author-url><authid>8242374500</authid><authname>Sax S.</authname><surname>Sax</surname><given-name>Sonja N.</given-name><initials>S.N.</initials><afid>107990362</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56587606100</author-url><authid>56587606100</authid><authname>Loftus C.</authname><surname>Loftus</surname><given-name>Christine T.</given-name><initials>C.T.</initials><afid>112587567</afid></author><authkeywords>Air pollution | Cardiovascular mortality | Environmental health policy | NAAQS (National Ambient Air Quality Standards) | Ozone exposure</authkeywords><intid>1785570507</intid><source-id>25176</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929659781"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929659781?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929659781&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929659781&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015010023"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929659781</prism:url><dc:identifier>SCOPUS_ID:84929659781</dc:identifier><eid>2-s2.0-84929659781</eid><dc:title>Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease</dc:title><dc:creator>Asakawa T.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>535-543</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.784</prism:doi><pii>S0021915015010023</pii><dc:description>© 2015 The Authors. Objective: Therapies for chronic kidney disease have changed greatly over the last decade. The aim of this study was to examine the changes in the clinical characteristics and carotid atherosclerosis of patients with end-stage kidney disease (ESKD) over the last 9 years. Methods: A cross-sectional study of 150 consecutive patients with ESKD who had initiated maintenance dialysis between January 2005 and December 2013 was conducted. The patients' mean age was 68±13 years. The group comprised 73% men, and 63% of the patients had diabetic nephropathy. The carotid artery-intima media thicknesses and the plaque scores (PS) were measured using carotid artery ultrasonography within 3 months of dialysis initiation. Changes in the patients' carotid atherosclerosis and clinical characteristics over the years were examined by categorizing the patients into 3 groups representing 3-year intervals based on when dialysis was initiated. Results: The PS declined from 12.8 to 5.4 (P=0.001). Low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol levels declined over the 9-year period (P=0.005 and P=0.006, respectively), and the ratio of statin users increased markedly from 24% to 54% (P=0.001). Univariate regression analysis identified a positive correlation between the PS and LDL-C (r=0.281; P=0.01), and a strong positive correlation was found between the PS and LDL-C after adjusting for various risk factors for atherosclerosis. Conclusion: Carotid atherosclerosis in patients with ESKD has decreased over the past 9 years, which may be a consequence of improvements in dyslipidemia management.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018642</affiliation-url><afid>60018642</afid><affilname>Toho University</affilname><name-variant>Toho University</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55774541600</author-url><authid>55774541600</authid><authname>Asakawa T.</authname><surname>Asakawa</surname><given-name>Takasuke</given-name><initials>T.</initials><afid>60018642</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56518715000</author-url><authid>56518715000</authid><authname>Hayashi T.</authname><surname>Hayashi</surname><given-name>Toshihide</given-name><initials>T.</initials><afid>60018642</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55736344500</author-url><authid>55736344500</authid><authname>Tanaka Y.</authname><surname>Tanaka</surname><given-name>Yuri</given-name><initials>Y.</initials><afid>60018642</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56066564500</author-url><authid>56066564500</authid><authname>Joki N.</authname><surname>Joki</surname><given-name>Nobuhiko</given-name><initials>N.</initials><afid>60018642</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55311342300</author-url><authid>55311342300</authid><authname>Hase H.</authname><surname>Hase</surname><given-name>Hiroki</given-name><initials>H.</initials><afid>60018642</afid></author><authkeywords>Carotid artery-intima media thickness | Chronic kidney disease | End-stage kidney disease | Low-density lipoprotein cholesterol | Non-high-density lipoprotein cholesterol | Plaque score</authkeywords><intid>35990640</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928822229"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928822229?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928822229&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928822229&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928822229</prism:url><dc:identifier>SCOPUS_ID:84928822229</dc:identifier><eid>2-s2.0-84928822229</eid><dc:title>Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications</dc:title><dc:creator>Owen J.</dc:creator><prism:publicationName>Current Hypertension Reports</prism:publicationName><prism:issn>15226417</prism:issn><prism:eIssn>15343111</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11906-015-0558-9</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Epidemiological studies have shown an increasing prevalence of obesity and the metabolic syndrome worldwide. Lifestyle modifications that include dietary changes, weight reduction, and exercise are the cornerstones in the treatment of this pathology. However, adherence to this approach often meets with failure in clinical practice; therefore, drug therapy should not be delayed. The ideal pharmacological antihypertensive regimen should target the underlying mechanisms involved in this syndrome, including sympathetic activation, increased renal tubular sodium reabsorption, and overexpression of the renin-angiotensin-aldosterone system by the adipocyte. Few prospective trials have been conducted in the search of the ideal antihypertensive regimen in patients with obesity and the metabolic syndrome. We summarize previously published ad hoc studies, prospective studies, and guideline publications regarding the treatment of hypertension in patients with obesity and the metabolic syndrome. We conclude that the optimal antihypertensive drug therapy in these patients has not been defined. Though caution exists regarding the use of thiazide diuretics due to potential metabolic derangements, there is insufficient data to show worsened cardiovascular or renal outcomes in patients treated with these drugs. In regard to beta blockers, the risk of accelerating conversion to diabetes and worsening of inflammatory mediators described in patients treated with traditional beta blockers appears much less pronounced or absent when using the vasodilating beta blockers. Renin-angiotensin-aldosterone system (RAAS) inhibition with an ACE or an ARB and treatment with calcium channel blockers appears safe and well tolerated in obesity-related hypertension and in patients with metabolic syndrome. Future prospective pharmacological studies in this population are needed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029426</affiliation-url><afid>60029426</afid><affilname>LSU Health Sciences Center - New Orleans</affilname><name-variant>Louisiana State University Health Sciences Center</name-variant><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55186432600</author-url><authid>55186432600</authid><authname>Owen J.</authname><surname>Owen</surname><given-name>Jonathan G.</given-name><initials>J.G.</initials><afid>60029426</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005780717</author-url><authid>7005780717</authid><authname>Reisin E.</authname><surname>Reisin</surname><given-name>Efrain</given-name><initials>E.</initials><afid>60029426</afid></author><authkeywords>Adipokines | Beta-blockers | Calcium channel blockers | Cardiometabolic syndrome | Diabetes | Hypertension | Leptin | Metabolic-syndrome | Obesity | Overweight | Pre-diabetes | Renin angiotensin aldosterone system | Thiazide diuretics</authkeywords><intid>35850505</intid><source-id>23135</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927130329"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927130329?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927130329&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927130329&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002270"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927130329</prism:url><dc:identifier>SCOPUS_ID:84927130329</dc:identifier><eid>2-s2.0-84927130329</eid><dc:title>Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men</dc:title><dc:creator>Ozturk K.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>380-386</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.009</prism:doi><pii>S0021915015002270</pii><dc:description>© 2015. Introduction: The possible cause of accelerated atherosclerosis in NAFLD may be the relationship with the MetS and its components. Our primary goal was to evaluate the relationship between NAFLD and subclinical atherosclerosis in adult male patients between 20 and 40 years of age. Moreover, we aimed to investigate the changes in this association according to the presence or absence of MetS. Method: Sixty-one male patients with biopsy-proven NAFLD and 41 healthy male volunteers were enrolled. In order to exclude any interference of confounding factors, we studied a specifically selected group with no additional cardiovascular risk. PWV, CIMT and FMD levels were measured in all patients and controls. Results: The levels of cf-PWV were significantly higher in SS and NASH patients compared to the control group (P&lt;0.001); no significant difference was found between SS and NASH patients (P&gt;0.05). We found significantly decreased FMD levels in patients with SS and NASH compared with control subjects (P&lt;0.001). Subjects with NASH had significantly greater CIMT measurements than the SS and controls (P=0.026, P&lt;0.001, respectively). Although, NAFLD patients with MetS had increased cf-PWV and CIMT and reduced FMD compared to healthy subjects (P&lt;0.05), no significant difference existed between NAFLD with Mets and NAFLD without MetS in terms of cf-PWV, CIMT and FMD (P&gt;0.05). Conclusion: The present study showed that the presence of NAFLD leads to increased risk of endothelial dysfunction and atherosclerosis in adult male patients, independent of MetS.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015944</affiliation-url><afid>60015944</afid><affilname>Gulhane School of Medicine</affilname><name-variant>Gulhane Medical School</name-variant><affiliation-city>Etlik</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015944</affiliation-url><afid>60015944</afid><affilname>Gulhane School of Medicine</affilname><name-variant>Gulhane Medical School</name-variant><affiliation-city>Etlik</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002746</affiliation-url><afid>60002746</afid><affilname>Harvard Medical School</affilname><name-variant>Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015944</affiliation-url><afid>60015944</afid><affilname>Gulhane School of Medicine</affilname><name-variant>Gulhane Medical School</name-variant><affiliation-city>Etlik</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015944</affiliation-url><afid>60015944</afid><affilname>Gulhane School of Medicine</affilname><name-variant>Gulhane Medical School</name-variant><affiliation-city>Etlik</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015944</affiliation-url><afid>60015944</afid><affilname>Gulhane School of Medicine</affilname><name-variant>Gulhane Medical School</name-variant><affiliation-city>Etlik</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55817803000</author-url><authid>55817803000</authid><authname>Ozturk K.</authname><surname>Ozturk</surname><given-name>Kadir</given-name><initials>K.</initials><afid>60015944</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004356165</author-url><authid>7004356165</authid><authname>Uygun A.</authname><surname>Uygun</surname><given-name>Ahmet</given-name><initials>A.</initials><afid>60015944</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56587527000</author-url><authid>56587527000</authid><authname>Guler A.</authname><surname>Guler</surname><given-name>Ahmet Kerem</given-name><initials>A.K.</initials><afid>60015944</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:34879676900</author-url><authid>34879676900</authid><authname>Demirci H.</authname><surname>Demirci</surname><given-name>Hakan</given-name><initials>H.</initials><afid>60015944</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36477634100</author-url><authid>36477634100</authid><authname>Ozdemir C.</authname><surname>Ozdemir</surname><given-name>Cafer</given-name><initials>C.</initials><afid>60002746</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56587573900</author-url><authid>56587573900</authid><authname>Cakir M.</authname><surname>Cakir</surname><given-name>Mehmet</given-name><initials>M.</initials><afid>60015944</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55064480300</author-url><authid>55064480300</authid><authname>Sakin Y.</authname><surname>Sakin</surname><given-name>Yusuf Serdar</given-name><initials>Y.S.</initials><afid>60015944</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24825634900</author-url><authid>24825634900</authid><authname>Turker T.</authname><surname>Turker</surname><given-name>Turker</given-name><initials>T.</initials><afid>60015944</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55486952800</author-url><authid>55486952800</authid><authname>Sari S.</authname><surname>Sari</surname><given-name>Sebahattin</given-name><initials>S.</initials><afid>60015944</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36623683500</author-url><authid>36623683500</authid><authname>Demirbas S.</authname><surname>Demirbas</surname><given-name>Seref</given-name><initials>S.</initials><afid>60015944</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6507177274</author-url><authid>6507177274</authid><authname>Karslioğlu Y.</authname><surname>Karslioğlu</surname><given-name>Yildirim</given-name><initials>Y.</initials><afid>60015944</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35547950500</author-url><authid>35547950500</authid><authname>Saglam M.</authname><surname>Saglam</surname><given-name>Mutlu</given-name><initials>M.</initials><afid>60015944</afid></author><authkeywords>Arterial stiffness | Carotid intima media thickness | Flow mediated dilatation | Nonalcoholic fatty liver disease</authkeywords><intid>535570327</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928655061"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928655061?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928655061&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928655061&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S002191501500163X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928655061</prism:url><dc:identifier>SCOPUS_ID:84928655061</dc:identifier><eid>2-s2.0-84928655061</eid><dc:title>Variability of the LDL-C lowering response to ezetimibe and ezetimibe+statin therapy in hypercholesterolemic patients</dc:title><dc:creator>Descamps O.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>482-489</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.004</prism:doi><pii>S002191501500163X</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objective: We compared the variability of LDL-C-lowering responses to treatment with ezetimibe+statins versus statins in hypercholesterolemic patients. Methods: An analysis of patient-level data pooled from 27 double-blind, placebo and/or active-controlled studies in 21,671 patients treated with ezetimibe+statins versus statins on first-line (statin-naïve/wash-out) or second-line (on statin, randomized to ezetimibe versus placebo [add-on] or ezetimibe versus uptitrated statin [uptitrate]) for 6-24wks. Variances (standard deviation [SD], coefficient of variation [CV], and root mean squared error [RMSE] adjusted for various factors) for % change from baseline in LDL-C were compared. Results: In first-line and second-line add-on studies, the variability (SD, RMSE) of % change from baseline in LDL-C was lower in ezetimibe+statin-treated patients versus statin-treated patients, ±covariates. Differences were small but statistically significant due to the large sample size. In second-line uptitrate studies, ezetimibe+statin treatment resulted in greater unadjusted variability (SD) versus statin therapy, while the adjusted variability (RMSE) was significantly lower. Relative variability (CV. =. SD/mean) was lower for ezetimibe+statins versus statin therapy for all study types, being more pronounced in second-line add-on and uptitrate studies, attributed to larger mean LDL-C reductions for ezetimibe+statins versus statin groups. When assessed by individual study/type, statin brand, potency or dose, the CVs remained lower for ezetimibe+statins versus statins in second-line studies. The SDs showed no consistent trend for either therapy. Conclusion: In hypercholesterolemic patients, the absolute variability of LDL-C-lowering responses to ezetimibe+statins was not greater versus statins alone and appeared lower when adjusted for other factors. Relative variability was lower in patients treated with statins+ezetimibe. A better understanding of the variability of the LDL-C lowering response may help guide clinicians in making therapeutic decisions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108342436</affiliation-url><afid>108342436</afid><affilname>Centre de Recherche Médicale de Jolimont</affilname><name-variant>Centre de Recherche Médicale de Jolimont</name-variant><affiliation-city/><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007995</affiliation-url><afid>60007995</afid><affilname>Merck &amp; Co., Inc.</affilname><name-variant>Merck Sharp and Dohme Research Laboratories</name-variant><affiliation-city>Readington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701764714</author-url><authid>6701764714</authid><authname>Descamps O.</authname><surname>Descamps</surname><given-name>Olivier</given-name><initials>O.</initials><afid>108342436</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55582602900</author-url><authid>55582602900</authid><authname>Tomassini J.</authname><surname>Tomassini</surname><given-name>Joanne E.</given-name><initials>J.E.</initials><afid>60007995</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55709981200</author-url><authid>55709981200</authid><authname>Lin J.</authname><surname>Lin</surname><given-name>Jianxin</given-name><initials>J.</initials><afid>60007995</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701370299</author-url><authid>6701370299</authid><authname>Polis A.</authname><surname>Polis</surname><given-name>Adam B.</given-name><initials>A.B.</initials><afid>60007995</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35735198000</author-url><authid>35735198000</authid><authname>Shah A.</authname><surname>Shah</surname><given-name>Arvind</given-name><initials>A.</initials><afid>60007995</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:25026745400</author-url><authid>25026745400</authid><authname>Brudi P.</authname><surname>Brudi</surname><given-name>Philippe</given-name><initials>P.</initials><afid>60007995</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:25957636100</author-url><authid>25957636100</authid><authname>Hanson M.</authname><surname>Hanson</surname><given-name>Mary E.</given-name><initials>M.E.</initials><afid>60007995</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003767355</author-url><authid>7003767355</authid><authname>Tershakovec A.</authname><surname>Tershakovec</surname><given-name>Andrew M.</given-name><initials>A.M.</initials><afid>60007995</afid></author><authkeywords>Ezetimibe | Hypercholesterolemia | LDL-C | Statin | Variability</authkeywords><intid>35823918</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930183001"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930183001?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930183001&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930183001&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1878540915000080"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930183001</prism:url><dc:identifier>SCOPUS_ID:84930183001</dc:identifier><eid>2-s2.0-84930183001</eid><dc:title>Takotsubo cardiomyopathy with transient left ventricular obstruction successfully treated with cibenzoline succinate: A case report</dc:title><dc:creator>Tomofuji K.</dc:creator><prism:publicationName>Journal of Cardiology Cases</prism:publicationName><prism:issn>18785409</prism:issn><prism:eIssn>18785409</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>155-157</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jccase.2015.01.005</prism:doi><pii>S1878540915000080</pii><dc:description>© 2015 Japanese College of Cardiology. An 84-year-old woman was urgently referred to our hospital owing to persistent malaise and chest pain. Takotsubo cardiomyopathy was diagnosed following transthoracic echocardiography, emergency coronary angiography, and left ventriculography. A left ventricular pressure tracing during cardiac catheterization revealed a 72. mmHg-intraventricular pressure gradient (LVPG). Although β-blockers are effective at reducing LVPG in takotsubo cardiomyopathy, such treatment was contraindicated in our patient owing to her history of bronchial asthma. Therefore, we administered intravenous cibenzoline succinate to attenuate her LVPG. The LVPG decreased to 18. mmHg within 10. min after intravenous cibenzoline succinate administration. During her subsequent hospitalization, the patient showed excellent functional recovery, without any complications. Left ventriculography, performed 21 days after admission, showed normal wall motion and a left ventricular ejection fraction of 68%.&lt;. Learning objective: The prognosis of takotsubo cardiomyopathy is generally good, however, fatal complications have been reported. Our case demonstrated a LVPG of 72. mmHg, and β-blockers were contraindicated because of bronchial asthma. Intravenous cibenzoline administration resulted in successful attenuation of the patient's LVPG. The present case suggests that cibenzoline might be effective for the treatment of takotsubo cardiomyopathy, especially in those contraindicated for β-blocker therapy.&gt;.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100348409</affiliation-url><afid>100348409</afid><affilname>Uwajima City Hospital</affilname><name-variant>Uwajima Municipal Hospital</name-variant><affiliation-city>Uwajima</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56566626800</author-url><authid>56566626800</authid><authname>Tomofuji K.</authname><surname>Tomofuji</surname><given-name>Katsuhiro</given-name><initials>K.</initials><afid>100348409</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35477287800</author-url><authid>35477287800</authid><authname>Ikeda S.</authname><surname>Ikeda</surname><given-name>Shuntaro</given-name><initials>S.</initials><afid>100348409</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56566273400</author-url><authid>56566273400</authid><authname>Murakami C.</authname><surname>Murakami</surname><given-name>Chika</given-name><initials>C.</initials><afid>100348409</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:51864245900</author-url><authid>51864245900</authid><authname>Ochiumi Y.</authname><surname>Ochiumi</surname><given-name>Yusuke</given-name><initials>Y.</initials><afid>100348409</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56565816700</author-url><authid>56565816700</authid><authname>Nakamura M.</authname><surname>Nakamura</surname><given-name>Masayuki</given-name><initials>M.</initials><afid>100348409</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36504156300</author-url><authid>36504156300</authid><authname>Kadota H.</authname><surname>Kadota</surname><given-name>Hisaki</given-name><initials>H.</initials><afid>100348409</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55252396500</author-url><authid>55252396500</authid><authname>Shimizu H.</authname><surname>Shimizu</surname><given-name>Hideaki</given-name><initials>H.</initials><afid>100348409</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56566047500</author-url><authid>56566047500</authid><authname>Oshima K.</authname><surname>Oshima</surname><given-name>Kiyotaka</given-name><initials>K.</initials><afid>100348409</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56566040500</author-url><authid>56566040500</authid><authname>Hamada M.</authname><surname>Hamada</surname><given-name>Mareomi</given-name><initials>M.</initials><afid>100348409</afid></author><authkeywords>Cibenzoline | Left ventricular pressure gradient | Takotsubo cardiomyopathy</authkeywords><intid>1036074653</intid><source-id>19600156852</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930178683"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930178683?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930178683&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930178683&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1878540915000298"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930178683</prism:url><dc:identifier>SCOPUS_ID:84930178683</dc:identifier><eid>2-s2.0-84930178683</eid><dc:title>Editorial: Sudden cardiovascular events and comprehensive cardiac rehabilitation: Come back from "a bolt out of the blue"</dc:title><dc:creator>Shimada K.</dc:creator><prism:publicationName>Journal of Cardiology Cases</prism:publicationName><prism:issn>18785409</prism:issn><prism:eIssn>18785409</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>164-165</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jccase.2015.03.008</prism:doi><pii>S1878540915000298</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009740</affiliation-url><afid>60009740</afid><affilname>Juntendo University School of Medicine</affilname><name-variant>Juntendo University School of Medicine</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9741377900</author-url><authid>9741377900</authid><authname>Shimada K.</authname><surname>Shimada</surname><given-name>Kazunori</given-name><initials>K.</initials><afid>60009740</afid></author><authkeywords>Anxiety | Cognitive behavior therapy | Comprehensive cardiac rehabilitation | Depression | Fulminant myocarditis</authkeywords><intid>36078032</intid><source-id>19600156852</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928523058"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928523058?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928523058&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928523058&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015010114"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928523058</prism:url><dc:identifier>SCOPUS_ID:84928523058</dc:identifier><eid>2-s2.0-84928523058</eid><dc:title>Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol</dc:title><dc:creator>Savinova O.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>520-525</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.793</prism:doi><pii>S0021915015010114</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objective: Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. The purpose of this study was to describe the effects of mono- and combination (Combo) therapy of these agents in patients with the metabolic syndrome. Methods: Very low density (VLDL), intermediate/low density (IDL/LDL, hereafter LDL), and high density lipoproteins (HDL) were isolated from 56 overweight patients with elevated triglyceride/HDL-C ratios at baseline and after 16 weeks of treatment with placebo, ERN (2g/day), P-OM3 (4g/day), or Combo and then analyzed by quantitative electrophoresis for apolipoproteins (apo) A1, A2, B, C2, C3 and E. Total plasma concentrations and the ratios of each apo with apoB (in VLDL and LDL) and with apoA1 (in HDL) were calculated. An apoC3 glycosylation index (a ratio between di- and mono-sialylated isoforms) was also determined in plasma and in each lipoprotein fraction. Results: ERN reduced plasma apoB (-11%, p&lt;0.05). Combo increased LDL apoE/apoB ratio (64%, p&lt;0.01) and LDL apoA1/apoB (91%, p&lt;0.05). ERN increased the apoC3 glycosylation index only in HDL (37%, p&lt;0.05), whereas P-OM3 and Combo increased the index in whole plasma (48% and 49%, respectively, p&lt;0.05 for both) and in every lipoprotein class (VLDL: 26%, p&lt;0.01 and 26%, p&lt;0.05; LDL: 55%, p&lt;0.01 and 61%, p&lt;0.01; HDL: 43%, p&lt;0.001 and 44%, p&lt;0.001, respectively). All findings were significant after adjustment for age, sex, body mass index (BMI), smoking, medications, and baseline apo value. Conclusions: ERN produced a beneficial reduction in plasma apoB. The enrichment of LDL with apoE and apoA1 was unique to the Combo group and might be beneficial owing to the atheroprotective properties of apoE and HDL2 (a likely source of apoA1 in LDL fraction). The effect of therapies on the apoC3 glycosylation index is a novel finding, the implications of which will require further study.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011677</affiliation-url><afid>60011677</afid><affilname>University of South Dakota, Sanford School of Medicine</affilname><name-variant>University of South Dakota School of Medicine</name-variant><affiliation-city>Vermillion</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011677</affiliation-url><afid>60011677</afid><affilname>University of South Dakota, Sanford School of Medicine</affilname><name-variant>University of South Dakota School of Medicine</name-variant><affiliation-city>Vermillion</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001439</affiliation-url><afid>60001439</afid><affilname>Pennsylvania State University</affilname><name-variant>Pennsylvania State University</name-variant><affiliation-city>State College</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603927849</author-url><authid>6603927849</authid><authname>Savinova O.</authname><surname>Savinova</surname><given-name>Olga V.</given-name><initials>O.V.</initials><afid>60011677</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55312815700</author-url><authid>55312815700</authid><authname>Fillaus K.</authname><surname>Fillaus</surname><given-name>Kristi</given-name><initials>K.</initials><afid>60011677</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402163908</author-url><authid>7402163908</authid><authname>Harris W.</authname><surname>Harris</surname><given-name>William S.</given-name><initials>W.S.</initials><afid>60011677</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202506867</author-url><authid>7202506867</authid><authname>Shearer G.</authname><surname>Shearer</surname><given-name>Gregory C.</given-name><initials>G.C.</initials><afid>60011677</afid><afid>60011677</afid><afid>60001439</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202506867</author-url><authid>7202506867</authid><authname>Shearer G.</authname><surname>Shearer</surname><given-name>Gregory C.</given-name><initials>G.C.</initials><afid>60011677</afid><afid>60011677</afid><afid>60001439</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202506867</author-url><authid>7202506867</authid><authname>Shearer G.</authname><surname>Shearer</surname><given-name>Gregory C.</given-name><initials>G.C.</initials><afid>60011677</afid><afid>60011677</afid><afid>60001439</afid></author><authkeywords>Apolipoproteins | Extended release niacin | Prescription omega-3 acid ethyl ester</authkeywords><intid>1785803248</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928402298"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928402298?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928402298&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928402298&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928402298</prism:url><dc:identifier>SCOPUS_ID:84928402298</dc:identifier><eid>2-s2.0-84928402298</eid><dc:title>The Kidney in Obesity</dc:title><dc:creator>Redon J.</dc:creator><prism:publicationName>Current Hypertension Reports</prism:publicationName><prism:issn>15226417</prism:issn><prism:eIssn>15343111</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1-9</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11906-015-0555-z</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Body mass index has been found to be the second most important contributor to relative risk for developing end state renal disease (ESRD), after proteinuria. The impact of obesity on the kidney includes a wide spectrum, from characteristic pathologic lesions to increment in urinary albumin excretion (UAE) and proteinuria/or decrease in glomerular filtration rate (GFR). The cause of renal disease associated to obesity is not well understood, but two relevant elements emerge. The first is the presence of obesity-related glomerulopathy, and the second is the fat deposit in the kidney with impact on renal haemodynamics and intrarenal regulation. The mechanisms linking obesity and renal damage are complex and include haemodynamic changes, inflammation, oxidative stress, apoptosis, and finally renal scarring. The protection of kidney damage needs to combine weight reduction with the proper control of the cardiometabolic risk factors associated, hypertension, metabolic syndrome, diabetes and dyslipidaemia. The search for specific treatments merits future research.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002644</affiliation-url><afid>60002644</afid><affilname>Universitat de ValEncia</affilname><name-variant>Universitat de València</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001602</affiliation-url><afid>60001602</afid><affilname>Instituto de Salud Carlos III</affilname><name-variant>Instituto de Salud Carlos III</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002644</affiliation-url><afid>60002644</afid><affilname>Universitat de ValEncia</affilname><name-variant>Universitat de València</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109530422</affiliation-url><afid>109530422</afid><affilname>INCLIVA</affilname><name-variant>INCLIVA</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35371149100</author-url><authid>35371149100</authid><authname>Redon J.</authname><surname>Redon</surname><given-name>Josep</given-name><initials>J.</initials><afid>60002644</afid><afid>60001602</afid><afid>109530422</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35371149100</author-url><authid>35371149100</authid><authname>Redon J.</authname><surname>Redon</surname><given-name>Josep</given-name><initials>J.</initials><afid>60002644</afid><afid>60001602</afid><afid>109530422</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35371149100</author-url><authid>35371149100</authid><authname>Redon J.</authname><surname>Redon</surname><given-name>Josep</given-name><initials>J.</initials><afid>60002644</afid><afid>60001602</afid><afid>109530422</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35371149100</author-url><authid>35371149100</authid><authname>Redon J.</authname><surname>Redon</surname><given-name>Josep</given-name><initials>J.</initials><afid>60002644</afid><afid>60001602</afid><afid>109530422</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003303623</author-url><authid>7003303623</authid><authname>Lurbe E.</authname><surname>Lurbe</surname><given-name>Empar</given-name><initials>E.</initials><afid>60001602</afid><afid>60002644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003303623</author-url><authid>7003303623</authid><authname>Lurbe E.</authname><surname>Lurbe</surname><given-name>Empar</given-name><initials>E.</initials><afid>60001602</afid><afid>60002644</afid></author><authkeywords>Chronic kidney disease | Obesity | Obesity glomerulopathy | Perivascular fat | Proteinuria</authkeywords><intid>1785779797</intid><source-id>23135</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929159334"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929159334?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929159334&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929159334&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1726490115000349"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929159334</prism:url><dc:identifier>SCOPUS_ID:84929159334</dc:identifier><eid>2-s2.0-84929159334</eid><dc:title>BMI better explains hypertension in Chinese senior adults and the relationship declines with age</dc:title><dc:creator>Chen H.</dc:creator><prism:publicationName>Aging Clinical and Experimental Research</prism:publicationName><prism:issn>15940667</prism:issn><prism:eIssn>17208319</prism:eIssn><prism:volume>27</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>271-279</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40520-014-0285-0</prism:doi><dc:description>© 2014, Springer International Publishing Switzerland. Background: Researchers have been examining the relationship between obesity and hypertension. However, whether overall or abdominal obesity better explains senior adults’ hypertension has not been studied. Objectives: The purpose of the study was to examine whether body mass index or waist circumference better predicts hypertension in Chinese senior adults and how the magnitude of the relationship is attenuated as they continue to age. Methods: The study was based on the 2010 National Physique Monitoring data. There were 7,542 senior adults aged 60–69 years living in urban, suburban, and rural areas of Shanghai City. The participants were categorized into five age groups: 60–61, 62–63, 64–65, 66–67, and 68–69 years. Results: The percentage of participants who had hypertension increased as people aged, which was mainly caused by the increase of systolic blood pressure. Logistic regression analysis showed that when body mass index or waist circumference was entered into the model, both were significant predictors for hypertension (p &lt; 0.05). However, when body mass index and waist circumference were mutually entered into the model, body mass index was the only important predictor (p &lt; 0.05). The values of odds ratios were found to decrease from the 60–61 to 68–69 years age groups. More senior adults have hypertension as they age. Conclusion: Body mass index, and not waist circumference, better predicts Chinese senior adults’ hypertension. However, age attenuates the effects of obesity on hypertension as the senior adults continue to age.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000711</affiliation-url><afid>60000711</afid><affilname>Valdosta State University</affilname><name-variant>Valdosta State University</name-variant><affiliation-city>Valdosta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023813</affiliation-url><afid>60023813</afid><affilname>Shanghai University</affilname><name-variant>Shanghai University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640536200</author-url><authid>56640536200</authid><authname>Chen H.</authname><surname>Chen</surname><given-name>Han</given-name><initials>H.</initials><afid>60000711</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640345500</author-url><authid>56640345500</authid><authname>Dai J.</authname><surname>Dai</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023813</afid></author><authkeywords>Body mass index | Hypertension | Senior adults | Waist circumference</authkeywords><intid>1035914005</intid><source-id>28496</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925635490"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925635490?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925635490&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925635490&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925635490</prism:url><dc:identifier>SCOPUS_ID:84925635490</dc:identifier><eid>2-s2.0-84925635490</eid><dc:title>Fibroblast Growth Factor Signaling in the Vasculature</dc:title><dc:creator>Yang X.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0509-6</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Despite their discovery as angiogenic factors and mitogens for endothelial cells more than 30 years ago, much remains to be determined about the role of fibroblast growth factors (FGFs) and their receptors in vascular development, homeostasis, and disease. In vitro studies show that members of the FGF family stimulate growth, migration, and sprouting of endothelial cells, and growth, migration, and phenotypic plasticity of vascular smooth muscle cells. Recent studies have revealed important roles for FGFs and their receptors in the regulation of endothelial cell sprouting and vascular homeostasis in vivo. Furthermore, recent work has revealed roles for FGFs in atherosclerosis, vascular calcification, and vascular dysfunction. The large number of FGFs and their receptors expressed in endothelial and vascular smooth muscle cells complicates these studies. In this review, we summarize recent studies in which new and unanticipated roles for FGFs and their receptors in the vasculature have been revealed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026218</affiliation-url><afid>60026218</afid><affilname>Maine Medical Center Research Institute</affilname><name-variant>Maine Medical Center Research Institute</name-variant><affiliation-city>Scarborough</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55351916300</author-url><authid>55351916300</authid><authname>Yang X.</authname><surname>Yang</surname><given-name>Xuehui</given-name><initials>X.</initials><afid>60026218</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56572387000</author-url><authid>56572387000</authid><authname>Liaw L.</authname><surname>Liaw</surname><given-name>Lucy</given-name><initials>L.</initials><afid>60026218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003292239</author-url><authid>7003292239</authid><authname>Prudovsky I.</authname><surname>Prudovsky</surname><given-name>Igor</given-name><initials>I.</initials><afid>60026218</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202275365</author-url><authid>7202275365</authid><authname>Brooks P.</authname><surname>Brooks</surname><given-name>Peter C.</given-name><initials>P.C.</initials><afid>60026218</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003334423</author-url><authid>7003334423</authid><authname>Vary C.</authname><surname>Vary</surname><given-name>Calvin</given-name><initials>C.</initials><afid>60026218</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602498772</author-url><authid>6602498772</authid><authname>Oxburgh L.</authname><surname>Oxburgh</surname><given-name>Leif</given-name><initials>L.</initials><afid>60026218</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003471814</author-url><authid>7003471814</authid><authname>Friesel R.</authname><surname>Friesel</surname><given-name>Robert</given-name><initials>R.</initials><afid>60026218</afid></author><authkeywords>Angiogenesis | Atherosclerosis | Endothelial cell | Fibroblast growth factor | Receptor tyrosine kinase | Vascular calcification | Vascular smooth muscle cell</authkeywords><intid>1035324356</intid><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929660400"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929660400?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929660400&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929660400&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S002191501500146X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929660400</prism:url><dc:identifier>SCOPUS_ID:84929660400</dc:identifier><eid>2-s2.0-84929660400</eid><dc:title>Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice</dc:title><dc:creator>Yang J.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>544-549</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.02.055</prism:doi><pii>S002191501500146X</pii><dc:description>© 2015. Aims: Inhibition of the classical renin-angiotensin system (RAS) has been proved to reduce atherosclerosis. Recently, angiotensin-(1-7) [Ang-(1-7)], a new component of RAS, has been shown to attenuate atherosclerosis formation. However, direct comparison of Ang-(1-7) and angiotensin II type 1 receptor blocker (ARB) on atherogenesis is sparse. Here, we investigated whether large dose of Ang-(1-7) and losartan are equivalent or the combination of both is superior in reducing atherosclerotic plaque formation. Methods and results: Invivo, we established an atherosclerosis model in ApoE-/- mice. All mice were fed a high fat diet during experiments. Mice were divided into control, Ang-(1-7), losartan, Ang-(1-7)+losartan groups for 4 weeks treatment. Ang-(1-7) did not change the blood pressure (BP) levels, while losartan produced a significant decrease in systolic BP. The attenuation of Ang-(1-7) and losartan in atherosclerosis plaque formation was similar. However, the decrease of atherosclerosis in mice with combination of Ang-(1-7) and losartan was more remarkable relative to that of Ang-(1-7) or losartan alone. The decreases of macrophages infiltration, superoxide production and improvement of endothelium function in aortic lesions were more significant in combination group. Invitro study, we found that combination of Ang-(1-7) and losartan notably inhibited VSMCs proliferation and migration. Conclusions: The anti-atherosclerosis effects of Ang-(1-7) and losartan in early lesion formation were equivalent. Combination use of both agents further enhanced the beneficial effects. Ang-(1-7) might add additional beneficial effect for patients with adequate ARB treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092862</affiliation-url><afid>60092862</afid><affilname>Qilu Hospital of Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004752</affiliation-url><afid>60004752</afid><affilname>Shandong University School of Medicine</affilname><name-variant>Shandong University School of Medicine ^</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55719591600</author-url><authid>55719591600</authid><authname>Yang J.</authname><surname>Yang</surname><given-name>Jianmin</given-name><initials>J.</initials><afid>60092862</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55539109700</author-url><authid>55539109700</authid><authname>Sun Y.</authname><surname>Sun</surname><given-name>Yu</given-name><initials>Y.</initials><afid>60004752</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55724059700</author-url><authid>55724059700</authid><authname>Dong M.</authname><surname>Dong</surname><given-name>Mei</given-name><initials>M.</initials><afid>60092862</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55683816900</author-url><authid>55683816900</authid><authname>Yang X.</authname><surname>Yang</surname><given-name>Xiaoyan</given-name><initials>X.</initials><afid>60092862</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35750487900</author-url><authid>35750487900</authid><authname>Meng X.</authname><surname>Meng</surname><given-name>Xiao</given-name><initials>X.</initials><afid>60092862</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56652523100</author-url><authid>56652523100</authid><authname>Niu R.</authname><surname>Niu</surname><given-name>Rongrong</given-name><initials>R.</initials><afid>60004752</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56659936700</author-url><authid>56659936700</authid><authname>Guan J.</authname><surname>Guan</surname><given-name>Juan</given-name><initials>J.</initials><afid>60004752</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55883682900</author-url><authid>55883682900</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yun</given-name><initials>Y.</initials><afid>60092862</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7405495596</author-url><authid>7405495596</authid><authname>Zhang C.</authname><surname>Zhang</surname><given-name>Cheng</given-name><initials>C.</initials><afid>60092862</afid></author><authkeywords>Angiotensin II type 1 receptor blocker | Angiotensin-(1-7) | Atherosclerosis</authkeywords><intid>1785992311</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926367272"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926367272?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926367272&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926367272&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014480015000684"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926367272</prism:url><dc:identifier>SCOPUS_ID:84926367272</dc:identifier><eid>2-s2.0-84926367272</eid><dc:title>Intestinal organoids: A model of intestinal fibrosis for evaluating anti-fibrotic drugs</dc:title><dc:creator>Rodansky E.</dc:creator><prism:publicationName>Experimental and Molecular Pathology</prism:publicationName><prism:issn>00144800</prism:issn><prism:eIssn>10960945</prism:eIssn><prism:volume>98</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>346-351</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yexmp.2015.03.033</prism:doi><pii>S0014480015000684</pii><dc:description>© 2015 Elsevier Inc. Background &amp; aims: Intestinal fibrosis is a critical complication of Crohn's disease (CD). Current in vitro models of intestinal fibrosis cannot model the complex intestinal architecture, while in vivo rodent models do not fully recapitulate human disease and have limited utility for large-scale screening. Here, we exploit recent advances in stem cell derived human intestinal organoids (HIOs) as a new human model of fibrosis in CD. Methods: Human pluripotent stem cells were differentiated into HIOs. We identified myofibroblasts, the key effector cells of fibrosis, by immunofluorescence staining for alpha-smooth muscle actin (αSMA), vimentin, and desmin. We examined the fibrogenic response of HIOs by treatment with transforming growth factor beta (TGFβ) in the presence or absence of the anti-fibrotic drug spironolactone. Fibrotic response was assayed by expression of fibrogenic genes (COL1A1 (collagen, type I, alpha 1), ACTA2 (alpha smooth muscle actin), FN1 (fibronectin 1), MYLK (myosin light chain kinase), and MKL1 (megakaryoblastic leukemia (translocation) 1)) and proteins (αSMA). Results: Immunofluorescent staining of organoids identified a population of myofibroblasts within the HIO mesenchyme. TGFβ stimulation of HIOs produced a dose-dependent pro-fibrotic response. Spironolactone treatment blocked the fibrogenic response of HIOs to TGFβ. Conclusions: HIOs contain myofibroblasts and respond to a pro-fibrotic stimulus in a manner that is consistent with isolated human myofibroblasts. HIOs are a promising model system that might bridge the gap between current in vitro and in vivo models of intestinal fibrosis in IBD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033182</affiliation-url><afid>60033182</afid><affilname>University of Michigan Medical School</affilname><name-variant>University of Michigan Medical School</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25121949700</author-url><authid>25121949700</authid><authname>Rodansky E.</authname><surname>Rodansky</surname><given-name>Eva S.</given-name><initials>E.S.</initials><afid>60033182</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55574222029</author-url><authid>55574222029</authid><authname>Johnson L.</authname><surname>Johnson</surname><given-name>Laura A.</given-name><initials>L.A.</initials><afid>60033182</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56454526600</author-url><authid>56454526600</authid><authname>Huang S.</authname><surname>Huang</surname><given-name>Sha</given-name><initials>S.</initials><afid>60033182</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7201643436</author-url><authid>7201643436</authid><authname>Spence J.</authname><surname>Spence</surname><given-name>Jason R.</given-name><initials>J.R.</initials><afid>60033182</afid><afid>60025778</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7201643436</author-url><authid>7201643436</authid><authname>Spence J.</authname><surname>Spence</surname><given-name>Jason R.</given-name><initials>J.R.</initials><afid>60033182</afid><afid>60025778</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7202138774</author-url><authid>7202138774</authid><authname>Higgins P.</authname><surname>Higgins</surname><given-name>Peter D R</given-name><initials>P.D.R.</initials><afid>60033182</afid></author><authkeywords>Drug screening | Fibrosis model | Myofibroblasts | Organoid | TGFβ</authkeywords><intid>35429645</intid><source-id>13247</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930180380"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930180380?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930180380&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930180380&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1878540915000110"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930180380</prism:url><dc:identifier>SCOPUS_ID:84930180380</dc:identifier><eid>2-s2.0-84930180380</eid><dc:title>Silent coronary spastic angina: A report of a case</dc:title><dc:creator>Sueda S.</dc:creator><prism:publicationName>Journal of Cardiology Cases</prism:publicationName><prism:issn>18785409</prism:issn><prism:eIssn>18785409</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>166-168</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jccase.2015.02.003</prism:doi><pii>S1878540915000110</pii><dc:description>© 2015 Japanese College of Cardiology. A 54-year-old man was admitted to our hospital due to abnormal electrocardiogram (ECG) changes. He had experienced no chest pain or chest discomfort during daily life until then. Ischemic ECG change was obtained by the treadmill exercise test but he complained of no chest pain or chest oppression. We performed coronary angiography and found near normal coronary artery with hypoplasty of right coronary artery. He complained of no chest symptoms irrespective of ischemic ECG change [ST depression in V3-6 leads (2.0-3.0. mm)], when intracoronary injection of 50. μg acetylcholine provoked subtotal spasm at mid left anterior descending artery and focal spasm at proximal left circumflex artery. After the administration of calcium-channel antagonist for four months, ischemic ECG changes were improved by the treadmill exercise test. He had experienced some slight fatigue during daily life and cold sweating during sleep three or four times a month before the medication. However, he had experienced less slight fatigue and no cold sweating during sleep after taking the calcium-channel antagonist. He experienced silent coronary spastic angina.&lt;. Learning objective: We describe a case of coronary spastic angina without any chest symptoms through their life and discuss silent/painless coronary spastic angina.&gt;.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101313447</affiliation-url><afid>101313447</afid><affilname>Niihama Prefectural Hospital</affilname><name-variant>Ehime Niihama Hospital</name-variant><affiliation-city>Ehime Prefecture</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005793660</author-url><authid>7005793660</authid><authname>Sueda S.</authname><surname>Sueda</surname><given-name>Shozo</given-name><initials>S.</initials><afid>101313447</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56542289600</author-url><authid>56542289600</authid><authname>Sasaki Y.</authname><surname>Sasaki</surname><given-name>Yasuhiro</given-name><initials>Y.</initials><afid>101313447</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56339783400</author-url><authid>56339783400</authid><authname>Habara H.</authname><surname>Habara</surname><given-name>Hirokazu</given-name><initials>H.</initials><afid>101313447</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54887523000</author-url><authid>54887523000</authid><authname>Kohno H.</authname><surname>Kohno</surname><given-name>Hiroaki</given-name><initials>H.</initials><afid>101313447</afid></author><authkeywords>Angina pectoris | Coronary spasm | Silent coronary spastic angina</authkeywords><intid>536079949</intid><source-id>19600156852</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928613802"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928613802?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928613802&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928613802&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928613802</prism:url><dc:identifier>SCOPUS_ID:84928613802</dc:identifier><eid>2-s2.0-84928613802</eid><dc:title>Training Healthcare Providers in Motivational Communication for Promoting Physical Activity and Exercise in Cardiometabolic Health Settings: Do We Know What We Are Doing?</dc:title><dc:creator>Rouleau C.</dc:creator><prism:publicationName>Current Cardiovascular Risk Reports</prism:publicationName><prism:issn>19329520</prism:issn><prism:eIssn>19329563</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12170-015-0457-2</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Regular physical activity (PA) is essential for secondary and tertiary prevention of cardiometabolic risk factors and disease, but low adherence to PA recommendations is common. Motivational communication (MC) represents a collection of evidence-based behavior change strategies drawn from motivational interviewing, cognitive-behavioral techniques, and behavior change theories that show promise for promoting PA adherence. However, dissemination of MC strategies in cardiometabolic healthcare settings has been limited by inconsistent reporting of training fidelity in intervention research, making it unclear how to optimally train healthcare providers. We discuss preliminary considerations for training individuals in the use of MC, including: being relatively intensive with more than self-directed learning, covering an array of behavior change strategies, offering ongoing mentorship and support, and being delivered by a skilled trainer who addresses diverse trainee needs. Future work is needed to expand upon these considerations and establish what constitutes competent MC training to impact cardiometabolic health outcomes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002306</affiliation-url><afid>60002306</afid><affilname>University of Calgary</affilname><name-variant>University of Calgary</name-variant><affiliation-city>Calgary</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027863</affiliation-url><afid>60027863</afid><affilname>Universite du Quebec a Montreal</affilname><name-variant>Université du Québec à Montréal</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031078</affiliation-url><afid>60031078</afid><affilname>Hopital du Sacre-Coeur, Montreal</affilname><name-variant>Hôpital du Sacré-Coeur</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033154</affiliation-url><afid>60033154</afid><affilname>Universite Concordia</affilname><name-variant>Concordia University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015913</affiliation-url><afid>60015913</afid><affilname>Dalhousie University</affilname><name-variant>Dalhousie University</name-variant><affiliation-city>Halifax</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028897</affiliation-url><afid>60028897</afid><affilname>University of Ottawa, Canada</affilname><name-variant>University of Ottawa</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:47961378900</author-url><authid>47961378900</authid><authname>Rouleau C.</authname><surname>Rouleau</surname><given-name>Codie R.</given-name><initials>C.R.</initials><afid>60002306</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603865096</author-url><authid>6603865096</authid><authname>Lavoie K.</authname><surname>Lavoie</surname><given-name>Kim L.</given-name><initials>K.L.</initials><afid>60027863</afid><afid>60031078</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603865096</author-url><authid>6603865096</authid><authname>Lavoie K.</authname><surname>Lavoie</surname><given-name>Kim L.</given-name><initials>K.L.</initials><afid>60027863</afid><afid>60031078</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005591384</author-url><authid>7005591384</authid><authname>Bacon S.</authname><surname>Bacon</surname><given-name>Simon L.</given-name><initials>S.L.</initials><afid>60031078</afid><afid>60033154</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005591384</author-url><authid>7005591384</authid><authname>Bacon S.</authname><surname>Bacon</surname><given-name>Simon L.</given-name><initials>S.L.</initials><afid>60031078</afid><afid>60033154</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:19838181200</author-url><authid>19838181200</authid><authname>Vallis M.</authname><surname>Vallis</surname><given-name>Michael</given-name><initials>M.</initials><afid>60015913</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506400404</author-url><authid>6506400404</authid><authname>Corace K.</authname><surname>Corace</surname><given-name>Kim</given-name><initials>K.</initials><afid>60028897</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14031247100</author-url><authid>14031247100</authid><authname>Campbell T.</authname><surname>Campbell</surname><given-name>Tavis S.</given-name><initials>T.S.</initials><afid>60002306</afid></author><authkeywords>Cardiometabolic risk | Cardiovascular disease | Cognitive-behavioral | Exercise | Motivational communication | Motivational interviewing | Physical activity | Training</authkeywords><intid>1535812755</intid><source-id>19500157062</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209750"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209750?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209750&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209750&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209750</prism:url><dc:identifier>SCOPUS_ID:84930209750</dc:identifier><eid>2-s2.0-84930209750</eid><dc:title>Radiographic appearances of uncommon paediatric implants and devices</dc:title><dc:creator>Urquia A.</dc:creator><prism:publicationName>Pediatric Radiology</prism:publicationName><prism:issn>03010449</prism:issn><prism:eIssn>14321998</prism:eIssn><prism:volume>45</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>905-914</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00247-014-3274-8</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. As childhood survival of chronic illness improves, long-term implanted devices will be encountered more frequently in routine radiology. In our paediatric tertiary referral hospital, we have come across several types of implanted devices that were not confidently recognised or identified by front-line staff and were often only identified by discussion with the patient, family or clinical team. This pictorial review highlights the appearance of nonvascular devices on paediatric radiographs in order to help clinicians identify the most frequent complications and to improve awareness of these important devices.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Great Ormond Street Hospital NHS Foundation Trust</affilname><name-variant>Department of Radiology</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663031400</author-url><authid>56663031400</authid><authname>Urquia A.</authname><surname>Urquia</surname><given-name>Arlen</given-name><initials>A.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55993401000</author-url><authid>55993401000</authid><authname>Watson T.</authname><surname>Watson</surname><given-name>Tom A.</given-name><initials>T.A.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507902996</author-url><authid>6507902996</authid><authname>Arthurs O.</authname><surname>Arthurs</surname><given-name>Owen J.</given-name><initials>O.J.</initials><afid/></author><authkeywords>Children | Devices | Equipment failure | Implants | Radiography</authkeywords><intid>36086548</intid><source-id>15753</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84919884240"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84919884240?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84919884240&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84919884240&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2214647414000282"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84919884240</prism:url><dc:identifier>SCOPUS_ID:84919884240</dc:identifier><eid>2-s2.0-84919884240</eid><dc:title>The WOMED model of benign thyroid disease: Acquired magnesium deficiency due to physical and psychological stressors relates to dysfunction of oxidative phosphorylation</dc:title><dc:creator>Moncayo R.</dc:creator><prism:publicationName>BBA Clinical</prism:publicationName><prism:issn>22146474</prism:issn><prism:volume>3</prism:volume><prism:pageRange>44-64</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbacli.2014.11.002</prism:doi><pii>S2214647414000282</pii><dc:description>© 2014. Background: The aim of this study was to discern whether a relation between biochemical parameters, sonography and musculoskeletal data exists in cases of hyperthyroidism and whether they are modifiable through supplementation with selenomethionine and magnesium citrate as well as by acupuncture and manual medicine methods. Results: A direct correlation between whole blood selenium and serum magnesium was found in subjects without thyroid disease and in menopausal women while it was reversed in cases of thyroid diseases as well as in patients with depression, infection, and in infertile women. Vascularization indices were elevated in cases of newly diagnosed benign thyroid diseases. Musculoskeletal changes i.e. lateral tension and idiopathic moving toes, as well as situations of physical and psychological stress and minor trauma and infection led to an increase of vascularization. Magnesium levels correlated negatively with these two conditions. The supplementation brought a reduction of the vascularization indices and reduced the incidence of idiopathic moving toes. Treatment of lateral tension required manual medicine methods and acupuncture (gastrocnemius). A small subgroup of patients showed a further reduction of hyper-vascularization after receiving coenzyme Q10. Conclusions: We interpret the elevated thyroid vascularization and low magnesium levels as signs of an inflammatory process related to the musculoskeletal changes. Improvement of thyroid function and morphology can be achieved after correcting the influence of stressors together with the supplementation regime. We hypothesize that the central biochemical event in thyroid disease is that of an acquired, altered mitochondrial function due to deficiency of magnesium, selenium, and coenzyme Q10.</dc:description><citedby-count>3</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100497966</affiliation-url><afid>100497966</afid><affilname>WOMED</affilname><name-variant>WOMED</name-variant><affiliation-city>Innsbruck</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56227982200</author-url><authid>56227982200</authid><authname>Moncayo R.</authname><surname>Moncayo</surname><given-name>Roy</given-name><initials>R.</initials><afid>100497966</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602124674</author-url><authid>6602124674</authid><authname>Moncayo H.</authname><surname>Moncayo</surname><given-name>Helga</given-name><initials>H.</initials><afid>100497966</afid></author><authkeywords>Coenzyme Q10 | Magnesium | Oxidative phosphorylation | Selenium | Uncoupling</authkeywords><intid>1034387011</intid><source-id>21100317907</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927520853"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927520853?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927520853&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927520853&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0278691515001052"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927520853</prism:url><dc:identifier>SCOPUS_ID:84927520853</dc:identifier><eid>2-s2.0-84927520853</eid><dc:title>A prototypic modified risk tobacco product exhibits reduced effects on chemotaxis and transendothelial migration of monocytes compared with a reference cigarette</dc:title><dc:creator>van der Toorn M.</dc:creator><prism:publicationName>Food and Chemical Toxicology</prism:publicationName><prism:issn>02786915</prism:issn><prism:eIssn>18736351</prism:eIssn><prism:volume>80</prism:volume><prism:pageRange>277-286</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.fct.2015.03.026</prism:doi><pii>S0278691515001052</pii><dc:description>© 2015 The Authors. Monocyte adhesion and migration to the subendothelial space represent critical steps in atherogenesis. Here, we investigated whether extracts from the aerosol of a prototypic modified risk tobacco product (pMRTP), based on heating rather than combusting tobacco, exhibited differential effects on the migratory behavior of monocytes compared with that from the reference cigarette, 3R4F. THP-1 cells, a monocytic cell line, and human coronary arterial endothelial cells (HCAECs) were used to investigate chemotaxis and transendothelial migration (TEM) of monocytes in conventional and impedance-based systems. THP-1 cells migrated through a monolayer of HCAECs in response to C-X-C motif ligand 12 (CXCL12), a chemokine involved in diverse cellular functions including chemotaxis and survival of stem cells. Treatment of THP-1 cells with extracts from 3R4F or pMRTP induced concentration-dependent increases in cytotoxicity (7-aminoactinomycin D), and inflammation (IL-8 and TNF-α). CXCL12-mediated chemotaxis and TEM were decreased in extract-treated THP-1 cells. Extracts from 3R4F were ~21 times more potent than those from pMRTP in all examined endpoints. Extracts from 3R4F and pMRTP induced concentration-dependent responses in assays of inflammation, cytotoxicity, chemotaxis, and TEM. Furthermore, our findings indicate that extracts from a pMRTP are significantly less cytotoxic and induce less inflammation than those from the reference cigarette, 3R4F.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107978017</affiliation-url><afid>107978017</afid><affilname>Philip Morris Products S.A.</affilname><name-variant>Philip Morris Products S.A.</name-variant><affiliation-city>Neuchatel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23010320800</author-url><authid>23010320800</authid><authname>van der Toorn M.</authname><surname>van der Toorn</surname><given-name>Marco</given-name><initials>M.</initials><afid>107978017</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56529444200</author-url><authid>56529444200</authid><authname>Frentzel S.</authname><surname>Frentzel</surname><given-name>Stefan</given-name><initials>S.</initials><afid>107978017</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56590053600</author-url><authid>56590053600</authid><authname>Goedertier D.</authname><surname>Goedertier</surname><given-name>Didier</given-name><initials>D.</initials><afid>107978017</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006100183</author-url><authid>7006100183</authid><authname>Peitsch M.</authname><surname>Peitsch</surname><given-name>Manuel</given-name><initials>M.</initials><afid>107978017</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:16202509100</author-url><authid>16202509100</authid><authname>Hoeng J.</authname><surname>Hoeng</surname><given-name>Julia</given-name><initials>J.</initials><afid>107978017</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701491476</author-url><authid>6701491476</authid><authname>De Leon H.</authname><surname>De Leon</surname><given-name>Hector</given-name><initials>H.</initials><afid>107978017</afid></author><authkeywords>Atherosclerosis | Endothelial cell | Inflammation | Modified risk tobacco products | THP-1 cell | Transmigration</authkeywords><intid>2035630367</intid><source-id>25096</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926500493"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926500493?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926500493&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926500493&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091743515000808"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926500493</prism:url><dc:identifier>SCOPUS_ID:84926500493</dc:identifier><eid>2-s2.0-84926500493</eid><dc:title>Healthy excessive weight in Portuguese women 4years after delivery of a liveborn</dc:title><dc:creator>Henriques A.</dc:creator><prism:publicationName>Preventive Medicine</prism:publicationName><prism:issn>00917435</prism:issn><prism:eIssn>10960260</prism:eIssn><prism:volume>75</prism:volume><prism:pageRange>49-55</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ypmed.2015.03.009</prism:doi><pii>S0091743515000808</pii><dc:description>© 2015 Elsevier Inc. Objective: To quantify the prevalence of healthy excessive weight and determinants of metabolic profile, considering women's reproductive life. Methods: We evaluated 1847 mothers of a birth cohort assembled after delivery and reevaluated 4. years later. A healthy profile was defined as the absence of hypertension, diabetes, dyslipidemia, C-reactive protein &lt;. 3. mg/l and being below the second tertile of HOMA-IR. Adjusted odds ratios (OR) and confidence intervals (95% CI) were computed using multinomial logistic regression, taking women with normal BMI as the reference category of the outcome. Results: Four years after delivery, 47% of women had normal BMI, 33% were overweight and 20% obese. In each BMI class, 61%, 33% and 12% presented a healthy metabolic profile, respectively. Family history of CVD/cardiometabolic risk factors was associated with a higher probability of obesity with a not healthy metabolic profile (OR = 1.39 95% CI: 0.98-1.98). Women who breastfed the enrolled child for &gt;. 26. weeks and practiced physical exercise were less likely to be obese and metabolically unhealthy (OR = 0.39 95% CI: 0.23-0.68; OR = 0.48 95% CI: 0.33-0.70, respectively), with no effect on healthy excessive weight. Conclusions: These results support the existence of a healthy excessive weight phenotype in women after motherhood, influenced by anthropometrics, genetic and lifestyles characteristics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007249</affiliation-url><afid>60007249</afid><affilname>Universidade do Porto</affilname><name-variant>Universidade do Porto</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007249</affiliation-url><afid>60007249</afid><affilname>Universidade do Porto</affilname><name-variant>Universidade do Porto</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113018922</affiliation-url><afid>113018922</afid><affilname>Centro Hospitalar São João</affilname><name-variant>Centro Hospitalar São João</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55797255400</author-url><authid>55797255400</authid><authname>Henriques A.</authname><surname>Henriques</surname><given-name>Ana</given-name><initials>A.</initials><afid>60007249</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55712944800</author-url><authid>55712944800</authid><authname>Santos A.</authname><surname>Santos</surname><given-name>Ana Cristina</given-name><initials>A.C.</initials><afid>60007249</afid><afid>60007249</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55712944800</author-url><authid>55712944800</authid><authname>Santos A.</authname><surname>Santos</surname><given-name>Ana Cristina</given-name><initials>A.C.</initials><afid>60007249</afid><afid>60007249</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102733078</author-url><authid>7102733078</authid><authname>Guimarães J.</authname><surname>Guimarães</surname><given-name>João Tiago</given-name><initials>J.T.</initials><afid>60007249</afid><afid>60007249</afid><afid>113018922</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102733078</author-url><authid>7102733078</authid><authname>Guimarães J.</authname><surname>Guimarães</surname><given-name>João Tiago</given-name><initials>J.T.</initials><afid>60007249</afid><afid>60007249</afid><afid>113018922</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102733078</author-url><authid>7102733078</authid><authname>Guimarães J.</authname><surname>Guimarães</surname><given-name>João Tiago</given-name><initials>J.T.</initials><afid>60007249</afid><afid>60007249</afid><afid>113018922</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005434514</author-url><authid>7005434514</authid><authname>Barros H.</authname><surname>Barros</surname><given-name>Henrique</given-name><initials>H.</initials><afid>60007249</afid><afid>60007249</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005434514</author-url><authid>7005434514</authid><authname>Barros H.</authname><surname>Barros</surname><given-name>Henrique</given-name><initials>H.</initials><afid>60007249</afid><afid>60007249</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56296798000</author-url><authid>56296798000</authid><authname>Azevedo A.</authname><surname>Azevedo</surname><given-name>Ana</given-name><initials>A.</initials><afid>60007249</afid><afid>60007249</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56296798000</author-url><authid>56296798000</authid><authname>Azevedo A.</authname><surname>Azevedo</surname><given-name>Ana</given-name><initials>A.</initials><afid>60007249</afid><afid>60007249</afid></author><authkeywords>Excessive weight | Healthy metabolic profile | Motherhood</authkeywords><intid>535456647</intid><source-id>17665</source-id></entry></search-results>
